Plasma HDL cholesterol and risk of myocardial infarcti study

Lancet, The

380, 572-580

DOI: 10.1016/s0140-6736(12)60312-2

Citation Report

#	Article	IF	Citations
1	Epidemiology and Prevention. American Journal of Hypertension, 1996, 9, 70A-76A.	2.0	0
2	Genetic Modulation of Lipid Profiles following Lifestyle Modification or Metformin Treatment: The Diabetes Prevention Program. PLoS Genetics, 2012, 8, e1002895.	3.5	29
3	Variation inAPOL1Contributes to Ancestry-Level Differences in HDLc-Kidney Function Association. International Journal of Nephrology, 2012, 2012, 1-10.	1.3	28
4	Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. Journal of Lipid Research, 2012, 53, 1755-1766.	4.2	125
5	ELISA System for Human Endothelial Lipase. Clinical Chemistry, 2012, 58, 1656-1664.	3.2	17
6	HDL functionality in diabetes mellitus: potential importance of glycation. Clinical Lipidology, 2012, 7, 561-578.	0.4	4
7	Working together in cardiovascular prevention: the common mission of the European Heart Journal and the European Journal of Preventive Cardiology. European Journal of Preventive Cardiology, 2012, 19, 1217-1226.	1.8	4
8	Tachometer for Reverse Cholesterol Transport?. Journal of the American Heart Association, 2012, 1, e003723.	3.7	8
9	HDL cholesterol is not HDLâ€"don't judge the book by its cover. Nature Reviews Cardiology, 2012, 9, 557-558.	13.7	14
10	HDL and Cardiovascular Risk. Circulation Research, 2012, 111, 1117-1120.	4.5	54
11	Genetic control of high density lipoprotein-cholesterol in AcB/BcA recombinant congenic strains of mice. Physiological Genomics, 2012, 44, 843-852.	2.3	3
12	Established and Emerging Approaches for the Management of Dyslipidaemia. Scientifica, 2012, 2012, 1-14.	1.7	2
13	Dietary cholesterol increases paraoxonase 1 enzyme activity. Journal of Lipid Research, 2012, 53, 2450-2458.	4.2	37
14	Cardioprotective effects of HDL cholesterol called into question. Nature Reviews Cardiology, 2012, 9, 374-374.	13.7	3
15	Interpreting noncoding genetic variation in complex traits and human disease. Nature Biotechnology, 2012, 30, 1095-1106.	17.5	445
16	Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. New England Journal of Medicine, 2012, 367, 2089-2099.	27.0	1,754
17	High-Density Lipoprotein Function, Dysfunction, and Reverse Cholesterol Transport. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 2813-2820.	2.4	304
18	Genomewide Association Studies and Common Disease â€" Realizing Clinical Utility. New England Journal of Medicine, 2012, 367, 2370-2371.	27.0	29

#	Article	IF	Citations
19	Plasma HDL cholesterol and risk of myocardial infarction. Lancet, The, 2012, 380, 1989-1990.	13.7	6
20	Plasma HDL cholesterol and risk of myocardial infarction. Lancet, The, 2012, 380, 1990.	13.7	8
21	Plasma HDL cholesterol and risk of myocardial infarction. Lancet, The, 2012, 380, 1990-1991.	13.7	3
22	Plasma HDL cholesterol and risk of myocardial infarction â€“ Authors' reply. Lancet, The, 2012, 380, 1991.	13.7	27
23	Cardiovascular Protection by ApoE and ApoE-HDL Linked to Suppression of ECM Gene Expression and Arterial Stiffening. Cell Reports, 2012, 2, 1259-1271.	6.4	159
24	High-Density Lipoproteins. Journal of the American College of Cardiology, 2012, 60, 2380-2383.	2.8	38
26	Novel Biological Functions of High-Density Lipoprotein Cholesterol. Circulation Research, 2012, 111, 1079-1090.	4.5	170
27	Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease. Human Molecular Genetics, 2012, 21, 4558-4571.	2.9	196
28	A new era for quantifying HDL and cardiovascular risk?. Nature Medicine, 2012, 18, 1346-1347.	30.7	58
29	Is it time to revise the HDL cholesterol hypothesis?. Nature Medicine, 2012, 18, 1344-1346.	30.7	241
30	Sex and Life Expectancy. Gender Medicine, 2012, 9, 390-401.	1.4	88
31	Dyslipidemias in the Prevention of Cardiovascular Disease: Risks and Causality. Current Cardiology Reports, 2012, 14, 709-720.	2.9	93
32	Regulation of endothelial lipase and systemic HDL cholesterol levels by SREBPs and VEGF-A. Atherosclerosis, 2012, 225, 335-340.	0.8	21
35	Will Cholesteryl Ester Transfer Protein Inhibition Succeed Primarily by Lowering Low-Density Lipoprotein Cholesterol?. Journal of the American College of Cardiology, 2012, 60, 2049-2052.	2.8	20
36	Drugs Targeting High-Density Lipoprotein Cholesterol for Coronary Artery Disease Management. Canadian Journal of Cardiology, 2012, 28, 667-677.	1.7	6
37	Targeting High Density Lipoproteins in the Prevention of Cardiovascular Disease?. Current Cardiology Reports, 2012, 14, 684-691.	2.9	29
38	Clinical Value of Drugs Targeting Inflammation for the Management of Coronary Artery Disease. Canadian Journal of Cardiology, 2012, 28, 678-686.	1.7	15
39	Women Up, Men Down: The Clinical Impact of Replacing the Framingham Risk Score with the Reynolds Risk Score in the United States Population. PLoS ONE, 2012, 7, e44347.	2.5	17

#	Article	IF	Citations
40	Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib. Drug Design, Development and Therapy, 2012, 6, 251.	4.3	11
41	Single nucleotide polymorphisms in CETP, SLC46A1, SLC19A1, CD36, BCMO1, APOA5, and ABCA1 are significant predictors of plasma HDL in healthy adults. Lipids in Health and Disease, 2013, 12, 66.	3.0	31
42	Hazardous alcohol consumption is associated with increased levels of B-type natriuretic peptide: evidence from two population-based studies. European Journal of Epidemiology, 2013, 28, 393-404.	5.7	19
43	Validating therapeutic targets through human genetics. Nature Reviews Drug Discovery, 2013, 12, 581-594.	46.4	548
44	Novel lipoprotein density profiling in healthy dogs of various breeds, healthy miniature schnauzers, and miniature schnauzers with hyperlipidemia. BMC Veterinary Research, 2013, 9, 47.	1.9	22
45	Impact of HDL genetic risk scores on coronary artery calcified plaque and mortality in individuals with type 2 diabetes from the Diabetes Heart Study. Cardiovascular Diabetology, 2013, 12, 95.	6.8	9
46	Insulin resistance in type 1 diabetes: what is â€˜double diabetesâ€™ and what are the risks?. Diabetologia, 2013, 56, 1462-1470.	6.3	172
47	Atherosclerosis and Transit of HDL Through the Lymphatic Vasculature. Current Atherosclerosis Reports, 2013, 15, 354.	4.8	23
48	Biomarkers and Sustainable Innovation in Cardiovascular Drug Development: Lessons from Near and Far Afield. Current Atherosclerosis Reports, 2013, 15, 321.	4.8	5
49	The Role of Early LDL Lowering to Prevent the Onset of Atherosclerotic Disease. Current Atherosclerosis Reports, 2013, 15, 312.	4.8	35
50	Monitoring of Lipids, Enzymes, and Creatine Kinase in Patients on Lipid-Lowering Drug Therapy. Current Cardiology Reports, 2013, 15, 397.	2.9	31
51	Genetics of Lipid Traits and Relationship to Coronary Artery Disease. Current Cardiology Reports, 2013, 15, 396.	2.9	13
52	From evolution to revolution: miRNAs as pharmacological targets for modulating cholesterol efflux and reverse cholesterol transport. Pharmacological Research, 2013, 75, 60-72.	7.1	40
53	A coding variant in SR-BI (I179N) significantly increases atherosclerosis in mice. Mammalian Genome, 2013, 24, 257-265.	2.2	6
54	HDL-C: clinical equipoise and vascular endothelial function. Expert Review of Cardiovascular Therapy, 2013, 11, 343-353.	1.5	19
56	Future of Cholesteryl Ester Transfer Protein (CETP) Inhibitors: A Pharmacological Perspective. Clinical Pharmacokinetics, 2013, 52, 615-626.	3.5	64
57	Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: A clinical update. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 799-807.	2.6	111
58	The positive relationship of serum paraoxonase-1 activity withÂapolipoprotein E is abrogated in metabolic syndrome. Atherosclerosis, 2013, 230, 6-11.	0.8	22

#	Article	IF	Citations
59	High-density lipoproteins: A consensus statement from the National Lipid Association. Journal of Clinical Lipidology, 2013, 7, 484-525.	1.5	276
60	Pharmacotherapies for lipid modification: beyond the statins. Nature Reviews Cardiology, 2013, 10, 560-570.	13.7	35
61	Hyperlipidemia as a Risk Factor for Cardiovascular Disease. Primary Care - Clinics in Office Practice, 2013, 40, 195-211.	1.6	703
62	Discovery and refinement of loci associated with lipid levels. Nature Genetics, 2013, 45, 1274-1283.	21.4	2,641
63	Common variants associated with plasma triglycerides and risk for coronary artery disease. Nature Genetics, 2013, 45, 1345-1352.	21.4	754
64	Genetic Determination of Plasma Cholesterol Efflux Capacity Is Gender-Specific and Independent of HDL-Cholesterol Levels. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 822-828.	2.4	40
65	Molecular Biology of Atherosclerosis. Physiological Reviews, 2013, 93, 1317-1542.	28.8	418
66	Lipids and the Endothelium: Bidirectional Interactions. Current Atherosclerosis Reports, 2013, 15, 365.	4.8	37
67	Interleukin 6 Stimulates Endothelial Binding and Transport of High-Density Lipoprotein Through Induction of Endothelial Lipase. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 2699-2706.	2.4	31
68	New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. European Heart Journal, 2013, 34, 1783-1789.	2.2	90
69	Myeloperoxidase in Cardiovascular Disease. Advances in Clinical Chemistry, 2013, 62, 1-32.	3.7	23
70	Jekyll and Hyde of HDL: a lipoprotein with a split personality. European Heart Journal, 2013, 34, 3531-3534.	2.2	12
71	Joint Linkage and Association Analysis with Exome Sequence Data Implicates SLC25A40 in Hypertriglyceridemia. American Journal of Human Genetics, 2013, 93, 1035-1045.	6.2	36
72	Genomic study in Mexicans identifies a new locus for triglycerides and refines European lipid loci. Journal of Medical Genetics, 2013, 50, 298-308.	3.2	116
73	Levels and Changes of HDL Cholesterol and Apolipoprotein A-I in Relation to Risk of Cardiovascular Events Among Statin-Treated Patients. Circulation, 2013, 128, 1504-1512.	1.6	162
74	Human genetics as a foundation for innovative drug development. Nature Biotechnology, 2013, 31, 975-978.	17.5	43
75	Function and Distribution of Apolipoprotein A1 in the Artery Wall Are Markedly Distinct From Those in Plasma. Circulation, 2013, 128, 1644-1655.	1.6	98
76	Disorders and borders: Psychiatric genetics and nosology. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2013, 162, 559-578.	1.7	47

#	Article	IF	Citations
77	Role of Metabolic Surgery in Less Obese or Non-Obese Subjects with Type 2 Diabetes: Influence Over Cardiovascular Events. Current Atherosclerosis Reports, 2013, 15, 355.	4.8	12
79	Dietary fatty acid intake is associated with paraoxonase 1 activity in a cohort-based analysis of 1,548 subjects. Lipids in Health and Disease, 2013, 12, 183.	3.0	15
81	Targeting high-density lipoproteins: Update on a promising therapy. Archives of Cardiovascular Diseases, 2013, 106, 601-611.	1.6	25
82	Serum amyloid A is independently related to apolipoprotein A-I but not to HDL-cholesterol in patients with angina pectoris. Clinical Biochemistry, 2013, 46, 1660-1663.	1.9	6
84	Advances in catheter-ablation treatment of AF. Nature Reviews Cardiology, 2013, 10, 63-64.	13.7	7
85	Genetics and Genomics for the Prevention and Treatment of Cardiovascular Disease: Update. Circulation, 2013, 128, 2813-2851.	1.6	100
86	Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding. Circulation, 2013, 127, 1404-1412.	1.6	222
87	Crystal Structure of Î”(185â€“243)ApoA-I Suggests a Mechanistic Framework for the Protein Adaptation to the Changing Lipid Load in Good Cholesterol: From Flatland to Sphereland via Double Belt, Belt Buckle, Double Hairpin and Trefoil/Tetrafoil. Journal of Molecular Biology, 2013, 425, 1-16.	4.2	36
88	Inflammation alters HDL composition and function: Implications for HDL-raising therapies. , 2013, 137, 341-351.		100
89	Genes for blood pressure: an opportunity to understand hypertension. European Heart Journal, 2013, 34, 951-961.	2.2	163
90	HDLâ€”is it too big to fail?. Nature Reviews Endocrinology, 2013, 9, 308-312.	9.6	26
91	Using Mendelian randomization to determine causative factors in cardiovascular disease. Journal of Internal Medicine, 2013, 273, 44-47.	6.0	24
92	Health in Europeâ€”a view from across the Atlantic. Lancet, The, 2013, 381, 1257-1259.	13.7	2
93	Emerging LDL therapies: Using human genetics to discover new therapeutic targets for plasma lipids. Journal of Clinical Lipidology, 2013, 7, S1-S5.	1.5	24
94	The associations of oxidized high-density lipoprotein lipids with risk factors for atherosclerosis: The Cardiovascular Risk in Young Finns Study. Free Radical Biology and Medicine, 2013, 65, 1284-1290.	2.9	26
95	Remnant Cholesterol. Journal of the American College of Cardiology, 2013, 61, 437-439.	2.8	26
96	Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease. Journal of the American College of Cardiology, 2013, 61, 427-436.	2.8	768
97	High-Density Lipoprotein and Residual Cardiovascular Risk. Journal of the American College of Cardiology, 2013, 62, 1842-1844.	2.8	4

#	Article	IF	Citations
98	Aging affects high-density lipoprotein composition and function. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2013, 1831, 1442-1448.	2.4	90
99	Low High-Density Lipoprotein Cholesterol Is Not a Risk Factor for Recurrent Vascular Events in Patients With Vascular Disease on Intensive Lipid-Lowering Medication. Journal of the American College of Cardiology, 2013, 62, 1834-1841.	2.8	42
100	Industry and Regulatory Performance in 2012: A Year in Review. Clinical Pharmacology and Therapeutics, 2013, 94, 359-366.	4.7	8
101	Unanswered questions in including HDL-cholesterol in the cardiovascular risk estimation. Is time still on our side?. Atherosclerosis, 2013, 226, 296-298.	0.8	6
102	Lipoprotein remnants and dense LDL are associated with features of unstable carotid plaque: A flag for non-HDL-C. Atherosclerosis, 2013, 230, 106-109.	0.8	26
103	Clinical Neurogenetics. Neurologic Clinics, 2013, 31, 915-928.	1.8	5
104	Polygenic familial hypercholesterolaemia: does it matter?. Lancet, The, 2013, 381, 1255-1257.	13.7	21
105	Los fibratos en el control del sÃndrome metabÃ³lico. Hipertension Y Riesgo Vascular, 2013, 30, 39-44.	0.6	1
106	Reply. Journal of the American College of Cardiology, 2013, 61, 1931-1932.	2.8	8
107	The Year in Atherothrombosis. Journal of the American College of Cardiology, 2013, 62, 1131-1143.	2.8	22
108	Does it Make Sense to Combine Statins with Other Lipid-Altering Agents Following AIM-HIGH, SHARP and ACCORD?. Current Atherosclerosis Reports, 2013, 15, 290.	4.8	3
109	Pathology: At the heart of the problem. Nature, 2013, 493, S10-S11.	27.8	1
110	Mendelian Randomization: How Genetics Is Pushing the Boundaries of Epidemiology to Identify New Causes of Heart Disease. Canadian Journal of Cardiology, 2013, 29, 30-36.	1.7	15
111	Impact of Intensive Lipid Lowering on Lipid Profiles Over Time and Tolerability in Stable Coronary Artery Disease: Insights From a Subanalysis of the Coronary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultrasound in Japanese Subjects (COSMOS). Cardiovascular Therapeutics, 2013, 31, 335-343.	2.5	6
112	HDL Cholesterol and Cardiovascular Outcomes: What Is the Evidence?. Current Cardiology Reports, 2013, 15, 349.	2.9	15
113	An effective and rapid determination by MALDI/TOF/TOF of methionine sulphoxide content of ApoAâ€‰in type 2 diabetic patients. Journal of Mass Spectrometry, 2013, 48, 105-110.	1.6	8
114	Hypercholesterolemia links hematopoiesis with atherosclerosis. Trends in Endocrinology and Metabolism, 2013, 24, 129-136.	7.1	83
115	Pharmacogenomics of high-density lipoprotein-cholesterol-raising therapies. Expert Review of Cardiovascular Therapy, 2013, 11, 355-364.	1.5	8

#	Article	IF	Citations
116	Abnormal High-Density Lipoprotein Induces Endothelial Dysfunction via Activation of Toll-like Receptor-2. Immunity, 2013, 38, 754-768.	14.3	261
117	Genetics of HDL-C: A Causal Link to Atherosclerosis?. Current Atherosclerosis Reports, 2013, 15, 326.	4.8	23
118	Triglyceride-rich lipoproteins and HDL: What do recent trials tell us?. Atherosclerosis, 2013, 228, 329-331.	0.8	1
119	Pharmacogenomics of lipid-lowering therapies. Pharmacogenomics, 2013, 14, 981-995.	1.3	20
120	Assessing the functional properties of high-density lipoproteins: an emerging concept in cardiovascular research. Biomarkers in Medicine, 2013, 7, 457-472.	1.4	62
121	The Cardioprotective Protein Apolipoprotein A1 Promotes Potent Anti-tumorigenic Effects. Journal of Biological Chemistry, 2013, 288, 21237-21252.	3.4	204
122	Foam cells in atherosclerosis. Clinica Chimica Acta, 2013, 424, 245-252.	1.1	570
123	Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nature Reviews Rheumatology, 2013, 9, 513-523.	8.0	212
124	HDL cholesterol studiesâ€"more of the same?. Nature Reviews Cardiology, 2013, 10, 70-72.	13.7	6
125	Meta-analysis methods for genome-wide association studies and beyond. Nature Reviews Genetics, 2013, 14, 379-389.	16.3	538
126	Pleiotropy in complex traits: challenges and strategies. Nature Reviews Genetics, 2013, 14, 483-495.	16.3	958
127	Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease. Pharmacogenomics, 2013, 14, 1495-1515.	1.3	35
130	High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease. Journal of Lipid Research, 2013, 54, 3227-3243.	4.2	132
133	Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. European Heart Journal, 2013, 34, 1826-1833.	2.2	353
134	Exploring causal associations between alcohol and coronary heart disease risk factors: findings from a Mendelian randomization study in the Copenhagen General Population Study. European Heart Journal, 2013, 34, 2519-2528.	2.2	81
135	Using Mendelian randomization to assess and develop clinical interventions: limitations and benefits. Journal of Comparative Effectiveness Research, 2013, 2, 209-212.	1.4	13
136	Cholesterol Efflux Capacity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1449-1451.	2.4	30
138	HDL and endothelial protection: examining evidence from HDL inherited disorders. Clinical Lipidology, 2013, 8, 361-370.	0.4	4

#	Article	IF	Citations
139	Frail HDLs and Stiff Arteries in Type 2 Diabetes in Juveniles. Diabetes, 2013, 62, 2662-2664.	0.6	2
140	Dalcetrapib in Patients with an Acute Coronary Syndrome. New England Journal of Medicine, 2013, 368, 869-870.	27.0	12
141	Diesel Exhaust Induces Systemic Lipid Peroxidation and Development of Dysfunctional Pro-Oxidant and Pro-Inflammatory High-Density Lipoprotein. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1153-1161.	2.4	127
142	Is It Time for HDL to Change Its Tune?. Circulation, 2013, 128, 1175-1176.	1.6	4
143	Mining the Human Phenome Using Allelic Scores That Index Biological Intermediates. PLoS Genetics, 2013, 9, e1003919.	3.5	84
144	Management of Low Levels of High-Density Lipoprotein-Cholesterol. Circulation, 2013, 128, 72-78.	1.6	15
145	Translation of High-Density Lipoprotein Function Into Clinical Practice. Circulation, 2013, 128, 1256-1267.	1.6	197
146	Risk Scores of Common Genetic Variants for Lipid Levels Influence Atherosclerosis and Incident Coronary Heart Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 2233-2239.	2.4	44
147	The Impact of Partial and Complete Loss-of-Function Mutations in Endothelial Lipase on High-Density Lipoprotein Levels and Functionality in Humans. Circulation: Cardiovascular Genetics, 2013, 6, 54-62.	5.1	53
148	Pegylation of High-Density Lipoprotein Decreases Plasma Clearance and Enhances Antiatherogenic Activity. Circulation Research, 2013, 113, e1-e9.	4.5	43
149	High-density lipoprotein cholesterol raising. Current Opinion in Cardiology, 2013, 28, 464-474.	1.8	21
151	Mild Renal Dysfunction and Metabolites Tied to Low HDL Cholesterol Are Associated With Monocytosis and Atherosclerosis. Circulation, 2013, 127, 988-996.	1.6	51
152	News on the genetics of lipoprotein metabolism and cardiovascular disease. Current Opinion in Lipidology, 2013, 24, 185-186.	2.7	2
153	Importance of high-density lipoprotein quality. Current Opinion in Nephrology and Hypertension, 2013, 22, 259-265.	2.0	14
154	Functional genomics of the human high-density lipoprotein receptor scavenger receptor BI. Current Opinion in Endocrinology, Diabetes and Obesity, 2013, 20, 124-131.	2.3	11
155	Hyperlipidaemia and cardiovascular disease. Current Opinion in Lipidology, 2013, 24, 366-368.	2.7	5
157	Editorial comment. Current Opinion in Lipidology, 2013, 24, 109-110.	2.7	0
158	HDL quality or cholesterol cargo. Current Opinion in Lipidology, 2013, 24, 351-356.	2.7	25

#	Article	IF	Citations
159	High-Density Lipoprotein. Circulation Research, 2013, 113, 1275-1277.	4.5	3
160	Evidence of a Polygenic Origin of Extreme High-Density Lipoprotein Cholesterol Levels. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1521-1528.	2.4	49
161	Use of allele scores as instrumental variables for Mendelian randomization. International Journal of Epidemiology, 2013, 42, 1134-1144.	1.9	351
162	Stabilization of atherosclerotic plaques: an update. European Heart Journal, 2013, 34, 3251-3258.	2.2	101
163	Structural basis for distinct functions of the naturally occurring Cys mutants of human apolipoprotein A-I. Journal of Lipid Research, 2013, 54, 3244-3257.	4.2	20
164	MRI-measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: the NIA plaque study. Heart, 2013, 99, 1675-1680.	2.9	39
165	Apolipoprotein E genotype, cardiovascular biomarkers and risk of stroke: Systematic review and meta-analysis of 14 015 stroke cases and pooled analysis of primary biomarker data from up to 60 883 individuals. International Journal of Epidemiology, 2013, 42, 475-492.	1.9	145
166	Endothelial Lipase Is a Critical Determinant of High-Density Lipoproteinâ€“Stimulated Sphingosine 1-Phosphateâ€“Dependent Signaling in Vascular Endothelium. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1788-1794.	2.4	36
168	Back to Basics: PCSK9 as a New Target for the LDL Receptor. Arquivos Brasileiros De Cardiologia, 2013, 102, e5-8.	0.8	2
169	Genetic Determinant for Amino Acid Metabolites and Changes in Body Weight and Insulin Resistance in Response to Weight-Loss Diets. Circulation, 2013, 127, 1283-1289.	1.6	67
170	Niacin, an old drug with a new twist. Journal of Lipid Research, 2013, 54, 2586-2594.	4.2	44
171	Paradoxical Association of Enhanced Cholesterol Efflux With Increased Incident Cardiovascular Risks. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1696-1705.	2.4	269
172	Regulation of signal transduction by HDL. Journal of Lipid Research, 2013, 54, 2315-2324.	4.2	75
173	Liver ABCA1 Deletion in LDLrKO Mice Does Not Impair Macrophage Reverse Cholesterol Transport or Exacerbate Atherogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 2288-2296.	2.4	35
174	Genomic Medicine for Improved Prediction and Primordial Prevention of Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 2049-2050.	2.4	9
175	Genetic Loci for Coronary Calcification and Serum Lipids Relate to Aortic and Carotid Calcification. Circulation: Cardiovascular Genetics, 2013, 6, 47-53.	5.1	19
176	Circulation Research Thematic Synopsis. Circulation Research, 2013, 112, .	4.5	0
177	High-density lipoproteins and cardiovascular disease: the plots thicken. Heart, 2013, 99, 222-224.	2.9	1

#	Article	IF	Citations
178	The effect of androgens on lipids. Current Opinion in Endocrinology, Diabetes and Obesity, 2013, 20, 132-139.	2.3	39
179	Niacin. Current Opinion in Lipidology, 2013, 24, 475-479.	2.7	23
180	Reappraisal of SFA and cardiovascular risk. Proceedings of the Nutrition Society, 2013, 72, 390-398.	1.0	17
181	HDL, Atherosclerosis, and Emerging Therapies. Cholesterol, 2013, 2013, 1-18.	1.6	70
182	Journey Through Cholesteryl Ester Transfer Protein Inhibition. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 360-366.	2.2	11
183	Adhesion molecules, endothelin-1 and lung function in seven population-based cohorts. Biomarkers, 2013, 18, 196-203.	1.9	23
184	The impact of gender and serum estradiol levels on <scp>HDL</scp>â€mediated reverse cholesterol transport. European Journal of Clinical Investigation, 2013, 43, 317-323.	3.4	28
185	High-Density Lipoprotein Cholesterol, Size, Particle Number, and Residual Vascular Risk After Potent Statin Therapy. Circulation, 2013, 128, 1189-1197.	1.6	203
186	Hypertension-misattributed kidney disease in African Americans. Kidney International, 2013, 83, 6-9.	5.2	30
187	Biochemistry and pathophysiology of intravascular and intracellular lipolysis. Genes and Development, 2013, 27, 459-484.	5.9	277
188	Novel common and rare genetic determinants of paraoxonase activity: FTO, SERPINA12, and ITGAL. Journal of Lipid Research, 2013, 54, 552-560.	4.2	17
189	Monogenic causes of elevated HDL cholesterol and implications for development of new therapeutics. Clinical Lipidology, 2013, 8, 635-648.	0.4	11
190	Therapeutic Approaches to the Regulation of Metabolism of High-Density Lipoprotein. Circulation Journal, 2013, 77, 2651-2663.	1.6	31
191	High-Density Lipoproteins. Circulation Journal, 2013, 77, 2432-2448.	1.6	143
193	Effects of high-amountâ€“high-intensity exercise on in vivo platelet activation: Modulation by lipid peroxidation and AGE/RAGE axis. Thrombosis and Haemostasis, 2013, 110, 1232-1240.	3.4	33
194	The Year in Cardiology 2012: focus on cardiovascular disease prevention. European Heart Journal, 2013, 34, 314-317.	2.2	9
195	Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. Vascular Health and Risk Management, 2013, 9, 617.	2.3	71
197	New targets and developments in lipoproteins control. Research Reports in Clinical Cardiology, 2013, , 77.	0.2	0

#	Article	IF	Citations
198	Genetic and Structure-Function Studies of Missense Mutations in Human Endothelial Lipase. PLoS ONE, 2013, 8, e55716.	2.5	13
199	Znf202 Affects High Density Lipoprotein Cholesterol Levels and Promotes Hepatosteatosis in Hyperlipidemic Mice. PLoS ONE, 2013, 8, e57492.	2.5	15
200	High Density Lipoprotein: Assembly, Structure, Cargo, and Functions. ISRN Physiology, 2013, 2013, 1-20.	0.4	21
201	Anacetrapib: potential for the prevention and treatment of coronary heart disease. Research Reports in Clinical Cardiology, 2013, , 39.	0.2	0
202	Effects of Lipid-Lowering Drugs on High-Density Lipoprotein Subclasses in Healthy Menâ€”A Randomized Trial. PLoS ONE, 2014, 9, e91565.	2.5	10
203	Plasma Activity of Endothelial Lipase Impacts High-Density Lipoprotein Metabolism and Coronary Risk Factors in Humans. Journal of Atherosclerosis and Thrombosis, 2014, 21, 313-321.	2.0	18
204	Lessons and Implications from Genome-Wide Association Studies (GWAS) Findings of Blood Cell Phenotypes. Genes, 2014, 5, 51-64.	2.4	12
205	High-Density Lipoprotein Ã¢â‚¬â€œ A Hero, a Mirage, or a Witness?. Frontiers in Cardiovascular Medicine, 2014, 1, 9.	2.4	3
206	Current guidelines for high-density lipoprotein cholesterol in therapy and future directions. Vascular Health and Risk Management, 2014, 10, 205.	2.3	21
207	Are the New Guidelines for the Use of Lipid-Lowering Agents Sound, and Should Their Adoption Be Encouraged?. Canadian Journal of Hospital Pharmacy, 2014, 67, 246-9.	0.1	4
208	Sphingolipids and HDL Metabolism. , 2014, , 133-158.		1
209	Not so "good" cholesterol. BMJ, The, 2014, 349, g4664-g4664.	6.0	2
210	Spotlight on HDL biology: new insights in metabolism, function, and translation. Cardiovascular Research, 2014, 103, 337-340.	3.8	16
211	Plasma PCSK9 Levels Are Elevated with Acute Myocardial Infarction in Two Independent Retrospective Angiographic Studies. PLoS ONE, 2014, 9, e106294.	2.5	75
212	HDLâ€ƀ is a Superior Predictor of Carotid Artery Disease in a Caseâ€Control Cohort of 1725 Participants. Journal of the American Heart Association, 2014, 3, e000902.	3.7	35
213	Prevalence of dyslipidemia and its association with insomnia in a community based population in China. BMC Public Health, 2014, 14, 1050.	2.9	26
214	Genetically low vitamin D concentrations and increased mortality: mendelian randomisation analysis in three large cohorts. BMJ, The, 2014, 349, g6330-g6330.	6.0	238
215	Cardiovascular Twist to the Rapidly Evolving Apolipoprotein L1 Story. Circulation Research, 2014, 114, 746-747.	4.5	6

#	Article	IF	Citations
216	High-Density Lipoproteins and Coronary Artery Disease. Angiology, 2014, 65, 696-702.	1.8	11
217	Disease Risk Factors Identified Through Shared Genetic Architecture and Electronic Medical Records. Science Translational Medicine, 2014, 6, 234ra57.	12.4	58
218	Reconstituted High-Density Lipoprotein Therapies. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1800-1802.	2.4	7
219	Combining genetic and nongenetic biomarkers to realize the promise of pharmacogenomics for inflammatory diseases. Pharmacogenomics, 2014, 15, 1931-1940.	1.3	7
220	Examining controversies and new frontiers in lipid management. Clinical Lipidology, 2014, 9, 587-595.	0.4	0
221	Increased Burden of Cardiovascular Disease in Carriers of APOL1 Genetic Variants. Circulation Research, 2014, 114, 845-850.	4.5	141
222	Methylation at CPT1A locus is associated with lipoprotein subfraction profiles. Journal of Lipid Research, 2014, 55, 1324-1330.	4.2	65
223	Evaluation of Links Between High-Density Lipoprotein Genetics, Functionality, and Aortic Valve Stenosis Risk in Humans. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 457-462.	2.4	24
224	An In-Silico Model of Lipoprotein Metabolism and Kinetics for the Evaluation of Targets and Biomarkers in the Reverse Cholesterol Transport Pathway. PLoS Computational Biology, 2014, 10, e1003509.	3.2	35
225	Genetic Determinants of Long-Term Changes in Blood Lipid Concentrations: 10-Year Follow-Up of the GLACIER Study. PLoS Genetics, 2014, 10, e1004388.	3.5	25
226	Genomics and Pharmacogenomics of Lipid-Lowering Therapies. , 2014, , 715-746.		0
227	The biggest challenges currently facing companion diagnostic advancement. Expert Review of Molecular Diagnostics, 2014, 14, 27-35.	3.1	5
228	Lower levels of high-density lipoprotein cholesterol in urban Africans presenting with communicable versus non-communicable forms of heart disease: the 'Heart of Soweto' hospital registry study. BMJ Open, 2014, 4, e005069-e005069.	1.9	3
229	Amino Acid Change in the Carbohydrate Response Element Binding Protein Is Associated With Lower Triglycerides and Myocardial Infarction Incidence Depending on Level of Adherence to the Mediterranean Diet in the PREDIMED Trial. Circulation: Cardiovascular Genetics, 2014, 7, 49-58.	5.1	35
230	High-density lipoprotein and endothelial function in patients with myocardial infarction: Pieces in a puzzle. Atherosclerosis, 2014, 237, 838-839.	0.8	0
231	Decreased cholesterol efflux capacity in patients with low cholesteryl ester transfer protein plasma levels. European Journal of Clinical Investigation, 2014, 44, 395-401.	3.4	25
232	High-density lipoprotein cholesterol targeting for novel drug discovery: where have we gone wrong?. Expert Opinion on Drug Discovery, 2014, 9, 119-124.	5.0	8
233	Testing concordance of instrumental variable effects in generalized linear models with application to Mendelian randomization. Statistics in Medicine, 2014, 33, 3986-4007.	1.6	7

#	Article	IF	Citations
234	Obesity favors apolipoprotein E- and C-III-containing high density lipoprotein subfractions associated with risk of heart disease. Journal of Lipid Research, 2014, 55, 2167-2177.	4.2	47
235	Beginning to Understand High-Density Lipoproteins. Endocrinology and Metabolism Clinics of North America, 2014, 43, 913-947.	3.2	85
236	Resistant starch type 4-enriched diet lowered blood cholesterols and improved body composition in a double blind controlled cross-over intervention. Molecular Nutrition and Food Research, 2014, 58, 1365-1369.	3.3	70
237	Beyond the Single SNP: Emerging Developments in Mendelian Randomization in the â€œOmicsâ€•Era. Current Epidemiology Reports, 2014, 1, 228-236.	2.4	18
238	An Experimentally Robust Model of Monomeric Apolipoprotein A-I Created from a Chimera of Two X-ray Structures and Molecular Dynamics Simulations. Biochemistry, 2014, 53, 7625-7640.	2.5	24
239	APOM and high-density lipoprotein cholesterol are associated with lung function and per cent emphysema. European Respiratory Journal, 2014, 43, 1003-1017.	6.7	37
240	Long-term risk of cardiovascular events across a spectrum of adverse major plasma lipid combinations in the Framingham Heart Study. American Heart Journal, 2014, 168, 878-883.e1.	2.7	58
241	Antipsoriatic treatment extends beyond the skin: recovering of highâ€‘density lipoprotein function. Experimental Dermatology, 2014, 23, 701-704.	2.9	21
242	Olive Oil Polyphenols Enhance High-Density Lipoprotein Function in Humans. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 2115-2119.	2.4	128
243	ApoAâ€‘I mutations, L202P and K131del, in HDL from heterozygotes with low HDLâ€C. Proteomics - Clinical Applications, 2014, 8, 241-250.	1.6	5
244	Cystatin <scp>C</scp> identifies cardiovascular risk better than creatinineâ€based estimates of glomerular filtration in middleâ€aged individuals without a history of cardiovascular disease. Journal of Internal Medicine, 2014, 275, 506-521.	6.0	38
245	Why do statins reduce cardiovascular disease more than other lipid modulating therapies?. European Journal of Clinical Investigation, 2014, 44, 1135-1140.	3.4	16
246	Instrumental variable methods for causal inference. Statistics in Medicine, 2014, 33, 2297-2340.	1.6	444
247	Re: "Temporal Relationship Between Uric Acid Concentration and Risk of Diabetes in a Community-Based Study Population". American Journal of Epidemiology, 2014, 179, 1147-1148.	3.4	2
248	Associations of the Baltic Sea diet with cardiometabolic risk factors â€“ a meta-analysis of three Finnish studies. British Journal of Nutrition, 2014, 112, 616-626.	2.3	32
249	Cardiovascular and cancer events in hyper-high-density lipoprotein cholesterolemic patients: a post hoc analysis of the MEGA study. Lipids in Health and Disease, 2014, 13, 133.	3.0	3
250	The individualistic fallacy, ecological studies and instrumental variables: a causal interpretation. Emerging Themes in Epidemiology, 2014, 11, 18.	2.7	68
251	Effects of dietary components on high-density lipoprotein measures in a cohort of 1,566 participants. Nutrition and Metabolism, 2014, 11, 44.	3.0	16

#	Article	IF	Citations
252	Association of cholesteryl ester transfer protein (CETP) gene polymorphism, high density lipoprotein cholesterol and risk of coronary artery disease: a meta-analysis using a Mendelian randomization approach. BMC Medical Genetics, 2014, 15, 118.	2.1	35
253	HDL quality and functionality: what can proteins and genes predict?. Expert Review of Cardiovascular Therapy, 2014, 12, 521-532.	1.5	28
254	Newer Therapeutic Strategies to Alter High-Density Lipoprotein Level and Function. Cardiology in Review, 2014, 22, 17-24.	1.4	1
255	High-Density Lipoprotein Functionality in Coronary Artery Disease. American Journal of the Medical Sciences, 2014, 347, 504-508.	1.1	34
256	Introduction of HDL Molecules, Past and Brief Future. , 2014, , 1-8.		0
257	Blood Lipids and the Incidence of Atrial Fibrillation: The Multiâ€Ethnic Study of Atherosclerosis and the Framingham Heart Study. Journal of the American Heart Association, 2014, 3, e001211.	3.7	99
258	Is High-Density Lipoprotein Cardioprotective or Simply a Marker of Cardiovascular Disease?. American Journal of Therapeutics, 2014, 21, 438-439.	0.9	5
259	Effect of Gastric Bypass Versus Diet on Cardiovascular Risk Factors. Annals of Surgery, 2014, 259, 694-699.	4.2	26
260	Atherosclerosis. Current Opinion in Lipidology, 2014, 25, 319-320.	2.7	1
261	Anacetrapib. Cardiology in Review, 2014, 22, 253-261.	1.4	3
262	Treatment options for low high-density lipoproteins. Current Opinion in Endocrinology, Diabetes and Obesity, 2014, 21, 134-139.	2.3	12
264	Personal Reflections on Big Science, Small Science, or the Right Mix. Circulation Research, 2014, 114, 1080-1082.	4.5	9
265	The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial. European Heart Journal, 2014, 35, 1792-1800.	2.2	76
266	More Than a Billion People Taking Statins?. JAMA - Journal of the American Medical Association, 2014, 311, 463.	7.4	170
267	Quantification of HDL Particle Concentration by Calibrated Ion Mobility Analysis. Clinical Chemistry, 2014, 60, 1393-1401.	3.2	76
268	New Therapies for Coronary Artery Disease: Genetics Provides a Blueprint. Science Translational Medicine, 2014, 6, 239ps4.	12.4	10
269	Meta-analysis of Cholesteryl Ester Transfer Protein TaqIB Polymorphism and Risk of Myocardial Infarction. Medicine (United States), 2014, 93, e160.	1.0	8
270	Temas de actualidad en cardiologÃa: riesgo vascular y rehabilitaciÃ³n cardiaca. Revista Espanola De Cardiologia, 2014, 67, 203-210.	1.2	13

#	Article	IF	Citations
271	Reversal of atherosclerosis with apolipoprotein A1: Back to basics. Atherosclerosis, 2014, 232, 217-219.	0.8	7
272	HDL does not influence the polarization of human monocytes toward an alternative phenotype. International Journal of Cardiology, 2014, 172, 179-184.	1.7	23
273	Comparative prognostic value of low-density lipoprotein cholesterol and C-reactive protein in patients with stable coronary artery disease treated with percutaneous coronary intervention and chronic statin therapy. Cardiovascular Revascularization Medicine, 2014, 15, 131-136.	0.8	14
274	Flow-mediated dilation, carotid wall thickness and HDL function in subjects with hyperalphalipoproteinemia. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 777-783.	2.6	28
275	Triglyceride-to-HDL cholesterol ratio. Herz, 2014, 39, 105-110.	1.1	31
276	Current perspectives in genetic cardiovascular disorders: from basic to clinical aspects. Heart and Vessels, 2014, 29, 129-141.	1.2	48
277	Association between objectively assessed sedentary time and physical activity with metabolic risk factors among people with recently diagnosed type 2 diabetes. Diabetologia, 2014, 57, 73-82.	6.3	88
278	Novel Therapies Focused on the High-Density Lipoprotein Particle. Circulation Research, 2014, 114, 193-204.	4.5	34
279	Genetic association of lipid metabolism related SNPs with myocardial infarction in the Pakistani population. Molecular Biology Reports, 2014, 41, 1545-1552.	2.3	9
280	Residual macrovascular risk in 2013: what have we learned?. Cardiovascular Diabetology, 2014, 13, 26.	6.8	149
282	Effects of Native and Myeloperoxidase-Modified Apolipoprotein A-I on Reverse Cholesterol Transport and Atherosclerosis in Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 779-789.	2.4	120
283	Association of Low-Frequency and Rare Coding-Sequence Variants with Blood Lipids and Coronary Heart Disease in 56,000 Whites and Blacks. American Journal of Human Genetics, 2014, 94, 223-232.	6.2	287
284	Advances in the Understanding of Plaque Composition andÂTreatment Options. Journal of the American College of Cardiology, 2014, 63, 1604-1616.	2.8	45
285	Future of Cholesteryl Ester Transfer Protein Inhibitors. Annual Review of Medicine, 2014, 65, 385-403.	12.2	62
287	Update in Cardiology: Vascular Risk and Cardiac Rehabilitation. Revista Espanola De Cardiologia (English Ed), 2014, 67, 203-210.	0.6	12
288	Obesity and Cardiovascular Disease. , 2014, , 285-294.		0
289	HDL-targeted therapies: progress, failures and future. Nature Reviews Drug Discovery, 2014, 13, 445-464.	46.4	289
290	High-Density Lipoproteins in the Prevention of Cardiovascular Disease: Changing the Paradigm. Clinical Pharmacology and Therapeutics, 2014, 96, 48-56.	4.7	60

#	Article	IF	Citations
291	Anti-Psoriatic Therapy Recovers High-Density Lipoprotein Composition and Function. Journal of Investigative Dermatology, 2014, 134, 635-642.	0.7	70
292	Should low high-density lipoprotein cholesterol (HDL-C) be treated?. Best Practice and Research in Clinical Endocrinology and Metabolism, 2014, 28, 353-368.	4.7	61
293	Importance of Evaluating Cell Cholesterol Influx With Efflux in Determining the Impact of Human Serum on Cholesterol Metabolism and Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 17-25.	2.4	42
294	ATP-Binding Cassette Transporters, Atherosclerosis, and Inflammation. Circulation Research, 2014, 114, 157-170.	4.5	206
295	High-Density Lipoprotein and Atherosclerosis Regression. Circulation Research, 2014, 114, 205-213.	4.5	145
296	Cardioprotective functions of HDLs. Journal of Lipid Research, 2014, 55, 168-179.	4.2	237
297	High-Density Lipoprotein. Circulation Research, 2014, 114, 171-182.	4.5	236
298	Cholesteryl Ester Transfer Protein Polymorphisms, Statin Use, and Their Impact on Cholesterol Levels and Cardiovascular Events. Clinical Pharmacology and Therapeutics, 2014, 95, 314-320.	4.7	12
299	An abundant dysfunctional apolipoprotein A1 in human atheroma. Nature Medicine, 2014, 20, 193-203.	30.7	316
301	Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patients. BMJ, The, 2014, 349, g4379-g4379.	6.0	361
302	Tolerability, pharmacokinetics and pharmacodynamics of <scp>TA</scp>â€8995, a selective cholesteryl ester transfer protein (<scp>CETP</scp>) inhibitor, in healthy subjects. British Journal of Clinical Pharmacology, 2014, 78, 498-508.	2.4	27
304	<scp>LDL</scp> receptor/lipoprotein recognition: endosomal weakening of ApoB and ApoE binding to the convex face of the <scp>LR</scp>5 repeat. FEBS Journal, 2014, 281, 1534-1546.	4.7	30
305	Longitudinal changes in highâ€density lipoprotein cholesterol and cardiovascular events in older adults. Clinical Endocrinology, 2014, 80, 662-670.	2.4	6
306	Role of Dietary Fats in Modulating Cardiometabolic Risk During Moderate Weight Gain: A Randomized Doubleâ€Blind Overfeeding Trial (LIPOGAIN Study). Journal of the American Heart Association, 2014, 3, e001095.	3.7	40
307	Small Dense Low-Density Lipoprotein-Cholesterol Concentrations Predict Risk for Coronary Heart Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1069-1077.	2.4	386
308	HDL-C vs HDL-P: How Changing One Letter Could Make a Difference in Understanding the Role of High-Density Lipoprotein in Disease. Clinical Chemistry, 2014, 60, e1-e3.	3.2	24
309	Genetics of lipid traits: Genome-wide approaches yield new biology and clues to causality in coronary artery disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 2010-2020.	3.8	9
310	Genetic association with low concentrations of high density lipoprotein-cholesterol in a pediatric population of the Middle East and North Africa: The CASPIAN-III study. Atherosclerosis, 2014, 237, 273-278.	0.8	13

#	Article	IF	Citations
311	Is Lp(a) Ready for Prime Time?â^—. Journal of the American College of Cardiology, 2014, 64, 861-862.	2.8	2
312	HDL in CKD: How Good Is the â€œGood Cholesterol?â€• Journal of the American Society of Nephrology: JASN, 2014, 25, 871-874.	6.1	15
313	HDL Cholesterol Efflux Capacity and Incident Cardiovascular Events. New England Journal of Medicine, 2014, 371, 2383-2393.	27.0	1,113
314	In vivo efficacy of HDL-like nanolipid particles containing multivalent peptide mimetics of apolipoprotein A-I. Journal of Lipid Research, 2014, 55, 2053-2063.	4.2	33
315	Treating low high-density lipoprotein cholesterol: what is the evidence?. Therapeutic Advances in Endocrinology and Metabolism, 2014, 5, 10-17.	3.2	8
316	High-density lipoprotein subfractions and carotid plaque: The Northern Manhattan Study. Atherosclerosis, 2014, 237, 163-168.	0.8	29
317	Reverse Cholesterol Transport in HDL Metabolism. , 2014, , 65-101.		0
318	Gene-Lifestyle Interactions in Complex Diseases: Design and Description of the GLACIER and VIKING Studies. Current Nutrition Reports, 2014, 3, 400-411.	4.3	15
319	Novel metabolic biomarkers of cardiovascular disease. Nature Reviews Endocrinology, 2014, 10, 659-672.	9.6	85
320	Insulin-like growth factor-II and insulin-like growth factor binding protein-2 prospectively predict longitudinal elevation of HDL-cholesterol in type 2 diabetes. Annals of Clinical Biochemistry, 2014, 51, 468-475.	1.6	12
321	A rare variant in APOC3 is associated with plasma triglyceride and VLDL levels in Europeans. Nature Communications, 2014, 5, 4871.	12.8	62
322	Serum concentrations of cholesterol, apolipoprotein A-I and apolipoprotein B in a total of 1694 meat-eaters, fish-eaters, vegetarians and vegans. European Journal of Clinical Nutrition, 2014, 68, 178-183.	2.9	80
323	Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: Results from a multi-center study. Journal of Steroid Biochemistry and Molecular Biology, 2014, 143, 424-433.	2.5	14
324	Induction of hepatic apolipoprotein A-I gene expression by the isoflavones quercetin and isoquercetrin. Life Sciences, 2014, 110, 8-14.	4.3	13
325	Low Nonfasting Triglycerides and Reduced All-Cause Mortality: A Mendelian Randomization Study. Clinical Chemistry, 2014, 60, 737-746.	3.2	147
326	MR_predictor: a simulation engine for Mendelian Randomization studies. Bioinformatics, 2014, 30, 3432-3434.	4.1	7
327	Genetic predisposition to obesity and risk of subclinical atherosclerosis. Gene, 2014, 549, 223-227.	2.2	4
328	Apolipoprotein E derived HDL mimetic peptide ATI-5261 promotes nascent HDL formation and reverse cholesterol transport in vitro. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2014, 1841, 1498-1512.	2.4	25

#	Article	IF	Citations
329	MicroRNA Control of High-Density Lipoprotein Metabolism and Function. Circulation Research, 2014, 114, 183-192.	4.5	73
330	Hepatic Apolipoprotein M (ApoM) Overexpression Stimulates Formation of Larger ApoM/Sphingosine 1-Phosphate-enriched Plasma High Density Lipoprotein. Journal of Biological Chemistry, 2014, 289, 2801-2814.	3.4	66
331	Atheroprotective role of high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P). Cardiovascular Research, 2014, 103, 395-404.	3.8	92
332	High-density lipoproteins as modulators of endothelial cell functions: alterations in patients with coronary artery disease. Cardiovascular Research, 2014, 103, 350-361.	3.8	83
333	Hyperuricaemia: the unintended consequence of insulin resistance/compensatory hyperinsulinaemia. Philanthropy gone awry. Journal of Internal Medicine, 2014, 276, 196-198.	6.0	2
334	HDL and cardiovascular disease. Lancet, The, 2014, 384, 618-625.	13.7	540
335	Dyslipidaemia in perspective. Lancet, The, 2014, 384, 566-568.	13.7	4
336	Triglycerides and cardiovascular disease. Lancet, The, 2014, 384, 626-635.	13.7	1,005
337	Testing Cardiovascular Drug Safety and Efficacy in Randomized Trials. Circulation Research, 2014, 114, 1156-1161.	4.5	5
338	Diabetic dyslipidemia. Metabolism: Clinical and Experimental, 2014, 63, 1469-1479.	3.4	344
339	Stem Cell Lineage Specification: You Become What You Eat. Cell Metabolism, 2014, 20, 389-391.	16.2	7
340	HDL inhibits the effects of oxidized phospholipids on endothelial cell gene expression via multiple mechanisms. Journal of Lipid Research, 2014, 55, 1678-1692.	4.2	6
341	HDL Cholesterol Is Not Associated with Lower Mortality in Patients with Kidney Dysfunction. Journal of the American Society of Nephrology: JASN, 2014, 25, 1073-1082.	6.1	86
342	A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics. Psychopharmacology, 2014, 231, 4703-4710.	3.1	31
343	Niacin and HDL Cholesterol â€" Time to Face Facts. New England Journal of Medicine, 2014, 371, 271-273.	27.0	43
344	Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. New England Journal of Medicine, 2014, 371, 203-212.	27.0	1,367
345	Rare coding variation in paraoxonase-1 is associated with ischemic stroke in the NHLBI Exome Sequencing Project. Journal of Lipid Research, 2014, 55, 1173-1178.	4.2	23
346	microRNAs and HDL life cycle. Cardiovascular Research, 2014, 103, 414-422.	3.8	47

#	Article	IF	Citations
347	LDL-cholesterol versus non-HDL-to-HDL-cholesterol ratio and risk for coronary heart disease in type 2 diabetes. European Journal of Preventive Cardiology, 2014, 21, 1420-1428.	1.8	39
348	HDL and cholesterol: life after the divorce?. Journal of Lipid Research, 2014, 55, 4-12.	4.2	72
349	Molecules That Mimic Apolipoprotein A-I: Potential Agents for Treating Atherosclerosis. Journal of Medicinal Chemistry, 2014, 57, 2169-2196.	6.4	56
350	Apolipoprotein A-I and Cholesterol Efflux. Circulation Research, 2014, 114, 1681-1683.	4.5	17
351	DHA-enriched highâ€“oleic acid canola oil improves lipid profile and lowers predicted cardiovascular disease risk in the canola oil multicenter randomized controlled trial. American Journal of Clinical Nutrition, 2014, 100, 88-97.	4.7	91
352	HDL: To Treat or Not To Treat?. Current Atherosclerosis Reports, 2014, 16, 429.	4.8	12
353	Towards a Molecular Systems Model of Coronary Artery Disease. Current Cardiology Reports, 2014, 16, 488.	2.9	19
354	Biomarkers of Coronary Artery Disease: The Promise of the Transcriptome. Current Cardiology Reports, 2014, 16, 513.	2.9	29
355	Using genetic variation for establishing causality of cardiovascular risk factors: overcoming confounding and reverse causality. Netherlands Heart Journal, 2014, 22, 186-189.	0.8	10
356	Dusty Punch Cards and an Eternal Enigma: High-Density Lipoproteins and Atherosclerosis. Drugs, 2014, 74, 513-520.	10.9	0
357	Effects of apolipoprotein A5 haplotypes on the ratio of triglyceride to high-density lipoprotein cholesterol and the risk for metabolic syndrome in Koreans. Lipids in Health and Disease, 2014, 13, 45.	3.0	15
358	Loss-of-Function Mutations inAPOC3and Risk of Ischemic Vascular Disease. New England Journal of Medicine, 2014, 371, 32-41.	27.0	749
359	Understanding high-density lipoprotein function in disease: Recent advances in proteomics unravel the complexity of its composition and biology. Progress in Lipid Research, 2014, 56, 36-46.	11.6	96
360	Mendelian Disorders of High-Density Lipoprotein Metabolism. Circulation Research, 2014, 114, 124-142.	4.5	43
361	APOC3, Coronary Disease, and Complexities of Mendelian Randomization. Cell Metabolism, 2014, 20, 387-389.	16.2	34
362	Inflammation, oxidative stress, and cardiovascular disease risk factors in adults with cystic fibrosis. Free Radical Biology and Medicine, 2014, 76, 261-277.	2.9	53
363	SR-BI/CD36 Chimeric Receptors Define Extracellular Subdomains of SR-BI Critical for Cholesterol Transport. Biochemistry, 2014, 53, 6173-6182.	2.5	26
364	Searching for a successful HDL-based treatment strategy. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2014, 1841, 162-167.	2.4	22

#	Article	IF	Citations
365	Clinical impact of direct HDLc and LDLc method bias in hypertriglyceridemia. A simulation study of the EAS-EFLM Collaborative Project Group. Atherosclerosis, 2014, 233, 83-90.	0.8	52
366	Mendelian randomization in health research: Using appropriate genetic variants and avoiding biased estimates. Economics and Human Biology, 2014, 13, 99-106.	1.7	134
367	Bioavailable dietary phosphate, a mediator of cardiovascular disease, may be decreased with plant-based diets, phosphate binders, niacin, and avoidance of phosphate additives. Nutrition, 2014, 30, 739-747.	2.4	21
368	HDL-cholesterol in coronary artery disease risk: Function or structure?. Clinica Chimica Acta, 2014, 429, 111-122.	1.1	58
369	Five-Year Incidence, Progression, and Risk Factors for Age-Related Macular Degeneration. Ophthalmology, 2014, 121, 1766-1772.	5.2	79
370	Treatment with omega-3 fatty acid ethyl-ester alters fatty acid composition of lipoproteins in overweight or obese adults with insulin resistance. Prostaglandins Leukotrienes and Essential Fatty Acids, 2014, 90, 69-75.	2.2	12
371	Macrophage-Independent Regulation of Reverse Cholesterol Transport by Liver X Receptors. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1650-1660.	2.4	26
372	Role of HDL in Those with Diabetes. Current Cardiology Reports, 2014, 16, 512.	2.9	36
373	The Effect of Nutritional Supplements on Serum High-Density Lipoprotein Cholesterol and Apolipoprotein A-I. American Journal of Cardiovascular Drugs, 2014, 14, 253-274.	2.2	14
374	Genetics of Coronary Artery Disease. Circulation Research, 2014, 114, 1890-1903.	4.5	111
377	Effects of bariatric surgery on HDL structure and functionality: results from a prospective trial. Journal of Clinical Lipidology, 2014, 8, 408-417.	1.5	33
379	Lymphatic transport of high-density lipoproteins and chylomicrons. Journal of Clinical Investigation, 2014, 124, 929-935.	8.2	160
380	Treatment of dyslipidemia. F1000prime Reports, 2014, 6, 17.	5.9	10
381	Unraveling New Therapeutic Targets of Coronary Artery Disease by Genetic Approaches. Circulation Journal, 2014, 79, 8-14.	1.6	6
382	Sphingomyelin regulation of plasma membrane asymmetry, efflux and reverse cholesterol transport. Clinical Lipidology, 2014, 9, 383-393.	0.4	6
383	Cholesterol associated to low density lipoproteins (LDL) and vascular risk reduction. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A new therapeutic target. Medicina ClÃnica (English Edition), 2015, 145, 67-69.	0.2	0
384	Perfil clÃnico e resultados da intervenÃ§Ã£o coronÃ¡ria percutÂ¢nea primÃ¡ria em pacientes jovens. Revista Brasileira De Cardiologia Invasiva, 2015, 23, 48-51.	0.1	2
385	Progress and promise in understanding the genetic basis of common diseases. Proceedings of the Royal Society B: Biological Sciences, 2015, 282, 20151684.	2.6	147

#	Article	IF	Citations
386	The many weak instruments problem and Mendelian randomization. Statistics in Medicine, 2015, 34, 454-468.	1.6	112
387	Adiponectin Genotype, Blood Pressures, and Arterial Stiffness: The Cardiometabolic Risk in Chinese (CRC) Study. Journal of Clinical Hypertension, 2015, 17, 395-400.	2.0	7
388	SEQMINER: An Râ€Package to Facilitate the Functional Interpretation of Sequenceâ€Based Associations. Genetic Epidemiology, 2015, 39, 619-623.	1.3	31
389	Genetics of coronary heart disease: towards causal mechanisms, novel drug targets and more personalized prevention. Journal of Internal Medicine, 2015, 278, 433-446.	6.0	30
392	Exploring causal associations of alcohol with cardiovascular and metabolic risk factors in a Chinese population using Mendelian randomization analysis. Scientific Reports, 2015, 5, 14005.	3.3	38
393	Low High-Density Lipoprotein and Risk of Myocardial Infarction. Clinical Medicine Insights: Cardiology, 2015, 9, CMC.S26624.	1.8	19
394	A review of the clinical evidence related to early treatment of elevated LDL for cardiovascular primary prevention: TableÂ1. Evidence-Based Medicine, 2015, 20, 162-169.	0.6	7
395	Clinical profile and outcomes of primary percutaneous coronary intervention in young patients. Revista Brasileira De Cardiologia Invasiva (English Edition), 2015, 23, 48-51.	0.1	4
396	Commentary on models of biobanks and implications for reproductive health innovation. Monash Bioethics Review, 2015, 33, 258-264.	0.8	1
397	Systems analysis of gene ontology and biological pathways involved in post-myocardial infarction responses. BMC Genomics, 2015, 16, S18.	2.8	9
398	Apolipoprotein A-I mimetic peptides in dyslipidemia and atherosclerosis: an investigational timeline. Clinical Lipidology, 2015, 10, 467-473.	0.4	0
399	Complementary phenolâ€enriched olive oil improves HDL characteristics in hypercholesterolemic subjects. A randomized, doubleâ€blind, crossover, controlled trial. The VOHF study. Molecular Nutrition and Food Research, 2015, 59, 1758-1770.	3.3	43
400	Novel therapeutics in hypertriglyceridemia. Current Opinion in Lipidology, 2015, 26, 484-491.	2.7	35
401	Some imminent but overlooked preanalytical and analytical challenges currently facing biomarkers and companion diagnostics. Annals of the New York Academy of Sciences, 2015, 1346, 63-70.	3.8	8
402	It's Time to Reassess the Highâ€Density Lipoprotein (HDL) Hypothesis: CSL112, a Novel Promising Reconstituted HDL Formulation. Journal of the American Heart Association, 2015, 4, e002371.	3.7	9
403	Impaired antioxidant HDL function is associated with premature myocardial infarction. European Journal of Clinical Investigation, 2015, 45, 731-738.	3.4	21
404	Lack of association of apolipoprotein E (Apo E) polymorphism with the prevalence of metabolic syndrome: the National Heart, Lung and Blood Institute Family Heart Study. Diabetes/Metabolism Research and Reviews, 2015, 31, 582-587.	4.0	5
405	High-Density Lipoprotein Processing and Premature Cardiovascular Disease. Methodist DeBakey Cardiovascular Journal, 2021, 11, 181.	1.0	4

#	Article	IF	Citations
406	Blackâ€“White Differences in the Relationship Between Alcohol Drinking Patterns and Mortality Among US Men and Women. American Journal of Public Health, 2015, 105, S534-S543.	2.7	43
407	HDL-cholesterol and cardiovascular disease. Current Opinion in Cardiology, 2015, 30, 536-542.	1.8	59
408	What does the future hold for cholesteryl ester transfer protein inhibition?. Current Opinion in Lipidology, 2015, 26, 526-535.	2.7	1
409	The Regression of Atherosclerosis: The Power of Multimodality Imaging. Journal of Clinical & Experimental Cardiology, 2015, 06, .	0.0	1
410	Single-nucleotide polymorphisms: a perspective of cardiovascular prevention. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2015, 61, 458-468.	0.7	3
411	Causal Inference in the Age of Decision Medicine. Journal of Data Mining in Genomics & Proteomics, 2015, 06, .	0.5	12
412	An Efficient Single Phase Method for the Extraction of Plasma Lipids. Metabolites, 2015, 5, 389-403.	2.9	136
413	Advances in the Study of the Antiatherogenic Function and Novel Therapies for HDL. International Journal of Molecular Sciences, 2015, 16, 17245-17272.	4.1	10
414	The role of the lymphatic system in cholesterol transport. Frontiers in Pharmacology, 2015, 6, 182.	3.5	58
415	HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis. Frontiers in Pharmacology, 2015, 6, 187.	3.5	32
416	Dysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and Lipidomics. Cholesterol, 2015, 2015, 1-22.	1.6	30
419	High-density lipoprotein cholesterol. Current Opinion in Endocrinology, Diabetes and Obesity, 2015, 22, 133-141.	2.3	12
420	Anthocyanin-rich black elderberry extract improves markers of HDL function and reduces aortic cholesterol in hyperlipidemic mice. Food and Function, 2015, 6, 1278-1287.	4.6	69
421	Mendelian Randomization Studies for a Continuous Exposure Under Case-Control Sampling. American Journal of Epidemiology, 2015, 181, 440-449.	3.4	9
422	Cholesteryl Ester-Transfer Protein Inhibitors Stimulate Aldosterone Biosynthesis in Adipocytes through Nox-Dependent Processes. Journal of Pharmacology and Experimental Therapeutics, 2015, 353, 27-34.	2.5	19
423	High-Density Lipoprotein (HDL) Phospholipid Content and Cholesterol Efflux Capacity Are Reduced in Patients With Very High HDL Cholesterol and Coronary Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1515-1519.	2.4	83
425	Mendelian randomization studies: a review of the approaches used and the quality of reporting. International Journal of Epidemiology, 2015, 44, 496-511.	1.9	256
426	Yes, hyperglycaemia is indeed a modifiable cardiac risk factor: so says Mendel. European Heart Journal, 2015, 36, 1424-1427.	2.2	5

#	Article	IF	Citations
427	Novel methodologies for biomarker discovery in atherosclerosis. European Heart Journal, 2015, 36, 2635-2642.	2.2	174
428	Triglyceride-Rich Lipoproteins and Coronary Artery Disease Risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, e3-9.	2.4	61
429	A Mendelian randomization study of the effect of type-2 diabetes on coronary heart disease. Nature Communications, 2015, 6, 7060.	12.8	111
430	Multivariable Mendelian Randomization: The Use of Pleiotropic Genetic Variants to Estimate Causal Effects. American Journal of Epidemiology, 2015, 181, 251-260.	3.4	909
431	Cholesterol Efflux Capacity as a Novel Biomarker for Incident Cardiovascular Events. Circulation Research, 2015, 116, 1646-1648.	4.5	6
432	Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raisingA systematic review and meta-analysis of relevant preclinical studies and clinical trials. European Journal of Pharmacology, 2015, 763, 48-63.	3.5	44
433	Anacetrapib in familial hypercholesterolaemia: pros and cons. Lancet, The, 2015, 385, 2124-2126.	13.7	4
434	Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet, The, 2015, 386, 452-460.	13.7	173
435	Twenty-five years of statins: where do we go from here?. Clinical Lipidology, 2015, 10, 33-45.	0.4	2
436	Can Genetics Modify the Influence of Healthy Lifestyle on Lipids in the Context of Obesity and Type 2 Diabetes?. Current Cardiovascular Risk Reports, 2015, 9, 1.	2.0	1
437	Increasing HDL-cholesterol and prevention of atherosclerosis: A critical perspective. Atherosclerosis Supplements, 2015, 18, 109-111.	1.2	37
438	Lipoproteins and Cardiovascular Disease Risk. Contemporary Endocrinology, 2015, , 57-65.	0.1	0
439	Differential effect of metabolic syndrome on various parameters of arterial stiffness. Blood Pressure, 2015, 24, 206-211.	1.5	5
440	Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein. Archives of Medical Research, 2015, 46, 379-391.	3.3	42
441	Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. Lancet Diabetes and Endocrinology,the, 2015, 3, 507-513.	11.4	389
442	High-density lipoprotein-based drug discovery for treatment of atherosclerosis. Expert Opinion on Drug Discovery, 2015, 10, 841-855.	5.0	8
443	MeRP: a high-throughput pipeline for Mendelian randomization analysis. Bioinformatics, 2015, 31, 957-959.	4.1	7
444	Mendelian randomization: where are we now and where are we going?. International Journal of Epidemiology, 2015, 44, 379-388.	1.9	155

#	Article	IF	Citations
445	The Swedish CArdioPulmonary BioImage Study: objectives and design. Journal of Internal Medicine, 2015, 278, 645-659.	6.0	239
446	AIBP: A Novel Molecule at the Interface of Cholesterol Transport, Angiogenesis, and Atherosclerosis. Methodist DeBakey Cardiovascular Journal, 2015, 11, 160-165.	1.0	12
447	Serum Lipid Levels, Body Mass Index, and Their Role in Coronary Artery Calcification. Circulation: Cardiovascular Genetics, 2015, 8, 327-333.	5.1	17
448	Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib. Journal of the American College of Cardiology, 2015, 66, 2201-2210.	2.8	105
449	The past, present and future of lipid-lowering therapy. Clinical Lipidology, 2015, 10, 481-498.	0.4	6
450	GWAS as a Driver of Gene Discovery in Cardiometabolic Diseases. Trends in Endocrinology and Metabolism, 2015, 26, 722-732.	7.1	29
451	Humble kidneys predict mighty heart troubles. Lancet Diabetes and Endocrinology,the, 2015, 3, 489-491.	11.4	16
452	Lipid phenotypes at the extremes of high-density lipoprotein cholesterol: The very large database of lipids-9. Journal of Clinical Lipidology, 2015, 9, 511-518.e5.	1.5	5
453	High-Density Lipoproteins in Stroke. Handbook of Experimental Pharmacology, 2015, 224, 509-526.	1.8	15
454	Quantification of HDL Proteins, Cardiac Events, and Mortality in Patients with Type 2 Diabetes on Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 224-231.	4.5	54
455	A genome-wide association study of saturated, mono- and polyunsaturated red blood cell fatty acids in the Framingham Heart Offspring Study. Prostaglandins Leukotrienes and Essential Fatty Acids, 2015, 94, 65-72.	2.2	76
456	The mathematical limits of genetic prediction for complex chronic disease. Journal of Epidemiology and Community Health, 2015, 69, 574-579.	3.7	21
457	Indolinyl-Thiazole Based Inhibitors of Scavenger Receptor-BI (SR-BI)-Mediated Lipid Transport. ACS Medicinal Chemistry Letters, 2015, 6, 375-380.	2.8	11
458	High-density lipoprotein particle concentration and subclinical atherosclerosis of the carotid arteries in Japanese men. Atherosclerosis, 2015, 239, 444-450.	0.8	18
460	Zebrafish as a model for apolipoprotein biology: comprehensive expression analysis and a role for ApoA-IV in regulating food intake. DMM Disease Models and Mechanisms, 2015, 8, 295-309.	2.4	88
461	HDL Cholesterol/HDL Particle Ratio. Journal of the American College of Cardiology, 2015, 65, 364-366.	2.8	6
462	Human genetics of HDL: Insight into particle metabolism and function. Progress in Lipid Research, 2015, 58, 14-25.	11.6	45
463	The TMAO-Generating Enzyme Flavin Monooxygenase 3 Is a Central Regulator of Cholesterol Balance. Cell Reports, 2015, 10, 326-338.	6.4	307

#	Article	IF	Citations
464	Statins and type 2 diabetes: genetic studies on target. Lancet, The, 2015, 385, 310-312.	13.7	24
465	Mendelian randomisation meta-analysis sheds doubt on protective associations between â€˜moderateâ€™ alcohol consumption and coronary heart disease. Evidence-Based Medicine, 2015, 20, 38-38.	0.6	16
466	Antisense Oligonucleotides, microRNAs, and Antibodies. Handbook of Experimental Pharmacology, 2015, 224, 649-689.	1.8	7
467	High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk. BBA Clinical, 2015, 3, 175-188.	4.1	140
468	Analysis of a cardiovascular disease genetic risk score in the Diabetes Heart Study. Acta Diabetologica, 2015, 52, 743-751.	2.5	11
469	Cardiovascular disease and osteoarthritis: common pathways and patient outcomes. European Journal of Clinical Investigation, 2015, 45, 405-414.	3.4	90
470	Underappreciated Opportunities for High-Density Lipoprotein Particles in Risk Stratification and Potential Targets of Therapy. Cardiovascular Drugs and Therapy, 2015, 29, 41-50.	2.6	16
471	A Systems Genetics Approach to Dyslipidemia in Children and Adolescents. OMICS A Journal of Integrative Biology, 2015, 19, 248-259.	2.0	5
472	Lipid Management. , 2015, , .		1
473	Applying genetics in inflammatory disease drug discovery. Drug Discovery Today, 2015, 20, 1176-1181.	6.4	6
475	Mendelian Randomization versus Path Models: Making Causal Inferences in Genetic Epidemiology. Human Heredity, 2015, 79, 194-204.	0.8	18
476	Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk?. Circulation, 2015, 132, 423-432.	1.6	24
478	Statins and Ezetimibe. , 2015, , 25-36.		1
479	The evolving role of CETP inhibition: beyond HDL cholesterol. Lancet, The, 2015, 386, 412-414.	13.7	11
480	Butter increased total and LDL cholesterol compared with olive oil but resulted in higher HDL cholesterol compared with a habitual diet. American Journal of Clinical Nutrition, 2015, 102, 309-315.	4.7	47
481	Genetic variants primarily associated with type 2 diabetes are related to coronary artery disease risk. Atherosclerosis, 2015, 241, 419-426.	0.8	26
482	Surface Density-Induced Pleating of a Lipid Monolayer Drives Nascent High-Density Lipoprotein Assembly. Structure, 2015, 23, 1214-1226.	3.3	36
483	Etiology-specific assessment of predictors of long-term survival in chronic systolic heart failure. IJC Heart and Vasculature, 2015, 7, 61-68.	1.1	5

#	Article	IF	Citations
484	Biogenesis of Nascent High Density Lipoprotein Particles. Structure, 2015, 23, 1153-1154.	3.3	3
485	High-density lipoprotein cholesterol, a protective or a risk factor for developing coronary heart disease? Tehran Lipid and Glucose Study. Journal of Clinical Lipidology, 2015, 9, 553-558.	1.5	11
486	Continuous decline in mortality from coronary heart disease in Japan despite a continuous and marked rise in total cholesterol: Japanese experience after the Seven Countries Study. International Journal of Epidemiology, 2015, 44, 1614-1624.	1.9	36
487	Increased cholesterol efflux capacity in metabolic syndrome: Relation with qualitative alterations in HDL and LCAT. Atherosclerosis, 2015, 242, 236-242.	0.8	30
488	Cholesteryl Ester Transfer Protein Inhibition Enhances Endothelial Repair and Improves Endothelial Function in the Rabbit. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 628-636.	2.4	16
489	HDL function as a predictor of coronary heart disease events: time to re-assess the HDL hypothesis?. Lancet Diabetes and Endocrinology,the, 2015, 3, 488-489.	11.4	5
490	LDL, HDL, VLDL, and CVD Prevention: Lessons from Genetics?. Current Cardiology Reports, 2015, 17, 610.	2.9	11
491	Dimethylglycine Deficiency and the Development of Diabetes. Diabetes, 2015, 64, 3010-3016.	0.6	61
493	Apolipoprotein M. Clinica Chimica Acta, 2015, 446, 21-29.	1.1	46
494	La mayor adherencia a un patrÃ³n de dieta mediterrÃ¡nea se asocia a una mejora del perfil lipÃdico plasmÃ¡tico: la cohorte del Aragon Health Workers Study. Revista Espanola De Cardiologia, 2015, 68, 290-297.	1.2	46
495	Optimizing statin treatment. Trends in Cardiovascular Medicine, 2015, 25, 226-227.	4.9	0
496	Low protective PON1 lactonase activity in an Arab population with high rates of coronary heart disease and diabetes. Clinica Chimica Acta, 2015, 445, 41-47.	1.1	12
497	Genome-wide association studies of late-onset cardiovascular disease. Journal of Molecular and Cellular Cardiology, 2015, 83, 131-141.	1.9	42
498	LDL cholesterol still a problem in old age? A Mendelian randomization study. International Journal of Epidemiology, 2015, 44, 604-612.	1.9	42
499	Statins, atherosclerosis regression and HDL: Insights from within the plaque. International Journal of Cardiology, 2015, 189, 168-171.	1.7	15
501	New Challenges for HDL-Modifying Therapies as a Strategy to Lower Cardiovascular Disease Events in Statin-Treated Patients. Cardiovascular Drugs and Therapy, 2015, 29, 1-3.	2.6	5
502	Debate: Testosterone Therapy Reduces Cardiovascular Risk in Men with Diabetes. Against the Motion. Current Cardiovascular Risk Reports, 2015, 9, 1.	2.0	0
503	HDL from apoA1 transgenic mice expressing the 4WF isoform is resistant to oxidative loss of function. Journal of Lipid Research, 2015, 56, 653-664.	4.2	10

#	Article	IF	Citations
504	Targeting High-Density Lipoproteins: Increasing De Novo Production Versus Decreasing Clearance. Drugs, 2015, 75, 713-722.	10.9	14
505	Human FABP1 T94A variant enhances cholesterol uptake. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2015, 1851, 946-955.	2.4	21
506	Clinical benefit from pharmacological elevation of high-density lipoprotein cholesterol: meta-regression analysis. Heart, 2015, 101, 847-853.	2.9	15
507	Triglycerides on the rise: should we swap seats on the seesaw?. European Heart Journal, 2015, 36, 774-776.	2.2	71
508	Genetic Evidence for PLASMINOGEN as a Shared Genetic Risk Factor of Coronary Artery Disease and Periodontitis. Circulation: Cardiovascular Genetics, 2015, 8, 159-167.	5.1	74
509	Effect of Naturally Random Allocation toÂLower Low-Density Lipoprotein Cholesterol on the Risk of Coronary Heart Disease Mediated by Polymorphisms inÂNPC1L1, HMGCR, or Both. Journal of the American College of Cardiology, 2015, 65, 1552-1561.	2.8	324
510	Mendelian randomization of blood lipids for coronary heart disease. European Heart Journal, 2015, 36, 539-550.	2.2	567
511	In cross-sectional observations, dietary quality is not associated with CVD risk in women; in men the positive association is accounted for by BMI. British Journal of Nutrition, 2015, 113, 1244-1253.	2.3	18
512	HDL and Atherothrombotic Vascular Disease. Handbook of Experimental Pharmacology, 2015, 224, 369-403.	1.8	24
513	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1â€”Full Report. Journal of Clinical Lipidology, 2015, 9, 129-169.	1.5	632
514	Dietary Fat Intake Modifies the Effect of a Common Variant in the LIPC Gene on Changes in Serum Lipid Concentrations during a Long-Term Weight-Loss Intervention Trial. Journal of Nutrition, 2015, 145, 1289-1294.	2.9	33
515	Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: A meta-analysis of randomized controlled trials. International Journal of Cardiology, 2015, 191, 138-148.	1.7	39
516	Obesity and Ischemic Heart Disease. Circulation Research, 2015, 116, 570-571.	4.5	7
517	Novel method for reducing plasma cholesterol: a ligand replacement therapy. Clinical Lipidology, 2015, 10, 83-90.	0.4	1
518	Atherosclerosis: Recent trials, new targets and future directions. International Journal of Cardiology, 2015, 192, 72-81.	1.7	28
519	Cholesterol Efflux and Reverse Cholesterol Transport. Handbook of Experimental Pharmacology, 2015, 224, 181-206.	1.8	109
520	Prevention and Treatment of Atherosclerotic Vascular Disease: Hypolipidemic Agents. , 2015, , 589-611.		0
521	Epidemiology: Disease Associations and Modulators of HDL-Related Biomarkers. Handbook of Experimental Pharmacology, 2015, 224, 259-283.	1.8	5

#	Article	IF	Citations
522	A new model of reverse cholesterol transport: enTICEing strategies to stimulate intestinal cholesterol excretion. Trends in Pharmacological Sciences, 2015, 36, 440-451.	8.7	55
523	Mendelian Randomization: New Applications in the Coming Age of Hypothesis-Free Causality. Annual Review of Genomics and Human Genetics, 2015, 16, 327-350.	6.2	298
524	Greater Adherence to a Mediterranean Dietary Pattern Is Associated With Improved Plasma Lipid Profile: the Aragon Health Workers Study Cohort. Revista Espanola De Cardiologia (English Ed), 2015, 68, 290-297.	0.6	23
525	HDL â€“ Hope Dies Last?. Current Opinion in Lipidology, 2015, 26, 150-151.	2.7	0
526	Genome-wide enrichment analysis between endometriosis and obesity-related traits reveals novel susceptibility loci. Human Molecular Genetics, 2015, 24, 1185-1199.	2.9	71
527	Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin. European Heart Journal, 2015, 36, 39-50.	2.2	65
528	Recent developments in genome and exome-wide analyses of plasma lipids. Current Opinion in Lipidology, 2015, 26, 96-102.	2.7	24
529	HDL re-examined. Current Opinion in Lipidology, 2015, 26, 127-132.	2.7	35
530	Apolipoprotein C-III. Current Opinion in Endocrinology, Diabetes and Obesity, 2015, 22, 119-125.	2.3	87
531	Mendelian randomization supports causality between maternal hyperglycemia and epigenetic regulation of leptin gene in newborns. Epigenetics, 2015, 10, 342-351.	2.7	101
532	Circulating Cholesteryl Ester Transfer Protein and Coronary Heart Disease. Circulation: Cardiovascular Genetics, 2015, 8, 114-121.	5.1	31
533	Kidney Injury Molecule-1 and the Loss of Kidney Function in Diabetic Nephropathy: A Likely Causal Link in Patients With Type 1 Diabetes. Diabetes Care, 2015, 38, 1130-1137.	8.6	61
534	Disturbed Laminar Blood Flow Vastly Augments Lipoprotein Retention in the Artery Wall. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1928-1935.	2.4	23
535	An atlas of genetic correlations across human diseases and traits. Nature Genetics, 2015, 47, 1236-1241.	21.4	3,145
536	Food Consumption and its Impact on Cardiovascular Disease: Importance of Solutions Focused on the Globalized FoodÂSystem. Journal of the American College of Cardiology, 2015, 66, 1590-1614.	2.8	343
538	Evaluation of an association between plasma total homocysteine and schizophrenia by a Mendelian randomization analysis. BMC Medical Genetics, 2015, 16, 54.	2.1	44
539	Is Insulin Resistance a Feature of or a Primary Risk Factor for Cardiovascular Disease?. Current Diabetes Reports, 2015, 15, 105.	4.2	40
540	Four-year stability of anthropometric and cardio-metabolic parameters in a prospective cohort of older adults. Biomarkers in Medicine, 2015, 9, 109-122.	1.4	10

#	Article	IF	Citations
541	High-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after percutaneous coronary intervention: A report from the CREDO-Kyoto registry cohort-2. Atherosclerosis, 2015, 242, 632-638.	0.8	13
542	Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA. Journal of Lipid Research, 2015, 56, 703-712.	4.2	73
543	Has the leaning tower of presumed health benefits from â€˜moderateâ€™ alcohol use finally collapsed?. Addiction, 2015, 110, 726-727.	3.3	91
544	Acquired lecithin:cholesterol acyltransferase deficiency as a major factor in lowering plasma <scp>HDL</scp> levels in chronic kidney disease. Journal of Internal Medicine, 2015, 277, 552-561.	6.0	57
545	ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. Journal of Lipid Research, 2015, 56, 1308-1317.	4.2	165
546	Current Applications of Genetic Risk Scores to Cardiovascular Outcomes and Subclinical Phenotypes. Current Epidemiology Reports, 2015, 2, 180-190.	2.4	70
547	Evaluation of Moderate Alcohol Use With QT Interval and Heart Rate Using Mendelian Randomization Analysis Among Older Southern Chinese Men in the Guangzhou Biobank Cohort Study. American Journal of Epidemiology, 2015, 182, 320-327.	3.4	11
548	ApoA-I-Directed Therapies for the Management of Atherosclerosis. Current Atherosclerosis Reports, 2015, 17, 60.	4.8	14
549	Prevalence and incidence of dyslipidaemia among adults in Africa: a systematic review and meta-analysis protocol. BMJ Open, 2015, 5, e007404-e007404.	1.9	14
550	PLTP activity inversely correlates with CAAD: effects of PON1 enzyme activity and genetic variants on PLTP activity. Journal of Lipid Research, 2015, 56, 1351-1362.	4.2	15
551	Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial. American Heart Journal, 2015, 170, 1061-1069.	2.7	74
552	Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. Journal of the National Cancer Institute, 2015, 107, djv219.	6.3	99
553	Type 2 Diabetes Mellitus and Dyslipidemia. Contemporary Endocrinology, 2015, , 99-113.	0.1	2
554	A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrateâ€“statin combination therapy. Atherosclerosis Supplements, 2015, 19, 1-12.	1.2	66
555	Anti-atherogenic properties of high-density lipoproteins in psychiatric patients before and after two months of atypical anti-psychotic therapy. Journal of Psychopharmacology, 2015, 29, 1262-1270.	4.0	5
556	Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low High-Density Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation. Clinical Infectious Diseases, 2015, 61, 840-849.	5.8	19
557	New and Emerging Biomarkers in Cardiovascular Disease. Current Diabetes Reports, 2015, 15, 88.	4.2	16
558	Insights into blood lipids from rare variant discovery. Current Opinion in Genetics and Development, 2015, 33, 25-31.	3.3	4

#	Article	IF	Citations
559	Cholesterol Metabolism in CKD. American Journal of Kidney Diseases, 2015, 66, 1071-1082.	1.9	84
560	HDL: Quality or quantity?. Atherosclerosis, 2015, 243, 121-123.	0.8	50
561	How an Artery Heals. Circulation Research, 2015, 117, 909-913.	4.5	10
562	â€œFleshing Outâ€•the Benefits of Adopting a Vegetarian Diet. Journal of the American Heart Association, 2015, 4, e002654.	3.7	4
563	Myocardial infarction in a 36-year-old man with combined ABCA1 and APOA-1 deficiency. Journal of Clinical Lipidology, 2015, 9, 396-399.	1.5	5
564	Targeting High-density Lipoproteins to Reduce Cardiovascular Risk: What Is the Evidence?. Clinical Therapeutics, 2015, 37, 2716-2731.	2.5	27
565	A selective review of the first 20 years of instrumental variables models in health-services research and medicine. Journal of Medical Economics, 2015, 18, 721-734.	2.1	18
566	Impact of Systemic Inflammation and Autoimmune Diseases on apoA-I and HDL Plasma Levels and Functions. Handbook of Experimental Pharmacology, 2015, 224, 455-482.	1.8	37
567	ApoA-I Mimetics. Handbook of Experimental Pharmacology, 2015, 224, 631-648.	1.8	33
568	Mendelian randomisation applied to drug development in cardiovascular disease: a review. Journal of Medical Genetics, 2015, 52, 71-79.	3.2	52
569	Away from home meals: associations with biomarkers of chronic disease and dietary intake in American adults, NHANES 2005â€“2010. International Journal of Obesity, 2015, 39, 820-827.	3.4	114
570	Inflammation modulation and cardiovascular disease prevention. European Journal of Preventive Cardiology, 2015, 22, 719-733.	1.8	47
571	Cardiac Drug Therapy. Contemporary Cardiology, 2015, , .	0.1	4
572	Implications of reverse cholesterol transport: Recent studies. Clinica Chimica Acta, 2015, 439, 154-161.	1.1	30
573	Paraoxonase 1 and HDL maturation. Clinica Chimica Acta, 2015, 439, 5-13.	1.1	78
574	HDL and atherosclerosis: Insights from inherited HDL disorders. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2015, 1851, 13-18.	2.4	56
575	Circulating lipid levels and risk of coronary artery disease in a large group of patients undergoing coronary angiography. Journal of Thrombosis and Thrombolysis, 2015, 39, 15-22.	2.1	13
576	HDL functionality and crystal-based sterile inflammation in atherosclerosis. Clinica Chimica Acta, 2015, 439, 18-23.	1.1	16

#	Article	IF	Citations
577	HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet, The, 2015, 385, 351-361.	13.7	562
578	Discovery of High-Density Lipoprotein Gene Targets from Classical Genetics to Genome-Wide Association Studies. , 2016, , 119-159.		2
579	Complications of Diabetes Mellitus. , 2016, , 1484-1581.		13
580	Role of Conventional Risk Factors in Genetic Susceptibility to Cardiovascular Diseases. , 2016, , 159-176.		0
581	High-density lipoprotein: quantity or quality?. Journal of Thoracic Disease, 2016, 8, 2975-2977.	1.4	8
582	High density lipoprotein cholesterol and risk of death. Journal of Thoracic Disease, 2016, 8, E1780-E1781.	1.4	2
583	Impact of variants in CETP and apo AI genes on serum HDL cholesterol levels in men and women from the Polish population. Archives of Medical Science, 2016, 6, 1188-1198.	0.9	3
584	HDL₂/HDL₃ Ratio Changes, Metabolic Syndrome Markers, and Other Factors in a Japanese Population. Journal of Atherosclerosis and Thrombosis, 2016, 23, 704-712.	2.0	6
585	Retinal Vessel Diameters and Their Relationship with Cardiovascular Risk and All-Cause Mortality in the Inter99 Eye Study: A 15-Year Follow-Up. Journal of Ophthalmology, 2016, 2016, 1-8.	1.3	29
586	Disorders of Lipid Metabolism. , 2016, , 1660-1700.		7
587	Leveraging genetically simple traits to identify small-effect variants for complex phenotypes. BMC Genomics, 2016, 17, 858.	2.8	42
588	Lipids in Coronary Heart Disease. , 2016, , 67-80.		0
589	Soy and Health Update: Evaluation of the Clinical and Epidemiologic Literature. Nutrients, 2016, 8, 754.	4.1	291
590	Human serum preÎ²1-high density lipoprotein levels are independently and negatively associated with coronary artery diseases. Nutrition and Metabolism, 2016, 13, 36.	3.0	14
591	Beneficial Effects of Exercise-Based Cardiac Rehabilitation on High-Density Lipoprotein-Mediated Cholesterol Efflux Capacity in Patients with Acute Coronary Syndrome. Journal of Atherosclerosis and Thrombosis, 2016, 23, 865-877.	2.0	23
592	High-Density Lipoprotein Mimetics: a Therapeutic Tool for Atherosclerotic Diseases. Journal of Atherosclerosis and Thrombosis, 2016, 23, 385-394.	2.0	19
593	Cholesterol as a Risk Factor for Subarachnoid Hemorrhage: A Systematic Review. PLoS ONE, 2016, 11, e0152568.	2.5	29
594	Association of Lipid-Related Genetic Variants with the Incidence of Atrial Fibrillation: The AFGen Consortium. PLoS ONE, 2016, 11, e0151932.	2.5	16

#	Article	IF	Citations
595	Metrics of High-Density Lipoprotein Function and Hospital Mortality in Acute Heart Failure Patients. PLoS ONE, 2016, 11, e0157507.	2.5	24
596	High-Density Lipoprotein, Lecithin: Cholesterol Acyltransferase, and Atherosclerosis. Endocrinology and Metabolism, 2016, 31, 223.	3.0	35
597	Genetics of Dyslipidemia. Arquivos Brasileiros De Cardiologia, 2016, 106, 434-8.	0.8	22
598	High-density lipoprotein cholesterol as a predictor of poor survival in patients with nasopharyngeal carcinoma. Oncotarget, 2016, 7, 42978-42987.	1.8	32
599	Serum Apo A-1 and Its Role as a Biomarker of Coronary Artery Disease. Cureus, 2016, 8, e941.	0.5	11
600	Hypertriglyceridemia, remnant cholesterol and cardiovascular risk: what genes can say. International Journal of Clinical Practice, 2016, 70, 142-146.	1.7	0
601	Olive oil phenolic compounds and high-density lipoprotein function. Current Opinion in Lipidology, 2016, 27, 47-53.	2.7	20
602	Rare Genetic Variants and High-Density Lipoprotein. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, e53-5.	2.4	11
603	Evaluation of an Association of Blood Homocysteine Levels With Gastric Cancer Risk From 27 Caseâ€“Control Studies. Medicine (United States), 2016, 95, e3700.	1.0	16
604	Small and medium sized HDL particles are protectively associated with coronary calcification in a cross-sectional population-based sample. Atherosclerosis, 2016, 251, 124-131.	0.8	29
605	The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity. Current Opinion in Lipidology, 2016, 27, 473-483.	2.7	348
606	Lipidâ€Free Apolipoprotein Aâ€I Reduces Progression of Atherosclerosis by Mobilizing Microdomain Cholesterol and Attenuating the Number of CD131 Expressing Cells: Monitoring Cholesterol Homeostasis Using the Cellular Ester to Total Cholesterol Ratio. Journal of the American Heart Association, 2016, 5, .	3.7	19
607	The Role of Host Genetics (and Genomics) in Tuberculosis. Microbiology Spectrum, 2016, 4, .	3.0	31
608	Distinct severity stages of obstructive sleep apnoea are correlated with unique dyslipidaemia: large-scale observational study. Thorax, 2016, 71, 347-355.	5.6	38
609	Cholesterol levels and long-term rates of community-acquired sepsis. Critical Care, 2016, 20, 408.	5.8	51
610	Meta-analysis of genome-wide association studies of HDL cholesterol response to statins. Journal of Medical Genetics, 2016, 53, 835-845.	3.2	28
611	The future of epidemiology: methods or matter?. International Journal of Epidemiology, 2016, 45, 1699-1716.	1.9	8
612	Serum calcium and risk of migraine: a Mendelian randomization study. Human Molecular Genetics, 2017, 26, ddw416.	2.9	26

#	Article	IF	Citations
613	Assessment of causality between serum gamma-glutamyltransferase and type 2 diabetes mellitus using publicly available data: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, dyw306.	1.9	24
614	Impaired Highâ€Ðensity Lipoprotein Antiâ€Oxidative Function Is Associated With Outcome in Patients With Chronic Heart Failure. Journal of the American Heart Association, 2016, 5, .	3.7	19
615	Genetics: Implications for Prevention and Management of Coronary Artery Disease. Journal of the American College of Cardiology, 2016, 68, 2797-2818.	2.8	92
616	Variants inANGPTL4and the Risk of Coronary Artery Disease. New England Journal of Medicine, 2016, 375, 2303-2306.	27.0	18
617	Genetics of Lipid and Lipoprotein Disorders and Traits. Current Genetic Medicine Reports, 2016, 4, 130-141.	1.9	61
618	The limitations of opportunistic epidemiology, pseudopod epidemiology. European Journal of Epidemiology, 2016, 31, 957-966.	5.7	3
619	Comprehensive Analysis of Established Dyslipidemia-Associated Loci in the Diabetes Prevention Program. Circulation: Cardiovascular Genetics, 2016, 9, 495-503.	5.1	5
620	Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV). American Heart Journal, 2016, 176, 83-92.	2.7	45
621	The effects of apolipoprotein B depletion on HDL subspecies composition and function. Journal of Lipid Research, 2016, 57, 674-686.	4.2	52
622	HDL functionality in reverse cholesterol transport â€" Challenges in translating data emerging from mouse models to human disease. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2016, 1861, 566-583.	2.4	73
623	Low-carbohydrate diets increase LDL-cholesterol, and thereby indicate increased risk of CVD. British Journal of Nutrition, 2016, 115, 2264-2266.	2.3	5
624	2016 European Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 2016, 37, 2315-2381.	2.2	5,370
625	Managing dyslipidaemia in type 2 diabetes mellitus. Best Practice and Research in Clinical Endocrinology and Metabolism, 2016, 30, 431-444.	4.7	14
626	Concentration of Smaller Highâ€Ðensity Lipoprotein Particle (HDLâ€P) Is Inversely Correlated With Carotid Intima Media Thickening After Confounder Adjustment: The Multi Ethnic Study of Atherosclerosis (MESA). Journal of the American Heart Association, 2016, 5, .	3.7	34
627	Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk. Current Cardiology Reports, 2016, 18, 65.	2.9	13
628	A loss-of-function variant in OSBPL1A predisposes to low plasma HDL cholesterol levels and impaired cholesterol efflux capacity. Atherosclerosis, 2016, 249, 140-147.	0.8	28
629	Detection and interpretation of shared genetic influences on 42 human traits. Nature Genetics, 2016, 48, 709-717.	21.4	990
630	VariantASGR1Associated with a Reduced Risk of Coronary Artery Disease. New England Journal of Medicine, 2016, 374, 2131-2141.	27.0	137

#	Article	IF	Citations
631	Cholesterol Efflux Capacity. Journal of the American College of Cardiology, 2016, 67, 2488-2491.	2.8	5
632	Deficiency of ATP-Binding Cassette Transporters A1 and G1 in Endothelial Cells Accelerates Atherosclerosis in Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1328-1337.	2.4	92
633	Triglycerides and Triglyceride-Rich Lipoproteins in the Causal Pathway of Cardiovascular Disease. American Journal of Cardiology, 2016, 118, 138-145.	1.6	134
634	Anti-atherosclerosis effect of different doses of CETP vaccine in rabbit model of atherosclerosis. Biomedicine and Pharmacotherapy, 2016, 81, 468-473.	5.6	5
635	Dysfunctional high-density lipoproteins in coronary heart disease: implications for diagnostics and therapy. Translational Research, 2016, 173, 30-57.	5.0	75
636	CETP Inhibition in CVD Prevention: an Actual Appraisal. Current Cardiology Reports, 2016, 18, 43.	2.9	14
637	Scavenger receptor class B1 â€" a target to reduce CHD risk?. Nature Reviews Cardiology, 2016, 13, 249-250.	13.7	0
638	Epidemiology of cardiovascular disease: recent novel outlooks on risk factors and clinical approaches. Expert Review of Cardiovascular Therapy, 2016, 14, 855-869.	1.5	37
639	Human Validation of Genes Associated With a Murine Atherosclerotic Phenotype. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1240-1246.	2.4	44
640	High density lipoprotein and metabolic disease: Potential benefits of restoring its functional properties. Molecular Metabolism, 2016, 5, 321-327.	6.5	16
641	Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease. Nature Genetics, 2016, 48, 634-639.	21.4	214
642	Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 206-212.	2.2	71
643	A causal network analysis in an observational study identifies metabolomics pathways influencing plasma triglyceride levels. Metabolomics, 2016, 12, 104.	3.0	15
644	Subfractions of High-Density Lipoprotein-Cholesterol and Carotid Intima-Media Thickness. Stroke, 2016, 47, 1508-1513.	2.0	16
645	The contribution of paraoxonase 1 and myeloperoxidase to HDL-cholesterol functionality. Biomedical Human Kinetics, 2016, 8, 51-57.	0.6	1
646	HDL Particle Size and Functional Heterogeneity. Circulation Research, 2016, 119, 704-707.	4.5	19
647	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Atherosclerosis, 2016, 253, 281-344.	0.8	1,189
648	Genetic analysis of emerging risk factors in coronary artery disease. Atherosclerosis, 2016, 254, 35-41.	0.8	11

#	Article	IF	Citations
649	Effects of hormonal contraception on systemic metabolism: cross-sectional and longitudinal evidence. International Journal of Epidemiology, 2016, 45, 1445-1457.	1.9	62
650	Is High-Density Lipoprotein Cholesterol Causally Related to Kidney Function?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 2252-2258.	2.4	21
651	High-density lipoprotein subclass profile and mortality in patients with coronary artery disease: Results from the GENES study. Archives of Cardiovascular Diseases, 2016, 109, 607-617.	1.6	7
652	Hypertriglyceridemia: the importance of identifying patients at risk. Postgraduate Medicine, 2016, 128, 848-858.	2.0	28
653	The TromsÃ¸ study 1974â€“2016: 40 years of cardiovascular research. Scandinavian Cardiovascular Journal, 2016, 50, 276-281.	1.2	25
654	Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes. JAMA Cardiology, 2016, 1, 692.	6.1	233
655	Disentangling the Causal Association of Plasma Lipid Traits and Type 2 Diabetes Using Human Genetics. JAMA Cardiology, 2016, 1, 631.	6.1	3
656	Insight into rheumatological cause and effect through the use of Mendelian randomization. Nature Reviews Rheumatology, 2016, 12, 486-496.	8.0	46
657	Mendelian Randomization as an Approach to Assess Causality Using Observational Data. Journal of the American Society of Nephrology: JASN, 2016, 27, 3253-3265.	6.1	639
658	Cholesterol efflux capacity: An introduction for clinicians. American Heart Journal, 2016, 180, 54-63.	2.7	50
659	High Density Lipoprotein Cholesterol and the Risk of All-Cause Mortality among U.S. Veterans. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1784-1793.	4.5	157
660	Impact of genetic deletion of platform apolipoproteins on the size distribution of the murine lipoproteome. Journal of Proteomics, 2016, 146, 184-194.	2.4	8
661	Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genetic Epidemiology, 2016, 40, 304-314.	1.3	4,142
662	Polygenic Epidemiology. Genetic Epidemiology, 2016, 40, 268-272.	1.3	160
663	Familial hypercholesterolaemia: cholesterol efflux and coronary disease. European Journal of Clinical Investigation, 2016, 46, 643-650.	3.4	30
664	Reâ€examining the highâ€density lipoprotein hypothesis. Journal of Diabetes Investigation, 2016, 7, 445-447.	2.4	2
665	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal, 2016, 37, 2999-3058.	2.2	2,393
666	Diagnosis and treatment of high density lipoprotein deficiency. Progress in Cardiovascular Diseases, 2016, 59, 97-106.	3.1	63

#	Article	IF	Citations
667	Missing heritability of complex diseases: Enlightenment by genetic variants from intermediate phenotypes. BioEssays, 2016, 38, 664-673.	2.5	52
669	Genetic variants inCETPincrease risk of intracerebral hemorrhage. Annals of Neurology, 2016, 80, 730-740.	5.3	33
670	2016 European Guidelines on cardiovascular disease prevention in clinical practice. Atherosclerosis, 2016, 252, 207-274.	0.8	415
671	Cholesterol Efflux Capacity and Subclasses of HDL Particles in Healthy Women Transitioning Through Menopause. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3419-3428.	3.6	50
672	Short-term isocaloric fructose restriction lowers apoC-III levels and yields less atherogenic lipoprotein profiles in children with obesity and metabolic syndrome. Atherosclerosis, 2016, 253, 171-177.	0.8	42
673	LDL-Cholesterol: Standards of Treatment 2016: A German Perspective. American Journal of Cardiovascular Drugs, 2016, 16, 323-336.	2.2	18
674	Cholesteryl ester transfer protein (CETP) I405V polymorphism and cardiovascular disease in eastern European Caucasians â€“ a cross-sectional study. BMC Geriatrics, 2016, 16, 144.	2.7	9
676	Using human genetics to discover new therapeutic targets for plasma lipids. Journal of Internal Medicine, 2016, 280, 487-495.	6.0	5
677	The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease. Cell, 2016, 167, 1415-1429.e19.	28.9	1,052
678	Impact of diet and exercise on proprotein convertase subtilisin/kexin 9: A mini-review. Vascular Pharmacology, 2016, 87, 10-13.	2.1	5
679	A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. Science Translational Medicine, 2016, 8, 341ra76.	12.4	100
680	Prevalence, clinical features, and prognosis of patients with extremely low high-density lipoprotein cholesterol. Journal of Clinical Lipidology, 2016, 10, 1311-1317.	1.5	9
681	Serum levels of mitochondrial inhibitory factor 1 are independently associated with long-term prognosis in coronary artery disease: the GENES Study. BMC Medicine, 2016, 14, 125.	5.5	24
682	HDL as a Causal Factor in Atherosclerosis: Insights from Human Genetics. Current Atherosclerosis Reports, 2016, 18, 71.	4.8	9
683	Impact of dietary resistant starch type 4 on human gut microbiota and immunometabolic functions. Scientific Reports, 2016, 6, 28797.	3.3	159
684	Geneticsâ€"Current and Future Role in the Prevention and Management of Coronary Artery Disease. Current Atherosclerosis Reports, 2016, 18, 78.	4.8	5
685	Metabolic profiling of alcohol consumption in 9778 young adults. International Journal of Epidemiology, 2016, 45, 1493-1506.	1.9	90
686	High-Density Lipoprotein Cholesterol andÂCause-Specific Mortality in IndividualsÂWithout Previous Cardiovascular Conditions. Journal of the American College of Cardiology, 2016, 68, 2073-2083.	2.8	253

#	Article	IF	Citations
687	Will Big Data Shine Light at the End of the Tunnel for HDL? â^—. Journal of the American College of Cardiology, 2016, 68, 2084-2085.	2.8	4
688	Mendelian randomization analysis of a timeâ€varying exposure for binary disease outcomes using functional data analysis methods. Genetic Epidemiology, 2016, 40, 744-755.	1.3	13
689	Re-evaluation of cholesteryl ester transfer protein function in atherosclerosis based upon genetics and pharmacological manipulation. Current Opinion in Lipidology, 2016, 27, 459-472.	2.7	25
690	Clinical trials with cholesteryl ester transfer protein inhibitors. Current Opinion in Lipidology, 2016, 27, 545-549.	2.7	15
691	Using Mendelian Randomization Studies to Assess Causality and Identify New Therapeutic Targets in Cardiovascular Medicine. Current Genetic Medicine Reports, 2016, 4, 207-212.	1.9	4
692	Genetic susceptibility to dyslipidemia and incidence of cardiovascular disease depending on a diet quality index in the MalmÃ¶ Diet and Cancer cohort. Genes and Nutrition, 2016, 11, 20.	2.5	6
693	The role of HDL in plaque stabilization and regression. Coronary Artery Disease, 2016, 27, 592-603.	0.7	16
694	HDL infusion for the management of atherosclerosis. Current Opinion in Lipidology, 2016, 27, 592-596.	2.7	12
695	Roles of High-Density Lipoprotein Cholesterol in Patients With Acute Myocardial Infarction. Medicine (United States), 2016, 95, e3319.	1.0	6
696	Developmental programming: Stateâ€ofâ€theâ€science and future directionsâ€“Summary from a Pennington Biomedical symposium. Obesity, 2016, 24, 1018-1026.	3.0	47
697	The impact of common polymorphisms in CETP and ABCA1 genes with the risk of coronary artery disease in Saudi Arabians. Human Genomics, 2016, 10, 8.	2.9	18
698	Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial. Atherosclerosis, 2016, 251, 454-459.	0.8	71
699	Where to now in cardiovascular disease prevention. Atherosclerosis, 2016, 251, 483-489.	0.8	2
700	High-Density Lipoproteins, Endothelial Function, and Mendelian Randomization. Circulation Research, 2016, 119, 13-15.	4.5	7
701	Adding Mendelian randomization to a meta-analysisâ€”a burgeoning opportunity. Tumor Biology, 2016, 37, 1527-1529.	1.8	6
702	Causal Inference in Medicine via Mendelian Randomization. , 2016, , 499-520.		0
703	Multiple apolipoprotein kinetics measured in human HDL by high-resolution/accurate mass parallel reaction monitoring. Journal of Lipid Research, 2016, 57, 714-728.	4.2	35
704	Metabolomics in epidemiology: from metabolite concentrations to integrative reaction networks. International Journal of Epidemiology, 2016, 45, 1319-1328.	1.9	40

#	Article	IF	Citations
705	Changes in lipoprotein lipase and endothelial lipase mass in familial hypercholesterolemia during three-drug lipid-lowering combination therapy. Lipids in Health and Disease, 2016, 15, 66.	3.0	7
706	Mendelian Randomization Analyses for Selection of Therapeutic Targets for Cardiovascular Disease Prevention: a Note of Circumspection. Cardiovascular Drugs and Therapy, 2016, 30, 65-74.	2.6	11
707	Selecting instruments for Mendelian randomization in the wake of genome-wide association studies. International Journal of Epidemiology, 2016, 45, 1600-1616.	1.9	232
708	2016 European Guidelines on cardiovascular disease prevention in clinical practice. European Journal of Preventive Cardiology, 2016, 23, NP1-NP96.	1.8	683
709	Mendelian Randomization for the Identification of Causal Pathways in Atherosclerotic Vascular Disease. Cardiovascular Drugs and Therapy, 2016, 30, 41-49.	2.6	10
710	Low HDL cholesterol as a cardiovascular risk factor in rural, urban, and rural-urban migrants: PERU MIGRANT cohort study. Atherosclerosis, 2016, 246, 36-43.	0.8	31
711	High-density lipoprotein and inflammation in cardiovascular disease. Translational Research, 2016, 173, 7-18.	5.0	35
712	Genome-wide DNA methylation study identifies genes associated with the cardiovascular biomarker GDF-15. Human Molecular Genetics, 2016, 25, 817-827.	2.9	32
713	Oxidized LDL induced extracellular trap formation in human neutrophils via TLR-PKC-IRAK-MAPK and NADPH-oxidase activation. Free Radical Biology and Medicine, 2016, 93, 190-203.	2.9	119
714	Volunteering and Cardiovascular Disease Risk: Does Helping Others Get â€œUnder the Skin?â€. Gerontologist, The, 2016, 56, 937-947.	3.9	40
715	Human genetics shines a light on ischaemic stroke. Lancet Neurology, The, 2016, 15, 130-131.	10.2	6
716	Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?. Expert Opinion on Pharmacotherapy, 2016, 17, 275-281.	1.8	9
717	New Insights into the High-Density Lipoprotein Dilemma. Trends in Endocrinology and Metabolism, 2016, 27, 44-53.	7.1	15
718	Mendelian randomization to assess causal effects of blood lipids on coronary heart disease. Current Opinion in Endocrinology, Diabetes and Obesity, 2016, 23, 124-130.	2.3	58
719	Systemic and renal lipids in kidney disease development and progression. American Journal of Physiology - Renal Physiology, 2016, 310, F433-F445.	2.7	97
720	Surprises From Genetic Analyses of Lipid Risk Factors for Atherosclerosis. Circulation Research, 2016, 118, 579-585.	4.5	131
721	Low levels of high-density lipoprotein cholesterol increase the risk of incident kidney disease and its progression. Kidney International, 2016, 89, 886-896.	5.2	101
722	Postprandial Studies Uncover Differing Effects on HDL Particles of Overt and Subclinical Hypothyroidism. Thyroid, 2016, 26, 356-364.	4.5	14

#	Article	IF	Citations
723	The unresolved mystery of high-density lipoprotein: time for a paradigm shift?. Translational Research, 2016, 173, 1-6.	5.0	2
724	Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. Science, 2016, 351, 1166-1171.	12.6	438
725	Wavelike charge density fluctuations and van der Waals interactions at the nanoscale. Science, 2016, 351, 1171-1176.	12.6	217
726	Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease. New England Journal of Medicine, 2016, 374, 1123-1133.	27.0	411
727	High-density lipoprotein subclass measurements improve mortality risk prediction, discrimination and reclassification in a cardiac catheterization cohort. Atherosclerosis, 2016, 246, 229-235.	0.8	56
728	Causal Assessment of Serum Urate Levels inÂCardiometabolic Diseases Through a Mendelian Randomization Study. Journal of the American College of Cardiology, 2016, 67, 407-416.	2.8	138
729	From Lipids to Inflammation. Circulation Research, 2016, 118, 732-749.	4.5	180
730	Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease. Circulation Research, 2016, 118, 535-546.	4.5	936
731	Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease. Circulation Research, 2016, 118, 547-563.	4.5	701
732	HDL as a prognostic biomarker for coronary atherosclerosis: the role of inflammation. Expert Opinion on Therapeutic Targets, 2016, 20, 907-921.	3.4	11
733	Generating a robust statistical causal structure over 13 cardiovascular disease risk factors using genomics data. Journal of Biomedical Informatics, 2016, 60, 114-119.	4.3	30
734	Is high high-density lipoprotein cholesterol beneficial for premature coronary heart disease? A meta-analysis. European Journal of Preventive Cardiology, 2016, 23, 704-713.	1.8	7
735	Statistical Methods for Drug Discovery. Statistics in the Health Sciences, 2016, , 53-81.	0.2	3
736	New Therapeutic Approaches to the Treatment of Dyslipidemia. Cell Metabolism, 2016, 23, 405-412.	16.2	67
737	Coronary Artery Disease and Its Risk Factors. Circulation Research, 2016, 118, 14-16.	4.5	9
738	Experimental Biology for the Identification of Causal Pathways in Atherosclerosis. Cardiovascular Drugs and Therapy, 2016, 30, 1-11.	2.6	5
739	Extended-Release Niacin/Laropiprant Improves Overall Efficacy of Postprandial Reverse Cholesterol Transport. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 285-294.	2.4	17
740	Lipids, Lipoproteins, and Cardiovascular Disease: Clinical Pharmacology Now and in the Future. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 804-814.	3.6	36

#	Article	IF	Citations
741	Genetics of Coronary Artery Disease. Circulation Research, 2016, 118, 564-578.	4.5	288
742	Mendelian randomisation study of the associations of vitamin B12 and folate genetic risk scores with blood pressure and fasting serum lipid levels in three Danish population-based studies. European Journal of Clinical Nutrition, 2016, 70, 613-619.	2.9	5
743	Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 100-108.	2.2	138
744	Best (but oft-forgotten) practices: the design, analysis, and interpretation of Mendelian randomization studies. American Journal of Clinical Nutrition, 2016, 103, 965-978.	4.7	437
745	The High-Density Lipoprotein Puzzle. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 777-782.	2.4	42
746	Management of residual risk after statin therapy. Atherosclerosis, 2016, 245, 161-170.	0.8	71
747	Learning from anomalies: the case of cholesterol and ischaemic heart disease. International Journal of Epidemiology, 2016, 45, 290-292.	1.9	0
748	Predictors of abdominal adipose tissue compartments: 18-year follow-up of young men with and without family history of diabetes. European Journal of Internal Medicine, 2016, 29, 26-31.	2.2	11
749	Plasma Î±-Linolenic and Long-Chain Ï‰-3 Fatty Acids Are Associated with a Lower Risk of Acute Myocardial Infarction in Singapore Chinese Adults. Journal of Nutrition, 2016, 146, 275-282.	2.9	12
750	The potential of cholesteryl ester transfer protein as a therapeutic target. Expert Opinion on Therapeutic Targets, 2016, 20, 47-59.	3.4	8
751	The future of low-density lipoprotein cholesterol lowering therapy: An end to statin exceptionalism?. European Journal of Preventive Cardiology, 2016, 23, 1062-1064.	1.8	5
752	HDLâ€"A molecule with a multi-faceted role in coronary artery disease. Clinica Chimica Acta, 2016, 452, 66-81.	1.1	29
753	Moderate Alcohol Consumption Is Not Associated with Reduced All-cause Mortality. American Journal of Medicine, 2016, 129, 180-186.e4.	1.5	55
754	Novel Pathways of Apolipoprotein A-I Metabolism in High-Density Lipoprotein of Different Sizes in Humans. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 156-165.	2.4	69
755	Dysfunctional HDL and atherosclerotic cardiovascular disease. Nature Reviews Cardiology, 2016, 13, 48-60.	13.7	547
756	Genes associated with diabetes: potential for novel therapeutic targets?. Expert Opinion on Therapeutic Targets, 2016, 20, 255-267.	3.4	12
757	Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology. European Heart Journal, 2016, 37, 747-754.	2.2	62
758	Lipoprotein Metabolism and the Treatment of Lipid Disorders. , 2016, , 715-736.e7.		5

#	Article	IF	Citations
759	The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events. European Journal of Preventive Cardiology, 2016, 23, 474-485.	1.8	12
760	Individual and Joint Associations of Methylenetetrahydrofolate Reductase C677T Genotype and Plasma Homocysteine With Dyslipidemia in a Chinese Population With Hypertension. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 287-293.	1.7	10
761	GALNT2 effect on HDL-cholesterol and triglycerides levels in humans: Evidence of pleiotropy?. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 281-282.	2.6	13
762	High density lipoproteins are modulators of protease activity: Implications in inflammation, complement activation, and atherothrombosis. Atherosclerosis, 2017, 259, 104-113.	0.8	48
763	Platelet tissue factor activity and membrane cholesterol are increased in hypercholesterolemia and normalized by rosuvastatin, but not by atorvastatin. Atherosclerosis, 2017, 257, 164-171.	0.8	27
764	Genetics for the Identification of Lipid Targets Beyond PCSK9. Canadian Journal of Cardiology, 2017, 33, 334-342.	1.7	8
765	Selection bias and relationships between alcohol consumption and mortality. Addiction, 2017, 112, 220-221.	3.3	9
766	The Genetic Architecture of Coronary Artery Disease: Current Knowledge and Future Opportunities. Current Atherosclerosis Reports, 2017, 19, 6.	4.8	38
767	Assessing Cardiovascular Risk and Testing in Type 2 Diabetes. Current Cardiology Reports, 2017, 19, 19.	2.9	19
768	Alcohol and Cardiovascular Disease: How Much is Too Much?. Current Atherosclerosis Reports, 2017, 19, 13.	4.8	45
769	Relation of Fasting Triglyceride-Rich Lipoprotein Cholesterol to Coronary Artery Calcium Score (from the ELSA-Brasil Study). American Journal of Cardiology, 2017, 119, 1352-1358.	1.6	26
770	Epigenetic Patterns in Blood Associated With Lipid Traits Predict Incident Coronary Heart Disease Events and Are Enriched for Results From Genome-Wide Association Studies. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	104
771	A novel approach to measuring macrophage-specific reverse cholesterol transport in vivo in humans. Journal of Lipid Research, 2017, 58, 752-762.	4.2	22
772	Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)â€"A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics. American Heart Journal, 2017, 187, 182-190.	2.7	66
773	Genetics of coronary artery disease: discovery, biology and clinical translation. Nature Reviews Genetics, 2017, 18, 331-344.	16.3	448
774	En route to precision medicine through the integration of biological sex into pharmacogenomics. Clinical Science, 2017, 131, 329-342.	4.3	31
775	â€˜Mendelian randomizationâ€™: an approach for exploring causal relations in epidemiology. Public Health, 2017, 145, 113-119.	2.9	59
776	Using Zebrafish for High-Throughput Screening of Novel Cardiovascular Drugs. JACC Basic To Translational Science, 2017, 2, 1-12.	4.1	34

#	Article	IF	Citations
777	Effects of curcumin on HDL functionality. Pharmacological Research, 2017, 119, 208-218.	7.1	157
778	Mediterranean Approach to Improving High-Density Lipoprotein Function. Circulation, 2017, 135, 644-647.	1.6	5
779	Genetic Association of Waist-to-Hip Ratio With Cardiometabolic Traits, Type 2 Diabetes, and Coronary Heart Disease. JAMA - Journal of the American Medical Association, 2017, 317, 626.	7.4	313
780	HDL efflux capacity, HDL particle size, and high-risk carotid atherosclerosis in a cohort of asymptomatic older adults: the Chicago Healthy Aging Study. Journal of Lipid Research, 2017, 58, 600-606.	4.2	65
781	Systematic Evaluation of Pleiotropy Identifies 6 Further Loci Associated WithÂCoronary ArteryÂDisease. Journal of the American College of Cardiology, 2017, 69, 823-836.	2.8	214
782	A novel role for CRTC2 in hepatic cholesterol synthesis through SREBPâ€2. Hepatology, 2017, 66, 481-497.	7.3	31
783	Thermogenic adipocytes promote HDL turnover and reverse cholesterol transport. Nature Communications, 2017, 8, 15010.	12.8	117
784	Serum Concentration of HDL Particles Predicts Mortality in Acute Heart Failure Patients. Scientific Reports, 2017, 7, 46642.	3.3	30
785	Increasing HDL-C levels with medication. Current Opinion in Lipidology, 2017, 28, 361-366.	2.7	12
786	Anacetrapib-driven triglyceride lowering explained: the fortuitous role of CETP in the intravascular catabolism of triglyceride-rich lipoproteins. Journal of Lipid Research, 2017, 58, 1031-1032.	4.2	2
787	A decade of progress on the genetic basis of coronary artery disease. Practical insights for the internist. European Journal of Internal Medicine, 2017, 41, 10-17.	2.2	14
788	Could high-density lipoprotein cholesterol predict increased cardiovascular risk?. Current Opinion in Endocrinology, Diabetes and Obesity, 2017, 24, 140-147.	2.3	19
789	HDL abnormalities in familial hypercholesterolemia: Focus on biological functions. Progress in Lipid Research, 2017, 67, 16-26.	11.6	51
790	Protein-Truncating Variants at the Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Heart Disease. Circulation Research, 2017, 121, 81-88.	4.5	68
791	Thyroid Signaling, Insulin Resistance, and 2 Diabetes Mellitus: A Mendelian Randomization Study. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1960-1970.	3.6	33
792	Changes in high-density lipoprotein-carried miRNA contribution to the plasmatic pool after consumption of dietarytransfat in healthy men. Epigenomics, 2017, 9, 669-688.	2.1	21
793	The Role of Emerging Risk Factors in Cardiovascular Outcomes. Current Atherosclerosis Reports, 2017, 19, 28.	4.8	43
794	Mendelian Randomization Implicates High-Density Lipoprotein Cholesterolâ€“Associated Mechanisms in Etiology of Age-Related Macular Degeneration. Ophthalmology, 2017, 124, 1165-1174.	5.2	109

#	Article	IF	Citations
795	How important are triglycerides as risk factors?. Journal of Cardiovascular Medicine, 2017, 18, e7-e12.	1.5	1
796	Data-driven metabolic subtypes predict future adverse events in individuals with type 1 diabetes. Diabetologia, 2017, 60, 1234-1243.	6.3	19
797	How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL. Atherosclerosis Supplements, 2017, 26, 16-24.	1.2	24
798	Clinical Outcomes in Trials Evaluating Lipid-Lowering Drugs. American Journal of Cardiovascular Drugs, 2017, 17, 447-452.	2.2	2
799	Human genetic insights into lipoproteins and risk of cardiometabolic disease. Current Opinion in Lipidology, 2017, 28, 113-119.	2.7	12
800	Pitavastatin and HDL: Effects on plasma levels and function(s). Atherosclerosis Supplements, 2017, 27, e1-e9.	1.2	21
801	The Genetics of Ischemic Heart Disease: From Current Knowledge to Clinical Implications. Revista Espanola De Cardiologia (English Ed), 2017, 70, 754-762.	0.6	6
802	Dietary Fats and Cardiovascular Disease: A Presidential Advisory From the American Heart Association. Circulation, 2017, 136, e1-e23.	1.6	884
803	HDL cholesterol concentration or HDL function: which matters?. European Heart Journal, 2017, 38, 2487-2489.	2.2	31
804	Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. New England Journal of Medicine, 2017, 376, 1933-1942.	27.0	593
805	Will genetic studies deliver the next generation of cardioprotective therapies?. European Journal of Preventive Cardiology, 2017, 24, 489-491.	1.8	1
806	2017 Position Paper of the Italian Society for Cardiovascular Prevention (SIPREC) for an Updated Clinical Management of Hypercholesterolemia and Cardiovascular Risk: Executive Document. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 313-329.	2.2	9
807	Lipid levels and risk of venous thrombosis: results from the MEGA-study. European Journal of Epidemiology, 2017, 32, 669-681.	5.7	35
808	Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. New England Journal of Medicine, 2017, 377, 211-221.	27.0	633
809	Serum inhibitory factor 1, high-density lipoprotein and cardiovascular diseases. Current Opinion in Lipidology, 2017, 28, 337-346.	2.7	9
810	New perspectives on biological HDL-targeted therapies. Expert Opinion on Biological Therapy, 2017, 17, 793-796.	3.1	8
811	Mendelian randomization in cardiometabolic disease: challenges in evaluating causality. Nature Reviews Cardiology, 2017, 14, 577-590.	13.7	443
812	HDL and the menopause. Current Opinion in Lipidology, 2017, 28, 328-336.	2.7	48

#	Article	IF	Citations
813	The impact of rare and low-frequency genetic variants in common disease. Genome Biology, 2017, 18, 77.	8.8	277
814	Mining the Genome for Therapeutic Targets. Diabetes, 2017, 66, 1770-1778.	0.6	14
815	Associations of parental age with health and social factors in adult offspring. Methodological pitfalls and possibilities. Scientific Reports, 2017, 7, 45278.	3.3	26
816	Genetic Analysis of Venous Thromboembolism in UK Biobank Identifies the ZFPM2 Locus and Implicates Obesity as a Causal Risk Factor. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	90
817	Reply. Journal of the American College of Cardiology, 2017, 69, 1759-1760.	2.8	0
818	A Shift in ApoM/S1P Between HDL-Particles in Women With Type 1 Diabetes Mellitus Is Associated With Impaired Anti-Inflammatory Effects of the ApoM/S1P Complex. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1194-1205.	2.4	48
819	HDL cholesterol: reappraisal of its clinical relevance. Clinical Research in Cardiology, 2017, 106, 663-675.	3.3	186
820	HDL and macrophages: explaining the clinical failures and advancing HDL-based therapeutics in cardiovascular diseases?. Expert Review of Cardiovascular Therapy, 2017, 15, 343-344.	1.5	2
821	Effects of Dietary Flavonoids on Reverse Cholesterol Transport, HDL Metabolism, and HDL function. Advances in Nutrition, 2017, 8, 226-239.	6.4	126
822	Effects of dyslipidaemia on monocyte production and function in cardiovascular disease. Nature Reviews Cardiology, 2017, 14, 387-400.	13.7	66
823	2016 European Guidelines on cardiovascular disease prevention in clinical practice. International Journal of Behavioral Medicine, 2017, 24, 321-419.	1.7	84
824	Serum triglyceride, high-density lipoprotein cholesterol, apolipoprotein B, and coronary heart disease in a Chinese population undergoing coronary angiography. Journal of Clinical Lipidology, 2017, 11, 646-656.	1.5	14
825	Big and Complex Data Analysis. Contributions To Statistics, 2017, , .	0.2	8
826	Demystifying HDL Cholesterolâ€"A â€œHuman Knockoutâ€•to the Rescue?. Clinical Chemistry, 2017, 63, 33-36.	3.2	5
827	Comprehensive genotyping in dyslipidemia: mendelian dyslipidemias caused by rare variants and Mendelian randomization studies using common variants. Journal of Human Genetics, 2017, 62, 453-458.	2.3	15
828	Analysis of Lipoprotein Subfractions in 920 Patients With and Without Type 2 Diabetes. Heart Lung and Circulation, 2017, 26, 211-218.	0.4	12
829	Exome-wide association study of plasma lipids in >300,000 individuals. Nature Genetics, 2017, 49, 1758-1766.	21.4	470
830	Exome chip meta-analysis identifies novel loci and East Asianâ€"specific coding variants that contribute to lipid levels and coronary artery disease. Nature Genetics, 2017, 49, 1722-1730.	21.4	129

#	Article	IF	Citations
831	ANGPTL3 serum concentration and rare genetic variants in Finnish population. Scandinavian Journal of Clinical and Laboratory Investigation, 2017, 77, 601-609.	1.2	6
832	Local Genetic Correlation Gives Insights into the Shared Genetic Architecture of Complex Traits. American Journal of Human Genetics, 2017, 101, 737-751.	6.2	220
833	Pharmacogenetics of Lipid-Lowering Agents: an Update Review on Genotype-Dependent Effects of HDL-Targetingand Statin Therapies. Current Atherosclerosis Reports, 2017, 19, 43.	4.8	7
834	Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein. Journal of Visualized Experiments, 2017, , .	0.3	7
835	The sirtuin family members SIRT1, SIRT3 and SIRT6: Their role in vascular biology and atherogenesis. Atherosclerosis, 2017, 265, 275-282.	0.8	144
836	Mendelian randomization analysis indicates serum urate has a causal effect on renal function in Chinese women. International Urology and Nephrology, 2017, 49, 2035-2042.	1.4	6
837	Association of high-density lipoprotein cholesterol concentration with different types of stroke and coronary heart disease: The Japan Public Health Center-based prospective (JPHC) study. Atherosclerosis, 2017, 265, 147-154.	0.8	43
838	Determinants of HDL Cholesterol Efflux Capacity after Virgin Olive Oil Ingestion: Interrelationships with Fluidity of HDL Monolayer. Molecular Nutrition and Food Research, 2017, 61, 1700445.	3.3	19
839	Polygenic determinants in extremes of high-density lipoprotein cholesterol. Journal of Lipid Research, 2017, 58, 2162-2170.	4.2	49
840	Large-Scale Analysis of Determinants, Stability, and Heritability of High-Density Lipoprotein Cholesterol Efflux Capacity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1956-1962.	2.4	33
841	Navigating the Future of Cardiovascular Drug Developmentâ€"Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference. Cardiovascular Drugs and Therapy, 2017, 31, 445-458.	2.6	8
842	LDL subfractions are associated with incident cardiovascular disease in the MalmÃ¶ Prevention Project Study. Atherosclerosis, 2017, 263, 287-292.	0.8	43
844	Genetic contribution to lipid levels in early life based on 158 loci validated in adults: the FAMILY study. Scientific Reports, 2017, 7, 68.	3.3	4
845	Commentary on Kerr and Colleagues (): More Evidence that Social and Health Limitations in Childhood Increase the Risk of Lifetime Abstention from Alcohol. Alcoholism: Clinical and Experimental Research, 2017, 41, 876-879.	2.4	0
846	Association of Highâ€Density Lipoproteinâ€Cholesterol Versus Apolipoprotein Aâ€I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancerâ€Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study. Journal of the American Heart Association, 2017, 6, .	3.7	13
847	Low-density lipoprotein 4: a novel predictor of coronary artery disease severity. Current Medical Research and Opinion, 2017, 33, 1979-1984.	1.9	11
849	No cardiovascular benefit with evacetrapib â€“ is this the end of the road for the â€˜cetrapibsâ€™?. Expert Opinion on Pharmacotherapy, 2017, 18, 1439-1442.	1.8	5
850	Î² 3 -Adrenergic receptor regulates hepatic apolipoprotein A-I gene expression. Journal of Clinical Lipidology, 2017, 11, 1168-1176.	1.5	3

#	Article	IF	Citations
851	What are the prospects of apolipoprotein profiling for cardiovascular disease?. Expert Review of Molecular Diagnostics, 2017, 17, 805-807.	3.1	2
852	Statin Effects on Metabolic Profiles. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	18
853	Surfactant protein D is a causal risk factor for COPD: results of Mendelian randomisation. European Respiratory Journal, 2017, 50, 1700657.	6.7	45
854	Mendelian Randomization. JAMA - Journal of the American Medical Association, 2017, 318, 1925.	7.4	1,253
855	ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen. Current Atherosclerosis Reports, 2017, 19, 62.	4.8	41
856	HDL functionality in type 1 diabetes. Atherosclerosis, 2017, 267, 99-109.	0.8	50
857	Novel Approaches for HDL-Directed Therapies. Current Atherosclerosis Reports, 2017, 19, 55.	4.8	10
858	HDL Cholesterol Metabolism and the Risk of CHD: New Insights from Human Genetics. Current Cardiology Reports, 2017, 19, 132.	2.9	85
859	Paradoxical coronary artery disease in humans with hyperalphalipoproteinemia is associated with distinct differences in the high-density lipoprotein phosphosphingolipidome. Journal of Clinical Lipidology, 2017, 11, 1192-1200.e3.	1.5	9
860	Host genetic variation and HIV disease: from mapping to mechanism. Immunogenetics, 2017, 69, 489-498.	2.4	54
861	A Long Road Ahead for Discovering NewÂHDL Metrics That Reflect Cardiovascular Disease Risk â^—. Journal of the American College of Cardiology, 2017, 70, 179-181.	2.8	3
862	Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype. Current Cardiology Reports, 2017, 19, 61.	2.9	12
863	The Immunology of Cardiovascular Homeostasis and Pathology. Advances in Experimental Medicine and Biology, 2017, , .	1.6	14
864	Atherosclerosis. Advances in Experimental Medicine and Biology, 2017, 1003, 121-144.	1.6	61
865	Dissecting the genetics of complex traits using summary association statistics. Nature Reviews Genetics, 2017, 18, 117-127.	16.3	379
866	Advanced glycation of high-density lipoprotein and the functionality of aldosterone release in type 2 diabetes. Hypertension Research, 2017, 40, 271-276.	2.7	3
867	Identifying geneâ€“gene interactions that are highly associated with four quantitative lipid traits across multiple cohorts. Human Genetics, 2017, 136, 165-178.	3.8	11
869	New Drugs for Atherosclerosis. Canadian Journal of Cardiology, 2017, 33, 350-357.	1.7	21

#	Article	IF	Citations
870	High-Density Lipoproteins: Biology, Epidemiology, and Clinical Management. Canadian Journal of Cardiology, 2017, 33, 325-333.	1.7	41
871	Weight loss surgery in adolescents corrects high-density lipoprotein subspecies and their function. International Journal of Obesity, 2017, 41, 83-89.	3.4	32
872	HDL Cholesterol Efflux Does Not Predict Cardiovascular Risk in Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2017, 28, 769-775.	6.1	45
873	Leveraging human genetics to guide drug target discovery. Trends in Cardiovascular Medicine, 2017, 27, 352-359.	4.9	26
874	Testing for Associations of Opposite Directionality in a Heterogeneous Population. Statistics in Biosciences, 2017, 9, 137-159.	1.2	1
875	HDL-cholesterol levels and risk of age-related macular degeneration: a multiethnic genetic study using Mendelian randomization. International Journal of Epidemiology, 2017, 46, 1891-1902.	1.9	73
876	Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities. International Journal of Epidemiology, 2017, 46, 2078-2089.	1.9	123
877	Association of high-density lipoprotein cholesterol with non-fatal cardiac and non-cardiac events: a CANHEART substudy. Open Heart, 2017, 4, e000731.	2.3	3
878	Peroxisome Proliferator Activated Receptor Gamma (PPARÎ³) Pro12Ala Gene Polymorphism and Oxidative Stress in Menopausal Women with Cardiovascular Disease from North Indian Population of Punjab. International Journal of Human Genetics, 2017, 17, 15-25.	0.1	2
879	13. HyperlipoproteinÃmie. , 2017, , 207-222.		0
880	37 Pathologische Laborbefunde (IV). , 2017, , .		0
881	The Role of Host Genetics (and Genomics) in Tuberculosis. , 2017, , 411-452.		0
882	Genetic determinants of growth hormone and GH-related phenotypes. BMC Genomics, 2017, 18, 822.	2.8	4
883	Role of Cholesterol in Heart Disease. , 2017, , .		0
884	Clinical Perspectives of Genetic Analyses on Dyslipidemia and Coronary Artery Disease. Journal of Atherosclerosis and Thrombosis, 2017, 24, 452-461.	2.0	21
885	Sphingosine-1-Phosphate and HDL Metabolism. , 2017, , 153-170.		1
886	Paraoxonase 1 and Its Clinical Relevance. , 2017, , 187-208.		1
887	Vegetarian Diets and the Risk of Type 2 Diabetes. , 2017, , 355-367.		2

#	Article	IF	Citations
888	Apolipoprotein A-I exchange is impaired in metabolic syndrome patients asymptomatic for diabetes and cardiovascular disease. PLoS ONE, 2017, 12, e0182217.	2.5	22
889	Interaction between TCF7L2 polymorphism and dietary fat intake on high density lipoprotein cholesterol. PLoS ONE, 2017, 12, e0188382.	2.5	30
890	The anti-inflammatory function of HDL is impaired in type 2 diabetes: role of hyperglycemia, paraoxonase-1 and low grade inflammation. Cardiovascular Diabetology, 2017, 16, 132.	6.8	71
891	High-density lipoprotein cholesterol efflux capacity is inversely associated with cardiovascular risk: a systematic review and meta-analysis. Lipids in Health and Disease, 2017, 16, 212.	3.0	63
892	Effect of low and high HDL-C levels on the prognosis of lupus nephritis patients: a prospective cohort study. Lipids in Health and Disease, 2017, 16, 232.	3.0	2
893	Association between high-density lipoprotein cholesterol level and pulmonary function in healthy Korean adolescents: the JS high school study. BMC Pulmonary Medicine, 2017, 17, 190.	2.0	11
894	Early markers of cardiovascular disease are associated with occupational exposure to polycyclic aromatic hydrocarbons. Scientific Reports, 2017, 7, 9426.	3.3	71
895	Sports and HDL-Quality Reflected By Serum Amyloid A and Surfactant Protein B. International Journal of Medical Sciences, 2017, 14, 1040-1048.	2.5	4
896	Therapies Targeting HDLc Levels and HDL Function. , 2017, , 257-300.		1
897	Cholesterol and Lipids. , 2017, , 9-21.		0
898	Molecular Mechanisms of Hyperalphalipoproteinemia. , 2017, , 1-21.		0
899	Cholesterol Uptake Capacity: A New Measure of HDL Functionality for Coronary Risk Assessment. journal of applied laboratory medicine, The, 2017, 2, 186-200.	1.3	34
900	A big data approach to examine the association of high density lipoprotein cholesterol and mortality: lessons for future investigations. Journal of Thoracic Disease, 2017, 9, 4926-4928.	1.4	0
901	Regression of Atherosclerosis: Insights from Animal and Clinical Studies. Annals of Global Health, 2018, 80, 13.	2.0	56
902	DFMG attenuates the activation of macrophages induced by coâ€‘culture with LPCâ€‘injured HUVEâ€‘12 cells via the TLR4/MyD88/NFâ€ÎºB signaling pathway. International Journal of Molecular Medicine, 2018, 41, 2619-2628.	4.0	10
903	HDL in CKDâ€"The Devil Is in the Detail. Journal of the American Society of Nephrology: JASN, 2018, 29, 1356-1371.	6.1	65
904	DFMG reverses proliferation and migration of vascular smooth muscle cells induced by co-culture with injured vascular endothelial cells via suppression of the TLR4-mediated signaling pathway. Molecular Medicine Reports, 2018, 17, 5692-5699.	2.4	9
905	Cardiovascular outcomes trial with anacetrapib in subjects with high cardiovascular risk â€“ are major benefits REVEALed?. Expert Opinion on Pharmacotherapy, 2018, 19, 611-615.	1.8	2

#	Article	IF	Citations
906	Harnessing the Power of Proteomics to Assess Drug Safety and Guide Clinical Trials. Circulation, 2018, 137, 1011-1014.	1.6	5
907	Saturated Fats from Butter but Not from Cheese Increase HDL-Mediated Cholesterol Efflux Capacity from J774 Macrophages in Men and Women with Abdominal Obesity. Journal of Nutrition, 2018, 148, 573-580.	2.9	18
908	Long noncoding RNA lncARSR promotes hepatic cholesterol biosynthesis via modulating Akt/SREBP-2/HMGCR pathway. Life Sciences, 2018, 203, 48-53.	4.3	32
909	Effects of Different Weight Loss Approaches on CVD Risk. Current Atherosclerosis Reports, 2018, 20, 27.	4.8	31
910	AIBP decreases atherogenesis by augmenting cholesterol efflux. Atherosclerosis, 2018, 273, 117-118.	0.8	4
911	Rare SCARB1 mutations associate with high-density lipoprotein cholesterol but not with coronary artery disease. European Heart Journal, 2018, 39, 2172-2178.	2.2	53
912	High-Density Lipoproteins. Cardiology Clinics, 2018, 36, 317-327.	2.2	14
913	From genome-wide association studies to Mendelian randomization: novel opportunities for understanding cardiovascular disease causality, pathogenesis, prevention, and treatment. Cardiovascular Research, 2018, 114, 1192-1208.	3.8	64
914	Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599â€˜912 current drinkers in 83 prospective studies. Lancet, The, 2018, 391, 1513-1523.	13.7	858
915	Cholesteryl Ester Transfer Protein Inhibitors as Agents to Reduce Coronary Heart Disease Risk. Cardiology Clinics, 2018, 36, 299-310.	2.2	11
916	Insights from population-based analyses of plasma lipids across the allele frequency spectrum. Current Opinion in Genetics and Development, 2018, 50, 1-6.	3.3	9
917	Increments in serum high-density lipoprotein cholesterol over time are not associated with improved outcomes in incident hemodialysis patients. Journal of Clinical Lipidology, 2018, 12, 488-497.	1.5	15
918	Challenges in Interpreting Multivariable Mendelian Randomization: Might â€œGood Cholesterolâ€•Be Good After All?. American Journal of Kidney Diseases, 2018, 71, 149-153.	1.9	15
919	Lipids, Lipoproteins, and Metabolites andÂRisk of Myocardial Infarction andÂStroke. Journal of the American College of Cardiology, 2018, 71, 620-632.	2.8	294
920	Big data from electronic health records for early and late translational cardiovascular research: challenges and potential. European Heart Journal, 2018, 39, 1481-1495.	2.2	163
921	A rare missense variant in NR1H4 associates with lower cholesterol levels. Communications Biology, 2018, 1, 14.	4.4	6
922	From High-Density Lipoprotein Cholesterol to Measurements of Function. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 487-499.	2.4	94
923	Causal associations between risk factors and common diseases inferred from GWAS summary data. Nature Communications, 2018, 9, 224.	12.8	629

#	Article	IF	Citations
925	A Critical Review of the Consensus Statement from the European Atherosclerosis Society Consensus Panel 2017. Pharmacology, 2018, 101, 184-218.	2.2	21
926	High-Density Lipoprotein Function in Cardiovascular Disease and Diabetes Mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, e10-e16.	2.4	39
927	Dyslipidemia. , 2018, , 303-309.		0
928	Managing Dyslipidemia in Type 2 Diabetes. Endocrinology and Metabolism Clinics of North America, 2018, 47, 153-173.	3.2	24
929	Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study. Prostate Cancer and Prostatic Diseases, 2018, 21, 252-259.	3.9	71
930	Modified risk associations of lipoproteins and apolipoproteins by chronic low-grade inflammation. Expert Review of Cardiovascular Therapy, 2018, 16, 39-48.	1.5	4
931	Review of biomarkers to assess the effects of switching from cigarettes to modified risk tobacco products. Biomarkers, 2018, 23, 213-244.	1.9	18
932	Impact of Aging on the Strength of Cardiovascular Risk Factors: A Longitudinal Study Over 40 Years. Journal of the American Heart Association, 2018, 7, .	3.7	85
933	Apolipoprotein A1 distribution pattern in the human Achilles tendon. Scandinavian Journal of Medicine and Science in Sports, 2018, 28, 1506-1513.	2.9	4
934	High density lipoprotein with apolipoprotein C-III is associated with carotid intima-media thickness among generally healthy individuals. Atherosclerosis, 2018, 269, 92-99.	0.8	11
935	Changes in HDL-c concentrations after 16 weeks of combined training in postmenopausal women: characteristics of positive and negative responders. Applied Physiology, Nutrition and Metabolism, 2018, 43, 38-44.	1.9	6
936	Consideration of Sex Differences in Design and Reporting of Experimental Arterial Pathology Studiesâ€"Statement From ATVB Council. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 292-303.	2.4	221
937	New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 119-127.	3.0	17
938	Causal Effect of Lipids and Lipoproteins on Atherosclerosis. Cardiology Clinics, 2018, 36, 203-211.	2.2	26
939	Lipids and Lipoproteins in Risk Prediction. Cardiology Clinics, 2018, 36, 213-220.	2.2	7
940	Why Drugs Fail in Late Stages of Development: Case Study Analyses from the Last Decade and Recommendations. AAPS Journal, 2018, 20, 46.	4.4	46
941	Assessing the Associations of Blood Metabolites With Osteoporosis: A Mendelian Randomization Study. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1850-1855.	3.6	19
942	Role of Blood Lipids in the Development of Ischemic Stroke and its Subtypes. Stroke, 2018, 49, 820-827.	2.0	132

#	Article	IF	Citations
943	Poststatin era in atherosclerosis management. Current Opinion in Lipidology, 2018, 29, 246-258.	2.7	7
944	Lipoprotein Disorders. , 2018, , 27-46.		1
945	Novel Approaches to Cardiovascular Diagnostics. , 2018, , 83-101.		0
946	Large-Scale Genomic Biobanks and Cardiovascular Disease. Current Cardiology Reports, 2018, 20, 22.	2.9	8
947	HDL Cholesterol, LDL Cholesterol, and Triglycerides as Risk Factors for CKD: A Mendelian Randomization Study. American Journal of Kidney Diseases, 2018, 71, 166-172.	1.9	90
948	PCSK 9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease. Diabetes, Obesity and Metabolism, 2018, 20, 270-282.	4.4	22
949	Association between Mediterranean diet adherence and dyslipidaemia in a cohort of adults living in the Mediterranean area. International Journal of Food Sciences and Nutrition, 2018, 69, 608-618.	2.8	21
950	Phenol-enriched olive oils improve HDL antioxidant content in hypercholesterolemic subjects. A randomized, double-blind, cross-over, controlled trial. Journal of Nutritional Biochemistry, 2018, 51, 99-104.	4.2	28
951	Causal effects of cardiovascular risk factors on onset of major age-related diseases: A time-to-event Mendelian randomization study. Experimental Gerontology, 2018, 107, 74-86.	2.8	16
952	Trials and Tribulations of CETP Inhibitors. Circulation Research, 2018, 122, 106-112.	4.5	210
953	Embracing polygenicity: a review of methods and tools for psychiatric genetics research. Psychological Medicine, 2018, 48, 1055-1067.	4.5	66
954	Current drugs, targets, and drug delivery systems for the treatment of dyslipidemia. Journal of Pharmaceutical Investigation, 2018, 48, 233-241.	5.3	3
955	High-Density Lipoprotein Subspecies Defined by Presence of Apolipoprotein C-III and Incident Coronary Heart Disease in Four Cohorts. Circulation, 2018, 137, 1364-1373.	1.6	85
956	The Influence of Big (Clinical) Data and Genomics on Precision Medicine and Drug Development. Clinical Pharmacology and Therapeutics, 2018, 103, 409-418.	4.7	42
957	A cross-sectional and longitudinal study between association of n-3 polyunsaturated fatty acids derived from fish consumption and high-density lipoprotein heterogeneity. Heart and Vessels, 2018, 33, 470-480.	1.2	9
958	Genetic Association of Lipids and Lipid Drug Targets With Abdominal Aortic Aneurysm. JAMA Cardiology, 2018, 3, 26.	6.1	75
959	Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nature Reviews Nephrology, 2018, 14, 57-70.	9.6	192
960	Effect of whole milk compared with skimmed milk on fasting blood lipids in healthy adults: a 3-week randomized crossover study. European Journal of Clinical Nutrition, 2018, 72, 249-254.	2.9	27

#	Article	IF	Citations
961	Effects of endurance training on serum lipids. Vascular Pharmacology, 2018, 101, 9-20.	2.1	38
962	Dynamic changes of the composition of plasma <scp>HDL</scp> particles in patients with cardiac disease: Spotlight on sphingosineâ€1â€phosphate/serum amyloid A ratio. Clinical and Experimental Pharmacology and Physiology, 2018, 45, 319-325.	1.9	3
963	Association of CETP Gene Variants With Risk for Vascular and Nonvascular Diseases Among Chinese Adults. JAMA Cardiology, 2018, 3, 34.	6.1	54
964	Increased prevalence of clinical and subclinical atherosclerosis in patients with damaging mutations in ABCA1 or APOA1. Journal of Clinical Lipidology, 2018, 12, 116-121.	1.5	23
965	Bariatric surgery improves lipoprotein profile in morbidly obese patients by reducing LDL cholesterol, apoB, and SAA/PON1 ratio, increasing HDL cholesterol, but has no effect on cholesterol efflux capacity. Journal of Clinical Lipidology, 2018, 12, 193-202.	1.5	31
966	HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology. Nature Reviews Cardiology, 2018, 15, 9-19.	13.7	105
968	The quest for immunotherapy in atherosclerosis: CANTOS study, interleukin-1Î² and vascular inflammation. Journal of Thoracic Disease, 2018, 10, 64-69.	1.4	7
969	Standard and Novel Biomarkers. , 2018, , 98-113.		1
970	Primary Prevention of Atherosclerotic Cardiovascular Disease. , 2018, , 433-458.		0
971	The pleiotropic vasoprotective functions of high density lipoproteins (HDL). Journal of Biomedical Research, 2018, 32, .	1.6	23
972	OBSOLETE: Biomarkers in Ischemic Heart Disease. , 2018, , .		0
973	1986 American Heart Association Bugher Program Pivotal to Current Management and Research of Heart Disease. Circulation Genomic and Precision Medicine, 2018, 11, e002222.	3.6	0
974	High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease. Drugs in Context, 2018, 7, 1-9.	2.2	129
975	Low HDL and High HDL Syndromes. , 2018, , 327-339.		1
976	High-Density Lipoproteinâ€“Targeted Therapiesâ€”Not Dead Yetâ€”Reply. JAMA Cardiology, 2018, 3, 1255.	6.1	1
977	A comprehensive evaluation of the genetic architecture of sudden cardiac arrest. European Heart Journal, 2018, 39, 3961-3969.	2.2	59
978	Mendelian Randomization Studies Promise to Shorten the Journey to FDAÂApproval. JACC Basic To Translational Science, 2018, 3, 690-703.	4.1	18
979	Distinct Proteomic Signatures in 16 HDL (High-Density Lipoprotein) Subspecies. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 2827-2842.	2.4	75

#	Article	IF	Citations
980	Additional value of a combined genetic risk score to standard cardiovascular stratification. Genetics and Molecular Biology, 2018, 41, 766-774.	1.3	7
981	USF1 deficiency alleviates inflammation, enhances cholesterol efflux and prevents cholesterol accumulation in macrophages. Lipids in Health and Disease, 2018, 17, 285.	3.0	16
982	Association of Serum Cholesterol EffluxÂCapacity With Mortality in PatientsÂWith ST-SegmentÂElevation Myocardial Infarction. Journal of the American College of Cardiology, 2018, 72, 3259-3269.	2.8	55
983	Examining the paradox of high high-density lipoprotein and elevated cardiovascular risk. Journal of Thoracic Disease, 2018, 10, 109-112.	1.4	23
985	How Eliminating Malaria May Also Prevent Iron Deficiency in African Children. Pharmaceuticals, 2018, 11, 96.	3.8	13
986	High density lipoprotein proteome is associated with cardiovascular risk factors and atherosclerosis burden as evaluated by coronary CT angiography. Atherosclerosis, 2018, 278, 278-285.	0.8	39
987	Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study. Journal of Clinical Lipidology, 2018, 12, 1493-1501.e11.	1.5	7
988	Genetics of blood lipids among ~300,000 multi-ethnic participants of the Million Veteran Program. Nature Genetics, 2018, 50, 1514-1523.	21.4	497
989	Cholesteryl ester transfer protein: An enigmatic pharmacology â€“ Antagonists and agonists. Atherosclerosis, 2018, 278, 286-298.	0.8	25
990	Plasma oxidized high-density lipoprotein and glycated apolipoprotein A-I concentrations in ST-segment elevation myocardial infarction patients with stress hyperglycaemia or high thrombus burden. Upsala Journal of Medical Sciences, 2018, 123, 158-166.	0.9	4
991	Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. American Heart Journal, 2018, 206, 80-93.	2.7	276
992	Principles of precision medicine and its application in toxicology. Journal of Toxicological Sciences, 2018, 43, 565-577.	1.5	15
993	Genetics of Coronary Atherosclerosis. , 2018, , 33-44.		0
994	Translating Evidence of HDL and Plaque Regression. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 1961-1968.	2.4	25
995	V-ATPase (Vacuolar ATPase) Activity Required for ABCA1 (ATP-Binding Cassette Protein A1)-Mediated Cholesterol Efflux. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 2615-2625.	2.4	11
996	Commentary on High-density Lipoprotein Versus Low-density Lipoprotein Therapy and Cardiovascular Outcomes in Patients with Acute Coronary Syndromes by Nikolaos Papageorgiou et al.. Current Cardiology Reviews, 2018, 14, 301-302.	1.5	0
997	High Low-Density Lipoprotein Cholesterol Inversely Relates to Dementia in Community-Dwelling Older Adults: The Shanghai Aging Study. Frontiers in Neurology, 2018, 9, 952.	2.4	23
998	CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I: safety and tolerability profiles and implications for management in patients with myocardial infarction. Expert Opinion on Investigational Drugs, 2018, 27, 997-1005.	4.1	18

#	Article	IF	Citations
999	Progress of Genomics in Atherosclerosis-Coronary Heart Disease and Myocardial Infarction. Translational Bioinformatics, 2018, , 219-240.	0.0	0
1001	Distinguishing genetic correlation from causation across 52 diseases and complex traits. Nature Genetics, 2018, 50, 1728-1734.	21.4	262
1002	Genetic and secondary causes of severe HDL deficiency and cardiovascular disease. Journal of Lipid Research, 2018, 59, 2421-2435.	4.2	49
1003	Role of ApoE gene polymorphism and nonconventional biochemical risk factors among very young individuals (aged less than 35 years) presenting with acute myocardial infarction. Indian Heart Journal, 2018, 70, S146-S156.	0.5	10
1004	Association of Genetically Enhanced Lipoprotein Lipaseâ€“Mediated Lipolysis and Low-Density Lipoprotein Cholesterolâ€“Lowering Alleles With Risk of Coronary Disease and Type 2 Diabetes. JAMA Cardiology, 2018, 3, 957.	6.1	55
1005	Can the Plasma Concentration Ratio of Triglyceride/High-Density Lipoprotein Cholesterol Identify Individuals at High Risk of Cardiovascular Disease During 40-Year Follow-Up?. Metabolic Syndrome and Related Disorders, 2018, 16, 433-439.	1.3	16
1006	A robust method to estimate regional polygenic correlation under misspecified linkage disequilibrium structure. Genetic Epidemiology, 2018, 42, 636-647.	1.3	3
1007	From lipid locus to drug target through human genomics. Cardiovascular Research, 2018, 114, 1258-1270.	3.8	17
1008	Genetic-Driven Druggable Target Identification and Validation. Trends in Genetics, 2018, 34, 558-570.	6.7	44
1009	Circulating Selenium and Prostate Cancer Risk: A Mendelian Randomization Analysis. Journal of the National Cancer Institute, 2018, 110, 1035-1038.	6.3	84
1010	Mendelian randomization: A powerful method to determine causality of biomarkers in diseases. International Journal of Cardiology, 2018, 268, 227-228.	1.7	2
1011	Risk factor profile and anatomic features of previously asymptomatic patients presenting with carotid-related stroke. Journal of Vascular Surgery, 2018, 68, 1390-1395.	1.1	26
1012	Quantifying the Impact of Rare and Ultra-rare Coding Variation across the Phenotypic Spectrum. American Journal of Human Genetics, 2018, 102, 1204-1211.	6.2	102
1013	Mendelian randomization: Its impact on cardiovascular disease. Journal of Cardiology, 2018, 72, 307-313.	1.9	23
1014	Hypertriglyceridemia in Diabetes Mellitus: Implications for Pediatric Care. Journal of the Endocrine Society, 2018, 2, 497-512.	0.2	19
1015	Lipids, Apolipoproteins, and Inflammatory Biomarkers of Cardiovascular Risk: What Have We Learned?. Clinical Pharmacology and Therapeutics, 2018, 104, 244-256.	4.7	14
1016	Biomarkers in Ischemic Heart Disease. , 2018, , 303-314.		0
1017	Adipose tissue palmitoleic acid is inversely associated with nonfatal acute myocardial infarction in Costa Rican adults. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 973-979.	2.6	5

#	Article	IF	Citations
1018	Causal Inference in Cancer Epidemiology: What Is the Role of Mendelian Randomization?. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 995-1010.	2.5	109
1020	Association of High-Density Lipoprotein Subclasses with Carotid Intima-Media Thickness: Shimane CoHRE Study. Journal of Atherosclerosis and Thrombosis, 2018, 25, 42-54.	2.0	10
1021	Impact of a one-year lifestyle modification program on cholesterol efflux capacities in men with abdominal obesity and dyslipidemia. American Journal of Physiology - Endocrinology and Metabolism, 2018, 315, E460-E468.	3.5	19
1022	Mendelian randomisation analysis of clustered causal effects of body mass on cardiometabolic biomarkers. BMC Bioinformatics, 2018, 19, 195.	2.6	2
1023	Effect of Serial Infusions of CER-001, a Pre-Î² High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial. JAMA Cardiology, 2018, 3, 815.	6.1	135
1024	Translating GWAS Findings to Novel Therapeutic Targets for Coronary Artery Disease. Frontiers in Cardiovascular Medicine, 2018, 5, 56.	2.4	21
1025	Scientific Contributions of Population-Based Studies to Cardiovascular Epidemiology in the GWAS Era. Frontiers in Cardiovascular Medicine, 2018, 5, 57.	2.4	7
1026	Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ: British Medical Journal, 2018, 362, k601.	2.3	1,880
1027	Making the Most out of Mendelâ€™s Laws inÂComplex Coronary Artery Disease. Journal of the American College of Cardiology, 2018, 72, 311-313.	2.8	0
1028	The Role of High-Density Lipoproteins in Diabetes and Its Vascular Complications. International Journal of Molecular Sciences, 2018, 19, 1680.	4.1	41
1029	Shared Genetic Contribution of Type 2 Diabetes and Cardiovascular Disease: Implications for Prognosis and Treatment. Current Diabetes Reports, 2018, 18, 59.	4.2	25
1030	Testosterone treatment in older men: clinical implications and unresolved questions from the Testosterone Trials. Lancet Diabetes and Endocrinology,the, 2018, 6, 659-672.	11.4	32
1031	Pathophysiology of Diabetic Dyslipidemia. Journal of Atherosclerosis and Thrombosis, 2018, 25, 771-782.	2.0	271
1032	Regulation of apolipoprotein A-I gene expression by the histamine H1 receptor: Requirement for NF-ÎºB. Life Sciences, 2018, 208, 102-110.	4.3	5
1033	Unravelling HDLâ€"Looking beyond the Cholesterol Surface to the Quality Within. International Journal of Molecular Sciences, 2018, 19, 1971.	4.1	51
1034	Genetics of coronary artery disease in the light of genome-wide association studies. Clinical Research in Cardiology, 2018, 107, 2-9.	3.3	46
1035	Plasma high density lipoproteins: Therapeutic targeting and links to atherogenic inflammation. Atherosclerosis, 2018, 276, 39-43.	0.8	45
1036	Therapeutic Agents Targeting Cardiometabolic Risk for Preventing and Treating Atherosclerotic Cardiovascular Diseases. Clinical Pharmacology and Therapeutics, 2018, 104, 257-268.	4.7	12

#	Article	IF	Citations
1037	High-density lipoprotein 3 cholesterol is a predictive factor for arterial stiffness: a community-based 4.8-year prospective study. Lipids in Health and Disease, 2018, 17, 5.	3.0	15
1038	Complete and Partial Lecithin:Cholesterol Acyltransferase Deficiency Is Differentially Associated With Atherosclerosis. Circulation, 2018, 138, 1000-1007.	1.6	56
1039	CETP (Cholesteryl Ester Transfer Protein) Concentration. Circulation Genomic and Precision Medicine, 2018, 11, e002034.	3.6	44
1040	Which Lipids Should Be Analyzed for Diagnostic Workup and Follow-up of Patients with Hyperlipidemias?. Current Cardiology Reports, 2018, 20, 88.	2.9	18
1041	A critical appraisal of the measurement of serum â€˜cholesterol efflux capacityâ€™ and its use as surrogate marker of risk of cardiovascular disease. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2018, 1863, 1257-1273.	2.4	18
1042	Clarifying questions about â€œrisk factorsâ€: predictors versus explanation. Emerging Themes in Epidemiology, 2018, 15, 10.	2.7	48
1043	Are serum concentrations of vitamin B-12 causally related to cardiometabolic risk factors and disease? A Mendelian randomization study. American Journal of Clinical Nutrition, 2018, 108, 398-404.	4.7	22
1044	The future of humans as model organisms. Science, 2018, 361, 552-553.	12.6	31
1045	Variants at the APOE/C1/C2/C4 Locus Modulate Cholesterol Efflux Capacity Independently of Highâ€Density Lipoprotein Cholesterol. Journal of the American Heart Association, 2018, 7, e009545.	3.7	25
1046	Genetic Epidemiology. Methods in Molecular Biology, 2018, , .	0.9	1
1047	HDL-cholesterol, genetics, and coronary artery disease: the myth of the â€˜good cholesterolâ€™?. European Heart Journal, 2018, 39, 2179-2182.	2.2	15
1048	PK/PD Disconnect Observed with a Reversible Endothelial Lipase Inhibitor. ACS Medicinal Chemistry Letters, 2018, 9, 673-678.	2.8	7
1049	Niacin. Advances in Food and Nutrition Research, 2018, 83, 83-149.	3.0	64
1050	A Primer in Mendelian Randomization Methodology with a Focus on Utilizing Published Summary Association Data. Methods in Molecular Biology, 2018, 1793, 211-230.	0.9	19
1051	Myeloperoxidase mediated HDL oxidation and HDL proteome changes do not contribute to dysfunctional HDL in Chinese subjects with coronary artery disease. PLoS ONE, 2018, 13, e0193782.	2.5	20
1052	Cardiovascular disease: The rise of the genetic risk score. PLoS Medicine, 2018, 15, e1002546.	8.4	138
1053	A snapshot of lipid levels in the Republic of Ireland in 2017. Irish Journal of Medical Science, 2019, 188, 241-247.	1.5	3
1054	Pharmacological Management of Dyslipidemia in Atherosclerosis: Limitations, Challenges, and New Therapeutic Opportunities. Angiology, 2019, 70, 197-209.	1.8	18

#	Article	IF	Citations
1055	Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study. Cardiovascular Research, 2019, 115, 204-212.	3.8	34
1056	Antiâ€ApoAâ€I IgG antibodies are not associated with carotid artery disease progression and firstâ€time cardiovascular events in middleâ€aged individuals. Journal of Internal Medicine, 2019, 285, 49-58.	6.0	4
1057	Utilizing stateâ€ofâ€theâ€art â€œomicsâ€•technology and bioinformatics to identify new biological mechanisms and biomarkers for coronary artery disease. Microcirculation, 2019, 26, e12488.	1.8	49
1058	The expression of hSR-B1 on platelets of patients with coronary artery disease (CAD). Clinical Hemorheology and Microcirculation, 2019, 71, 9-15.	1.7	1
1059	Deepening our understanding of HDL proteome. Expert Review of Proteomics, 2019, 16, 749-760.	3.0	38
1060	HDL Cholesterol Level and Mortality Occurrence in the Elderly: Is the Good Cholesterol Always Good?. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4114-4116.	3.6	6
1061	Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options. Lancet, The, 2019, 394, 697-708.	13.7	67
1062	Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk: An Endocrine Society* Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3939-3985.	3.6	42
1063	The role of adiponectin in cholesterol efflux and HDL biogenesis and metabolism. Metabolism: Clinical and Experimental, 2019, 100, 153953.	3.4	52
1064	Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options. Current Cardiology Reports, 2019, 21, 110.	2.9	24
1065	Modified and Dysfunctional Lipoproteins in Atherosclerosis: Effectors or Biomarkers?. Current Medicinal Chemistry, 2019, 26, 1512-1524.	2.4	17
1066	Association of extremely high levels of high-density lipoprotein cholesterol with endothelial dysfunction in men. Journal of Clinical Lipidology, 2019, 13, 664-672.e1.	1.5	18
1067	High Cardiovascular Risk Profile in Young Patients on the Kidney Transplant Waiting List. Transplantation Proceedings, 2019, 51, 1717-1726.	0.6	1
1068	Powerful three-sample genome-wide design and robust statistical inference in summary-data Mendelian randomization. International Journal of Epidemiology, 2019, 48, 1478-1492.	1.9	121
1069	Rounding the corner on residual risk: Implications of REDUCEâ€IT for omegaâ€3 polyunsaturated fatty acids treatment in secondary prevention of atherosclerotic cardiovascular disease. Clinical Cardiology, 2019, 42, 829-838.	1.8	13
1070	Optimal Non-invasive Strategies to Reduce Recurrent Atherosclerotic Cardiovascular Disease Risk. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 38.	0.9	1
1071	Association Mapping and Disease: Evolutionary Perspectives. Methods in Molecular Biology, 2019, 1910, 533-553.	0.9	0
1072	Association between high-density lipoprotein cholesterol and all-cause mortality in the general population of northern China. Scientific Reports, 2019, 9, 14426.	3.3	25

#	Article	IF	Citations
1074	High-density Lipoprotein-cholesterol Subfractions and Coronary Artery Calcium: The ELSA-Brasil Study. Archives of Medical Research, 2019, 50, 362-367.	3.3	14
1076	HDL therapy today: from atherosclerosis, to stent compatibility to heart failure. Annals of Medicine, 2019, 51, 345-359.	3.8	26
1077	Infusions of Large Synthetic HDL Containing Trimeric apoA-I Stabilize Atherosclerotic Plaques in Hypercholesterolemic Rabbits. Canadian Journal of Cardiology, 2019, 35, 1400-1408.	1.7	11
1078	Multi-ancestry sleep-by-SNP interaction analysis in 126,926 individuals reveals lipid loci stratified by sleep duration. Nature Communications, 2019, 10, 5121.	12.8	62
1079	Systems genetics applications in metabolism research. Nature Metabolism, 2019, 1, 1038-1050.	11.9	35
1080	Lower than average HDL cholesterol efflux capacity in Lithuanian population. Lipids in Health and Disease, 2019, 18, 186.	3.0	1
1081	Highlighting Residual Atherosclerotic Cardiovascular Disease Risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, e1-e9.	2.4	45
1082	Integrative transcriptome imputation reveals tissue-specific and shared biological mechanisms mediating susceptibility to complex traits. Nature Communications, 2019, 10, 3834.	12.8	68
1083	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis, 2019, 290, 140-205.	0.8	1,753
1084	HDL flux is higher in patients with nonalcoholic fatty liver disease. American Journal of Physiology - Endocrinology and Metabolism, 2019, 317, E852-E862.	3.5	26
1085	Serum concentration of full-length- and carboxy-terminal fragments of endothelial lipase predicts future cardiovascular risks in patients with coronary artery disease. Journal of Clinical Lipidology, 2019, 13, 839-846.	1.5	4
1086	Deconstructing the sources of genotype-phenotype associations in humans. Science, 2019, 365, 1396-1400.	12.6	170
1087	Association Between HDL Cholesterol and QTc Interval: A Population-Based Epidemiological Study. Journal of Clinical Medicine, 2019, 8, 1527.	2.4	9
1088	Associations of ABCG1-mediated cholesterol efflux capacity with coronary artery lipid content assessed by near-infrared spectroscopy. Cardiovascular Diagnosis and Therapy, 2019, 9, 310-318.	1.7	9
1089	Anti-Inflammatory Effects of HDL (High-Density Lipoprotein) in Macrophages Predominate Over Proinflammatory Effects in Atherosclerotic Plaques. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, e253-e272.	2.4	86
1090	Heart Disease and Stroke Statisticsâ€"2019 Update: A Report From the American Heart Association. Circulation, 2019, 139, e56-e528.	1.6	6,192
1091	Lipid-Lowering Agents. Circulation Research, 2019, 124, 386-404.	4.5	124
1092	Thyroid Function and the Risk of Atrial Fibrillation. JAMA Cardiology, 2019, 4, 97.	6.1	6

#	Article	IF	Citations
1093	High-Density Lipoprotein Function and Dysfunction in Health and Disease. Cardiovascular Drugs and Therapy, 2019, 33, 207-219.	2.6	69
1094	Multilevel omics: A next step on the way to understanding pulmonary arterial hypertension?. Thorax, 2019, 74, 317-318.	5.6	1
1095	Olive Oil and Health Effects. Reference Series in Phytochemistry, 2019, , 1071-1096.	0.4	2
1096	HDL cholesterol and ASCVD risk stratification: A debate. Atherosclerosis, 2019, 283, 7-12.	0.8	43
1097	Cross-disorder analysis of schizophrenia and 19 immune-mediated diseases identifies shared genetic risk. Human Molecular Genetics, 2019, 28, 3498-3513.	2.9	65
1098	Genome-wide association analysis of HDL-C in a Lebanese cohort. PLoS ONE, 2019, 14, e0218443.	2.5	5
1099	Genetics, Dyslipidemia, and Cardiovascular Disease: New Insights. Current Cardiology Reports, 2019, 21, 68.	2.9	49
1100	Anti-obesity effects of Spirulina platensis protein hydrolysate by modulating brain-liver axis in high-fat diet fed mice. PLoS ONE, 2019, 14, e0218543.	2.5	30
1101	Paraoxonase 1, HDL Subclasses and Post Surgery Acute Inflammation: A Pilot Study. Antioxidants, 2019, 8, 192.	5.1	8
1102	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMÎ±) paradigm: conceptual framework and therapeutic potential. Cardiovascular Diabetology, 2019, 18, 71.	6.8	104
1103	Lymphatic system identification, pathophysiology and therapy in the cardiovascular diseases. Journal of Molecular and Cellular Cardiology, 2019, 133, 99-111.	1.9	26
1104	Cholesterol efflux capacity, HDL cholesterol, and risk of coronary heart disease: a nested case-control study in men. Journal of Lipid Research, 2019, 60, 1457-1464.	4.2	27
1105	Association of ABCA1 Haplotypes with Coronary Artery Disease. Laboratory Medicine, 2019, 51, 157-168.	1.2	4
1106	Placental secretion of apolipoprotein A1 and E: the anti-atherogenic impact of the placenta. Scientific Reports, 2019, 9, 6225.	3.3	30
1107	Mendelian randomization studies on atherosclerotic cardiovascular disease: evidence and limitations. Science China Life Sciences, 2019, 62, 758-770.	4.9	15
1108	Current pharmacotherapeutic options for primary dyslipidemia in adults. Expert Opinion on Pharmacotherapy, 2019, 20, 1277-1288.	1.8	18
1109	HDL and Reverse Cholesterol Transport. Circulation Research, 2019, 124, 1505-1518.	4.5	419
1110	Genetic Association of Finger Photoplethysmography-Derived Arterial Stiffness Index With Blood Pressure and Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 1253-1261.	2.4	35

#	Article	IF	Citations
1111	Lipoprotein(a): An underrecognized genetic risk factor for malignant coronary artery disease in young Indians. Indian Heart Journal, 2019, 71, 184-198.	0.5	40
1112	Emerging Lipid-Lowering Therapies in Secondary Prevention. Current Cardiovascular Risk Reports, 2019, 13, 1.	2.0	0
1113	The time for lipoprotein(a) based intervention has arrived: where will the light shine?. Journal of Thoracic Disease, 2019, 11, S433-S436.	1.4	3
1114	Residual cardiovascular risk among people with diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 28-38.	4.4	31
1115	Association of an HDL Apolipoproteomic Score With Coronary Atherosclerosis and Cardiovascular Death. Journal of the American College of Cardiology, 2019, 73, 2135-2145.	2.8	26
1116	Recombinant LCAT (Lecithin:Cholesterol Acyltransferase) Rescues Defective HDL (High-Density) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Thrombosis, and Vascular Biology, 2019, 39, 915-924.	2.4	41
1117	Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia. Annals of Clinical Biochemistry, 2019, 56, 338-356.	1.6	27
1118	Lower HDL-cholesterol, a known marker of cardiovascular risk, was associated with depression in type 1 diabetes: a cross sectional study. Lipids in Health and Disease, 2019, 18, 65.	3.0	20
1119	Substantial fat mass loss reduces low-grade inflammation and induces positive alteration in cardiometabolic factors in normal-weight individuals. Scientific Reports, 2019, 9, 3450.	3.3	34
1120	Rethinking good cholesterol: a clinicians' guide to understanding HDL. Lancet Diabetes and Endocrinology,the, 2019, 7, 575-582.	11.4	38
1121	Genomic Medicineâ€“Progress, Pitfalls, and Promise. Cell, 2019, 177, 45-57.	28.9	143
1122	Genetics of Common, Complex Coronary Artery Disease. Cell, 2019, 177, 132-145.	28.9	166
1123	The Genetic Basis of Metabolic Disease. Cell, 2019, 177, 146-161.	28.9	104
1124	Trials in â€œTrueâ€•Dyslipidemic Patients Are Urged to Reconsider Comprehensive Lipid Management as a Means to Reduce Residual Cardiovascular Risk. Clinical Pharmacology and Therapeutics, 2019, 106, 960-967.	4.7	2
1126	Association Between Serum Highâ€Ðensity Lipoprotein Cholesterol Levels and Progression of Chronic Kidney Disease: Results From the KNOWâ€CKD. Journal of the American Heart Association, 2019, 8, e011162.	3.7	32
1127	The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk. Endocrine Reviews, 2019, 40, 537-557.	20.1	262
1128	2018 William Allan Award: Discovering the Genes for Common Disease: From Families to Populations. American Journal of Human Genetics, 2019, 104, 375-383.	6.2	0
1129	2018 Curt Stern Award Address. American Journal of Human Genetics, 2019, 104, 384-388.	6.2	0

#	Article	IF	Citations
1130	Stroke genetics: discovery, biology, and clinical applications. Lancet Neurology, The, 2019, 18, 587-599.	10.2	138
1131	Breastfeeding in Infancy and Lipid Profile in Adolescence. Pediatrics, 2019, 143, .	2.1	19
1132	Computational Approaches for Identification of Pleiotropic Biomarker Profiles in Psychiatry. Advances in Experimental Medicine and Biology, 2019, 1134, 111-128.	1.6	0
1133	A Novel Cell-Free, Non-Fluorescent Method to Measure LOX-1-Binding Activity Corresponding to The Functional Activity of HDL. Journal of Atherosclerosis and Thrombosis, 2019, 26, 947-958.	2.0	9
1134	Mendelian Randomization Analysis Support Causal Associations of HbA1c with Circulating Triglyceride, Total and Low-density Lipoprotein Cholesterol in a Chinese Population. Scientific Reports, 2019, 9, 5525.	3.3	7
1135	Evaluation of GDF15 as a therapeutic target of cardiometabolic diseases in human: A Mendelian randomization study. EBioMedicine, 2019, 41, 85-90.	6.1	33
1136	Very high high-density lipoprotein cholesterol is associated with increased all-cause mortality in South Koreans. Atherosclerosis, 2019, 283, 43-51.	0.8	36
1137	Lipoprotein signatures of cholesteryl ester transfer protein and HMG-CoA reductase inhibition. PLoS Biology, 2019, 17, e3000572.	5.6	29
1138	The Battle of the HDL Subfractions. Cardiovascular Revascularization Medicine, 2019, 20, 943-944.	0.8	0
1139	Modulation of cholesterol efflux capacity in patients with myocardial infarction. Current Opinion in Cardiology, 2019, 34, 714-720.	1.8	4
1140	The biochemical and genetic diagnosis of lipid disorders. Current Opinion in Lipidology, 2019, 30, 56-62.	2.7	26
1141	The Fluid Aspect of the Mediterranean Diet in the Prevention and Management of Cardiovascular Disease and Diabetes: The Role of Polyphenol Content in Moderate Consumption of Wine and Olive Oil. Nutrients, 2019, 11, 2833.	4.1	129
1142	HDL modification. Current Opinion in Lipidology, 2019, 30, 24-29.	2.7	20
1143	From HDL-cholesterol to HDL-function: cholesterol efflux capacity determinants. Current Opinion in Lipidology, 2019, 30, 101-107.	2.7	28
1144	High-density lipoprotein: our elusive friend. Current Opinion in Lipidology, 2019, 30, 314-319.	2.7	10
1145	HDL from an Alzheimer's disease perspective. Current Opinion in Lipidology, 2019, 30, 224-234.	2.7	70
1146	Genetic Determinants of Lipids and Cardiovascular Disease Outcomes. Circulation Genomic and Precision Medicine, 2019, 12, e002711.	3.6	83
1147	Integrative genomic analysis identified common regulatory networks underlying the correlation between coronary artery disease and plasma lipid levels. BMC Cardiovascular Disorders, 2019, 19, 310.	1.7	9

#	Article	IF	Citations
1148	SPPARM alpha. Current Opinion in Lipidology, 2019, 30, 419-427.	2.7	11
1149	Homogeneity in the association of body mass index with type 2 diabetes across the UK Biobank: A Mendelian randomization study. PLoS Medicine, 2019, 16, e1002982.	8.4	34
1150	Genetics of early-onset coronary artery disease. Current Opinion in Cardiology, 2019, 34, 706-713.	1.8	6
1151	Age-related cardiovascular risk in adult patients with congenital heart disease. International Journal of Cardiology, 2019, 277, 90-96.	1.7	11
1152	Increasing high-density lipoprotein cholesterol levels for cardiovascular benefit: The end of a dream?. European Journal of Preventive Cardiology, 2019, 26, 531-532.	1.8	5
1153	Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia. Cellular Signalling, 2019, 55, 53-64.	3.6	23
1154	High-Density Lipoprotein and High-Density Lipoprotein Cholesterol. , 2019, , 61-69.		1
1155	Predicting Polygenic Risk of Psychiatric Disorders. Biological Psychiatry, 2019, 86, 97-109.	1.3	252
1156	Comment on Rehm: Alcohol, cohort studies and allâ€cause mortality: Where to from here?. Drug and Alcohol Review, 2019, 38, 9-10.	2.1	3
1157	Cholesterol Mass Efflux Capacity, Incident Cardiovascular Disease, and Progression of Carotid Plaque. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 89-96.	2.4	91
1158	Effects of Gender-Affirming Hormones on Lipid, Metabolic, and Cardiac Surrogate Blood Markers in Transgender Persons. Clinical Chemistry, 2019, 65, 119-134.	3.2	56
1159	Assessment of HDL Cholesterol Removal Capacity: Toward Clinical Application. Journal of Atherosclerosis and Thrombosis, 2019, 26, 111-120.	2.0	20
1160	High-resolution genetic mapping of putative causal interactions between regions of open chromatin. Nature Genetics, 2019, 51, 128-137.	21.4	80
1161	Mendelian randomization reveals unexpected effects of CETP on the lipoprotein profile. European Journal of Human Genetics, 2019, 27, 422-431.	2.8	30
1162	Associations between risk of overall mortality, cause-specific mortality and level of inflammatory factors with extremely low and high high-density lipoprotein cholesterol levels among American adults. International Journal of Cardiology, 2019, 276, 242-247.	1.7	30
1163	Potential causal associations of serum 25-hydroxyvitamin D with lipids: a Mendelian randomization approach of the HUNT study. European Journal of Epidemiology, 2019, 34, 57-66.	5.7	11
1164	Olive Oil and Health Effects. Reference Series in Phytochemistry, 2019, , 1-26.	0.4	0
1165	HDL and cardiovascular disease. Pathology, 2019, 51, 142-147.	0.6	56

#	Article	IF	Citations
1166	No causal effects of serum urate levels on the risk of chronic kidney disease: A Mendelian randomization study. PLoS Medicine, 2019, 16, e1002725.	8.4	97
1167	Generalizing polygenic risk scores from Europeans to Hispanics/Latinos. Genetic Epidemiology, 2019, 43, 50-62.	1.3	89
1168	Capitalizing on Insights from Human Genetics to Identify Novel Therapeutic Targets for Coronary Artery Disease. Annual Review of Medicine, 2019, 70, 19-32.	12.2	6
1169	Identifying genetic markers associated with susceptibility to cardiovascular diseases. Future Science OA, 2019, 5, FSO350.	1.9	11
1170	Cholesteryl Ester Transfer Protein Influences High-Density Lipoprotein Levels and Survival in Sepsis. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 854-862.	5.6	62
1171	Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis. European Journal of Preventive Cardiology, 2019, 26, 533-543.	1.8	42
1172	ANGPTL3 Inhibitorsã€€â€• Their Role in Cardiovascular Disease Through Regulation of Lipid Metabolism â€•. Circulation Journal, 2019, 83, 267-273.	1.6	26
1173	Diet, exercise and weight loss and dyslipidaemia. Pathology, 2019, 51, 222-226.	0.6	43
1174	Cholesterol transport system: An integrated cholesterol transport model involved in atherosclerosis. Progress in Lipid Research, 2019, 73, 65-91.	11.6	155
1175	Handling Missing Data in Instrumental Variable Methods for Causal Inference. Annual Review of Statistics and Its Application, 2019, 6, 125-148.	7.0	2
1177	Nonfasting versus fasting lipid profile for cardiovascular risk prediction. Pathology, 2019, 51, 131-141.	0.6	112
1178	High-density lipoprotein cholesterol levels, cardiovascular disease risk, and cancer: a relation which does not apply to all?. Cardiovascular Research, 2019, 115, 6-7.	3.8	3
1179	Psychiatric genetics and the structure of psychopathology. Molecular Psychiatry, 2019, 24, 409-420.	7.9	281
1180	Îhe Antioxidant Function of HDL in Atherosclerosis. Angiology, 2020, 71, 112-121.	1.8	28
1181	A Bayesian approach to Mendelian randomization with multiple pleiotropic variants. Biostatistics, 2020, 21, 86-101.	1.5	37
1182	Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. Lancet Diabetes and Endocrinology,the, 2020, 8, 50-67.	11.4	114
1183	Modification of HDL by reactive aldehydes alters select cardioprotective functions of HDL in macrophages. FEBS Journal, 2020, 287, 695-707.	4.7	13
1184	National trends in total cholesterol obscure heterogeneous changes in HDL and non-HDL cholesterol and total-to-HDL cholesterol ratio: a pooled analysis of 458 population-based studies in Asian and Western countries. International Journal of Epidemiology, 2020, 49, 173-192.	1.9	44

#	Article	IF	Citations
1185	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal, 2020, 41, 111-188.	2.2	4,871
1186	The nonlinear association between outdoor temperature and cholesterol levels, with modifying effect of individual characteristics and behaviors. International Journal of Biometeorology, 2020, 64, 367-375.	3.0	9
1187	Causal Inference for Genetically Determined Levels of High-Density Lipoprotein Cholesterol and Risk of Infectious Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 267-278.	2.4	78
1188	Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality. Diabetologia, 2020, 63, 253-260.	6.3	95
1189	Genetics and Genomics of Atherosclerotic Cardiovascular Disease. , 2020, , 209-230.		0
1190	PCSK9 inhibitors: Ratification of the role of LDL cholesterol in cardiovascular prevention. Towards a convergence of European and North American prevention guidelines?. Revista Clínica Espanõla, 2020, 220, 374-382.	0.5	0
1191	High-density lipoprotein cholesterol efflux capacity and cardiovascular risk in autoimmune and non-autoimmune diseases. Metabolism: Clinical and Experimental, 2020, 104, 154141.	3.4	11
1192	A brief history of human disease genetics. Nature, 2020, 577, 179-189.	27.8	441
1193	Benefits and Risks of Moderate Alcohol Consumption on Cardiovascular Disease: Current Findings and Controversies. Nutrients, 2020, 12, 108.	4.1	84
1194	A Mendelian randomization analysis of circulating lipid traits and breast cancer risk. International Journal of Epidemiology, 2020, 49, 1117-1131.	1.9	41
1195	A Compendium of the Biological Effects of Apolipoprotein A-I_{Milano}. Journal of Pharmacology and Experimental Therapeutics, 2020, 372, 54-62.	2.5	11
1196	Association of Genetically Predicted Lipid Levels With the Extent of Coronary Atherosclerosis in Icelandic Adults. JAMA Cardiology, 2020, 5, 13.	6.1	29
1197	Brothers in Arms: ABCA1- and ABCG1-Mediated Cholesterol Efflux as Promising Targets in Cardiovascular Disease Treatment. Pharmacological Reviews, 2020, 72, 152-190.	16.0	89
1198	Low High-Density Lipoprotein Cholesterol to Monitor Long-Term Average Increased Triglycerides. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1657-e1666.	3.6	24
1199	Using genetics to guide treatment and drug development in cardiovascular medicine: time to reveal the proof in the pudding. Cardiovascular Research, 2020, 116, e30-e32.	3.8	1
1200	Genetically Decreased Circulating Vascular Endothelial Growth Factor and Osteoporosis Outcomes: A Mendelian Randomization Study. Journal of Bone and Mineral Research, 2020, 35, 649-656.	2.8	9
1201	The causal role of elevated uric acid and waist circumference on the risk of metabolic syndrome components. International Journal of Obesity, 2020, 44, 865-874.	3.4	18
1202	HDL and Reverse Remnant-Cholesterol Transport (RRT): Relevance to Cardiovascular Disease. Trends in Molecular Medicine, 2020, 26, 1086-1100.	6.7	51

#	Article	IF	Citations
1203	Interaction between high-density lipoproteins and inflammation: Function matters more than concentration!. Advanced Drug Delivery Reviews, 2020, 159, 94-119.	13.7	50
1204	Triglycerides, HDL cholesterol and atherogenic dyslipidaemia in the 2019 European guidelines for the management of dyslipidaemias. ClÃnica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2020, 32, 209-218.	0.2	2
1205	Mendelian randomization while jointly modeling cis genetics identifies causal relationships between gene expression and lipids. Nature Communications, 2020, 11, 4930.	12.8	20
1206	MR-LDP: a two-sample Mendelian randomization for GWAS summary statistics accounting for linkage disequilibrium and horizontal pleiotropy. NAR Genomics and Bioinformatics, 2020, 2, lqaa028.	3.2	27
1207	A new oral testosterone undecanoate therapy comes of age for the treatment of hypogonadal men. Therapeutic Advances in Urology, 2020, 12, 175628722093723.	2.0	17
1208	Remnant cholesterol as a risk factor for cardiovascular, cancer or other causes mortality: A competing risks analysis. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 2093-2102.	2.6	13
1209	Metabolic and cardiovascular outcomes of bariatric surgery. Current Opinion in Lipidology, 2020, 31, 246-256.	2.7	14
1210	Mendelian randomization and pleiotropy analysis. Quantitative Biology, 2021, 9, 122-132.	0.5	28
1211	An iterative approach to detect pleiotropy and perform Mendelian Randomization analysis using GWAS summary statistics. Bioinformatics, 2021, 37, 1390-1400.	4.1	22
1212	Mouse models of atherosclerosis and their suitability for the study of myocardial infarction. Basic Research in Cardiology, 2020, 115, 73.	5.9	49
1213	Obesity-Related Changes in High-Density Lipoprotein Metabolism and Function. International Journal of Molecular Sciences, 2020, 21, 8985.	4.1	75
1214	Effets de la corticothÃ©rapie systÃ©mique sur le mÃ©tabolisme des HDL. Medecine Des Maladies Metaboliques, 2020, 14, 529-535.	0.1	0
1215	Lipoprotein ability to exchange and remove lipids from model membranes as a function of fatty acid saturation and presence of cholesterol. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2020, 1865, 158769.	2.4	12
1216	Influence of the maternal high-intensity-interval-training on the cardiac Sirt6 and lipid profile of the adult male offspring in rats. PLoS ONE, 2020, 15, e0237148.	2.5	6
1217	The Impact of Dietary Glycemic Index and Glycemic Load on Postprandial Lipid Kinetics, Dyslipidemia and Cardiovascular Risk. Nutrients, 2020, 12, 2204.	4.1	12
1218	Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting. Advanced Drug Delivery Reviews, 2020, 159, 4-33.	13.7	113
1219	Cholesteryl ester transfer protein inhibitors in precision medicine. Clinica Chimica Acta, 2020, 510, 733-740.	1.1	4
1220	Comprehensive Investigation of Circulating Biomarkers and Their Causal Role in Atherosclerosis-Related Risk Factors and Clinical Events. Circulation Genomic and Precision Medicine, 2020, 13, e002996.	3.6	15

#	Article	IF	Citations
1221	Who Benefits From Taking a Statin, and When?. Circulation, 2020, 142, 838-840.	1.6	5
1222	Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. European Heart Journal, 2020, 41, 3936-3945.	2.2	188
1223	Highâ€density lipoproteinâ€related cholesterol metabolism in Alzheimerâ€™s disease. Journal of Neurochemistry, 2021, 159, 343-377.	3.9	8
1224	HDL (High-Density Lipoprotein) Remodeling and Magnetic Resonance Imagingâ€“Assessed Atherosclerotic Plaque Burden. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 2481-2493.	2.4	10
1225	PTWAS: investigating tissue-relevant causal molecular mechanisms of complex traits using probabilistic TWAS analysis. Genome Biology, 2020, 21, 232.	8.8	46
1226	Antiâ€inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial. Journal of the American Heart Association, 2020, 9, e016507.	3.7	21
1227	Polycyclic aromatic hydrocarbons (PAHs) and esophageal carcinoma in Handan-Xingtai district, North China: a preliminary study based on cancer risk assessment. Environmental Monitoring and Assessment, 2020, 192, 596.	2.7	10
1228	Prognostic effect of high-density lipoprotein cholesterol level in patients with atherosclerotic cardiovascular disease under statin treatment. Scientific Reports, 2020, 10, 21835.	3.3	5
1229	High-Density Lipoprotein-Targeted Therapies for Heart Failure. Biomedicines, 2020, 8, 620.	3.2	9
1230	High-density lipoprotein cholesterol and all-cause mortality by sex and age: a prospective cohort study among 15.8 million adults. International Journal of Epidemiology, 2021, 50, 902-913.	1.9	20
1231	Impact of a 2-year trial of nutritional ketosis on indices of cardiovascular disease risk in patients with type 2 diabetes. Cardiovascular Diabetology, 2020, 19, 208.	6.8	40
1232	The public health rationale for reducing saturated fat intakes: Is a maximum of 10% energy intake a good recommendation?. Nutrition Bulletin, 2020, 45, 271-280.	1.8	12
1233	TriglicÃ©ridos, colesterol HDL y dislipidemia aterogÃ©nica en la guÃa europea para el control de las dislipidemias 2019. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2020, 32, 209-218.	0.8	3
1234	Trimethylamine N-oxide and the reverse cholesterol transport in cardiovascular disease: a cross-sectional study. Scientific Reports, 2020, 10, 18675.	3.3	29
1235	For Non-HDL Cholesterol, â€œLower Is Betterâ€•but â€œLower for Longerâ€•May Be Best. Circulation Research, 2020, 126, 836-838.	4.5	2
1236	The Use of Genetic Correlation and Mendelian Randomization Studies to Increase Our Understanding of Relationships between Complex Traits. Current Epidemiology Reports, 2020, 7, 104-112.	2.4	21
1237	Genetic risk scores for coronary artery disease and its traditional risk factors: Their role in the progression of coronary artery calcificationâ€”Results of the Heinz Nixdorf Recall study. PLoS ONE, 2020, 15, e0232735.	2.5	7
1239	The Evolving Understanding and Approach to Residual Cardiovascular Risk Management. Frontiers in Cardiovascular Medicine, 2020, 7, 88.	2.4	82

#	Article	IF	Citations
1240	Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis. Nature Reviews Rheumatology, 2020, 16, 361-379.	8.0	119
1241	Causes and Consequences of Hypertriglyceridemia. Frontiers in Endocrinology, 2020, 11, 252.	3.5	122
1242	Lipid efflux mechanisms, relation to disease and potential therapeutic aspects. Advanced Drug Delivery Reviews, 2020, 159, 54-93.	13.7	18
1243	Genetic overlap and causal inferences between kidney function and cerebrovascular disease. Neurology, 2020, 94, e2581-e2591.	1.1	31
1244	Integrating untargeted metabolomics, genetically informed causal inference, and pathway enrichment to define the obesity metabolome. International Journal of Obesity, 2020, 44, 1596-1606.	3.4	12
1245	Association of High-Density Lipoprotein Cholesterol With Cognitive Function: Findings From the PROspective Study of Pravastatin in the Elderly at Risk. Journal of Aging and Health, 2020, 32, 1267-1274.	1.7	4
1246	Association of high-density lipoprotein levels with baseline coronary plaque volumes by coronary CTA in the EVAPORATE trial. Atherosclerosis, 2020, 305, 34-41.	0.8	7
1247	Leisure time physical activity is associated with improved HDL functionality in high cardiovascular risk individuals: a cohort study. European Journal of Preventive Cardiology, 2021, 28, 1392-1401.	1.8	10
1248	Genomics of hypertriglyceridemia. Advances in Clinical Chemistry, 2020, 97, 141-169.	3.7	10
1249	In-depth Mendelian randomization analysis of causal factors for coronary artery disease. Scientific Reports, 2020, 10, 9208.	3.3	9
1250	Effects of eicosapentaenoic acid and docosahexaenoic acidversusÎ±-linolenic acid supplementation on cardiometabolic risk factors: a meta-analysis of randomized controlled trials. Food and Function, 2020, 11, 1919-1932.	4.6	16
1251	Lipid disorders in children living with overweight and obesity- large cohort study from Poland. Lipids in Health and Disease, 2020, 19, 47.	3.0	31
1252	High-Density Lipoproteins and Apolipoprotein A1. Sub-Cellular Biochemistry, 2020, 94, 399-420.	2.4	61
1253	Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping. Journal of Hepatology, 2020, 73, 263-276.	3.7	137
1254	Assessment Causality in Associations Between Serum Uric Acid and Risk of Schizophrenia: A Two-Sample Bidirectional Mendelian Randomization Study . Clinical Epidemiology, 2020, Volume 12, 223-233.	3.0	16
1255	Tangier disease: update for 2020. Current Opinion in Lipidology, 2020, 31, 80-84.	2.7	29
1256	Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial. BMJ Open Diabetes Research and Care, 2020, 8, e000943.	2.8	15
1257	Mendelâ€™s laws, Mendelian randomization and causal inference in observational data: substantive and nomenclatural issues. European Journal of Epidemiology, 2020, 35, 99-111.	5.7	129

#	Article	IF	Citations
1258	Risk Assessment in Oral Health. , 2020, , .		2
1259	On the Chameleonic Behaviour of Cholesterol through a Fractal/Multifractal Model. Computational and Mathematical Methods in Medicine, 2020, 2020, 1-11.	1.3	0
1260	Bayesian network analysis incorporating genetic anchors complements conventional Mendelian randomization approaches for exploratory analysis of causal relationships in complex data. PLoS Genetics, 2020, 16, e1008198.	3.5	39
1261	Effects of Virgin Olive Oil and Phenol-Enriched Virgin Olive Oils on Lipoprotein Atherogenicity. Nutrients, 2020, 12, 601.	4.1	14
1262	The Alcoholâ€“High-Density Lipoprotein Athero-Protective Axis. Biomolecules, 2020, 10, 987.	4.0	7
1263	HDL cholesterol and apolipoprotein A-I concentrations and risk of atherosclerotic cardiovascular disease: Human genetics to unravel causality. Atherosclerosis, 2020, 299, 53-55.	0.8	12
1264	Dab2 gene variant is associated with increased coronary artery disease risk in Chinese Han population. Medicine (United States), 2020, 99, e20924.	1.0	4
1265	Triglyceride-rich particles: new actors in valvular aortic stenosis. European Heart Journal, 2020, 41, 2300-2303.	2.2	3
1266	Serum level of HDL particles are independently associated with long-term prognosis in patients with coronary artery disease: The GENES study. Scientific Reports, 2020, 10, 8138.	3.3	29
1267	Advanced Glycated apoA-IV Loses Its Ability to Prevent the LPS-Induced Reduction in Cholesterol Efflux-Related Gene Expression in Macrophages. Mediators of Inflammation, 2020, 2020, 1-11.	3.0	6
1268	Evaluation of lipid services in the Republic of Ireland. Irish Journal of Medical Science, 2020, 189, 925-931.	1.5	1
1269	Site-specific 5-hydroxytryptophan incorporation into apolipoprotein A-I impairs cholesterol efflux activity and high-density lipoprotein biogenesis. Journal of Biological Chemistry, 2020, 295, 4836-4848.	3.4	13
1270	HDL Subclass Analysis in Predicting Metabolic Syndrome in Koreans With High HDL Cholesterol Levels. Annals of Laboratory Medicine, 2020, 40, 297-305.	2.5	8
1271	Apolipoprotein A-I concentrations and risk of coronary artery disease: A Mendelian randomization study. Atherosclerosis, 2020, 299, 56-63.	0.8	47
1272	The Effect of Coconut Oil Consumption on Cardiovascular Risk Factors. Circulation, 2020, 141, 803-814.	1.6	75
1273	Genetic determinants of blood lipids and cerebral small vessel disease: role of high-density lipoprotein cholesterol. Brain, 2020, 143, 597-610.	7.6	51
1274	Mendelian Randomization Study of Obesity and Cerebrovascular Disease. Annals of Neurology, 2020, 87, 516-524.	5.3	76
1275	Dysfunctional High-Density Lipoproteins Are Associated With a Greater Incidence of Acute Coronary Syndrome in a Population at High Cardiovascular Risk. Circulation, 2020, 141, 444-453.	1.6	54

#	Article	IF	Citations
1276	Methionine sulfoxide reductase A attenuates atherosclerosis via repairing dysfunctional HDL in scavenger receptor class B type I deficient mice. FASEB Journal, 2020, 34, 3805-3819.	0.5	6
1277	The Rise and Fall â€œingâ€•of the HDL Hypothesis. Drugs, 2020, 80, 353-362.	10.9	7
1278	Bariatric Surgery Improves HDL Function Examined by ApoA1 Exchange Rate and Cholesterol Efflux Capacity in Patients with Obesity and Type 2 Diabetes. Biomolecules, 2020, 10, 551.	4.0	27
1279	A lifeâ€time of hazardous drinking and harm to health among older adults: findings from the Whitehall II prospective cohort study. Addiction, 2020, 115, 1855-1866.	3.3	15
1280	High Density Lipoproteins: Metabolism, Function, and Therapeutic Potential. Frontiers in Cardiovascular Medicine, 2020, 7, 39.	2.4	52
1281	Correlation without a cause: an epidemiological odyssey. International Journal of Epidemiology, 2020, 49, 4-14.	1.9	45
1282	High density lipoprotein functionality and cardiovascular events and mortality: A systematic review and meta-analysis. Atherosclerosis, 2020, 302, 36-42.	0.8	59
1283	HDL functions and their interaction in patients with ST elevation myocardial infarction: a case control study. Lipids in Health and Disease, 2020, 19, 75.	3.0	12
1284	The Use of Genomics to Drive Kidney Disease Drug Discovery and Development. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1342-1351.	4.5	5
1285	High-density lipoproteins during sepsis: from bench to bedside. Critical Care, 2020, 24, 134.	5.8	110
1286	Framinghamâ€™s Contribution to Gene Identification for CV Risk Factors and Coronary Disease. Global Heart, 2013, 8, 59.	2.3	3
1287	HDL: Fact, fiction, or function? HDL cholesterol and cardiovascular risk. European Journal of Preventive Cardiology, 2021, 28, 166-173.	1.8	26
1288	Pleiotropy and Cross-Disorder Genetics Among Psychiatric Disorders. Biological Psychiatry, 2021, 89, 20-31.	1.3	75
1289	Potential causal role of l-glutamine in sickle cell disease painful crises: A Mendelian randomization analysis. Blood Cells, Molecules, and Diseases, 2021, 86, 102504.	1.4	14
1290	Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition. Annual Review of Medicine, 2021, 72, 447-458.	12.2	12
1291	The MalmÃ¶ Offspring Study (MOS): design, methods and first results. European Journal of Epidemiology, 2021, 36, 103-116.	5.7	41
1292	PCSK9: Associated with cardiac diseases and their risk factors?. Archives of Biochemistry and Biophysics, 2021, 704, 108717.	3.0	20
1293	Human apolipoprotein A-II reduces atherosclerosis in knock-in rabbits. Atherosclerosis, 2021, 316, 32-40.	0.8	18

#	Article	IF	Citations
1294	HDL (High-Density Lipoprotein) Subclasses, Lipid Content, and Function Trajectories Across the Menopause Transition. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 951-961.	2.4	29
1295	Low High-Density Lipoprotein Cholesterol and High White Blood Cell Counts. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 976-987.	2.4	14
1296	Peptide-based high-density lipoprotein promotes adipose tissue browning and restrains development of atherosclerosis and type 2 diabetes. Nano Today, 2021, 36, 101054.	11.9	10
1297	The loss-of-function mutation of CETP affects HDLc levels but not ApoA1 in patients with acute myocardial infarction. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 602-607.	2.6	6
1298	Three two-site apoA-I immunoassays using phage expressed detector antibodies â€“ Preliminary clinical evaluation with cardiac patients. Journal of Pharmaceutical and Biomedical Analysis, 2021, 194, 113772.	2.8	1
1299	Dynamic monitoring of active calcification in atherosclerosis by 18Fâ€“NaF PET imaging. International Journal of Cardiovascular Imaging, 2021, 37, 731-739.	1.5	11
1300	Lipid and metabolic syndrome traits in coronary artery disease: a Mendelian randomization study. Journal of Lipid Research, 2021, 62, 100044.	4.2	32
1301	MR-Clust: clustering of genetic variants in Mendelian randomization with similar causal estimates. Bioinformatics, 2021, 37, 531-541.	4.1	42
1302	Reflection on modern methods: when worlds collideâ€”prediction, machine learning and causal inference. International Journal of Epidemiology, 2021, 49, 2058-2064.	1.9	55
1303	Most important advances in preventive cardiology during this past decade: Viewpoint from the American Society for Preventive Cardiology. Trends in Cardiovascular Medicine, 2021, 31, 49-56.	4.9	12
1304	Cardiovascular Disease Epidemiology and Risk Factors: General Concepts. Contemporary Cardiology, 2021, , 1-22.	0.1	0
1305	Precision Medicine and Informatics. , 2021, , 941-966.		0
1306	Coronary artery disease in the absence of traditional risk factors: a call for action. European Heart Journal, 2021, 42, 3822-3824.	2.2	25
1307	Lipoprotein and Lipid Metabolism. , 2021, , 235-278.		2
1308	Plasma concentrations of lipoproteins and risk of lower-limb peripheral artery disease in people with type 2 diabetes: the SURDIAGENE study. Diabetologia, 2021, 64, 668-680.	6.3	12
1309	Evaluation of atherogenic lipoprotein-cholesterol to HDL cholesterol ratio as a prognostic test for ST-segment elevation myocardial infarction. International Journal of Medical Sciences, 2021, 18, 2897-2904.	2.5	0
1310	Graphical analysis for phenome-wide causal discovery in genotyped population-scale biobanks. Nature Communications, 2021, 12, 350.	12.8	13
1311	Atherosclerotic cardiovascular disease in hyperalphalipoproteinemia due to LIPG variants. Journal of Clinical Lipidology, 2021, 15, 142-150.e2.	1.5	5

#	Article	IF	Citations
1312	HDL-c and arterial calcification in midlife women: does an HDL paradox exist?. Menopause, 2021, 28, 231-233.	2.0	4
1313	High-Density Lipoprotein Cholesterol and the Risk of Myocardial Infarction, Stroke, and Cause-Specific Mortality: a Nationwide Cohort Study in Korea. Journal of Lipid and Atherosclerosis, 2021, 10, 74.	3.5	18
1314	(r)HDL in theranostics: how do we apply HDL's biology for precision medicine in atherosclerosis management?. Biomaterials Science, 2021, 9, 3185-3208.	5.4	5
1315	The Role of Phospholipid Transfer Protein in the Development of Atherosclerosis. Current Atherosclerosis Reports, 2021, 23, 9.	4.8	13
1317	HDL-C and Cardiovascular Risk: You Don't Need to Worry about Extremely High HDL-C Levels. Journal of Lipid and Atherosclerosis, 2021, 10, 57.	3.5	7
1319	Association of serum HDL-cholesterol and apolipoprotein A1 levels with risk of severe SARS-CoV-2 infection. Journal of Lipid Research, 2021, 62, 100061.	4.2	44
1320	Analysis of Predictive Parameters in Prediction of the Occurrence of Myocardial Infarction Using Artificial Neural Networks. IFMBE Proceedings, 2021, , 184-190.	0.3	0
1321	The Role of the ATP-Binding Cassette A1 (ABCA1) in Human Disease. International Journal of Molecular Sciences, 2021, 22, 1593.	4.1	73
1322	Development of genome-wide polygenic risk scores for lipid traits and clinical applications for dyslipidemia, subclinical atherosclerosis, and diabetes cardiovascular complications among East Asians. Genome Medicine, 2021, 13, 29.	8.2	18
1323	Development and Validation of a Predictive Model for Coronary Artery Disease Using Machine Learning. Frontiers in Cardiovascular Medicine, 2021, 8, 614204.	2.4	9
1324	INTERDISCIPLINARY CLINICAL PRACTICE GUIDELINES "MANAGEMENT OF OBESITY AND ITS COMORBIDITIES". Obesity and Metabolism, 2021, 18, 5-99.	1.2	49
1325	Endothelial Lipase Exerts its Anti-Atherogenic Effect through Increased Catabolism of Î²-VLDLs. Journal of Atherosclerosis and Thrombosis, 2021, 28, 157-168.	2.0	3
1326	Vitamin D, calcium and cardiovascular health: Foods or supplements? â€" What is the evidence in 2021?. ClÃnica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2021, 33, 70-72.	0.2	0
1327	Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development. Nature Reviews Cardiology, 2021, 18, 435-453.	13.7	88
1328	Vitamina D, Calcio y Salud Cardiovascular: Â¿Alimentos o Suplementos? â€"Â¿CuÃ¡l es la Evidencia en 2021?. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2021, 33, 70-72.	0.8	0
1329	The Association between HDL-C and Subclinical Atherosclerosis Depends on CETP Plasma Concentration: Insights from the IMPROVE Study. Biomedicines, 2021, 9, 286.	3.2	7
1330	ANGPLT3 in cardio-metabolic disorders. Molecular Biology Reports, 2021, 48, 2729-2739.	2.3	9
1331	High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives. Cells, 2021, 10, 574.	4.1	42

#	Article	IF	Citations
1332	Case report: 68 yo Chinese-American woman with high HDL-C and ischemic stroke attributed to intracranial atherosclerotic stenosis. Journal of Clinical Lipidology, 2021, 15, 248-254.	1.5	0
1333	Genetics of Triglyceride-Rich Lipoproteins Guide Identification of Pharmacotherapy for Cardiovascular Risk Reduction. Cardiovascular Drugs and Therapy, 2021, 35, 677-690.	2.6	11
1334	Prospective Study on Plasma MicroRNAâ€4286 and Incident Acute Coronary Syndrome. Journal of the American Heart Association, 2021, 10, e018999.	3.7	10
1335	Genetic Risk Stratification. JACC Basic To Translational Science, 2021, 6, 287-304.	4.1	19
1336	Evaluating the direct effects of childhood adiposity on adult systemic metabolism: a multivariable Mendelian randomization analysis. International Journal of Epidemiology, 2021, 50, 1580-1592.	1.9	30
1337	Investigating the relationships between unfavourable habitual sleep and metabolomic traits: evidence from multi-cohort multivariable regression and Mendelian randomization analyses. BMC Medicine, 2021, 19, 69.	5.5	14
1338	Shared associations identify causal relationships between gene expression and immune cell phenotypes. Communications Biology, 2021, 4, 279.	4.4	3
1339	A Mendelian randomization study of the role of lipoprotein subfractions in coronary artery disease. ELife, 2021, 10, .	6.0	25
1340	Knowledge and attitudes towards hypertriglyceridaemia and associated residual risk amongst cardiologists in Turkey. Minerva Cardiology and Angiology, 2021, 69, 185-190.	0.7	0
1341	Changing Perspectives on HDL: From Simple Quantity Measurements to Functional Quality Assessment. Journal of Lipids, 2021, 2021, 1-11.	4.8	15
1342	Editorial commentary: A new era for preventive cardiology. Trends in Cardiovascular Medicine, 2022, 32, 195-197.	4.9	0
1343	Raloxifene has favorable effects on the lipid profile in women explaining its beneficial effect on cardiovascular risk: A meta-analysis of randomized controlled trials. Pharmacological Research, 2021, 166, 105512.	7.1	18
1344	Metabolic Dyslipidemia and Cardiovascular Outcomes in Type 2 Diabetes Mellitus: Findings From the Look AHEAD Study. Journal of the American Heart Association, 2021, 10, e016947.	3.7	49
1345	The changing landscape of atherosclerosis. Nature, 2021, 592, 524-533.	27.8	921
1346	ApoE and ApoE Nascent-Like HDL Particles at Model Cellular Membranes: Effect of Protein Isoform and Membrane Composition. Frontiers in Chemistry, 2021, 9, 630152.	3.6	6
1347	HDL Cholesterol and Non-Cardiovascular Disease: A Narrative Review. International Journal of Molecular Sciences, 2021, 22, 4547.	4.1	28
1348	Age and sex specific effects of APOE genotypes on ischemic heart disease and its risk factors in the UK Biobank. Scientific Reports, 2021, 11, 9229.	3.3	11
1349	Low HDL concentration in rs2048327-G carriers can predispose men to develop coronary heart disease: Tehran Cardiometabolic genetic study (TCGS). Gene, 2021, 778, 145485.	2.2	4

#	Article	IF	Citations
1350	Clinical biomarkers and associations with healthspan and lifespan: Evidence from observational and genetic data. EBioMedicine, 2021, 66, 103318.	6.1	12
1351	Reversal of hypertriglyceridemia in diabetic BTBR ob/ob mice does not prevent nephropathy. Laboratory Investigation, 2021, 101, 935-941.	3.7	8
1352	Blocking endothelial lipase with monoclonal antibody MEDI5884 durably increases high density lipoprotein in nonhuman primates and in a phase 1 trial. Science Translational Medicine, 2021, 13, .	12.4	16
1353	Coronary heart disease risk: Low-density lipoprotein and beyond. Trends in Cardiovascular Medicine, 2022, 32, 181-194.	4.9	56
1354	Weight loss and its influence on high-density lipoprotein cholesterol (HDL-C) concentrations: A noble clinical hesitation. Clinical Nutrition ESPEN, 2021, 42, 90-92.	1.2	32
1355	HDL in Immune-Inflammatory Responses: Implications beyond Cardiovascular Diseases. Cells, 2021, 10, 1061.	4.1	23
1356	High-density lipoproteins, reverse cholesterol transport and atherogenesis. Nature Reviews Cardiology, 2021, 18, 712-723.	13.7	91
1357	High Density Lipoproteins and Diabetes. Cells, 2021, 10, 850.	4.1	34
1358	Effect of High-Density Lipoprotein Cholesterol Levels on Overall Survival and Major Adverse Cardiovascular and Cerebrovascular Events. American Journal of Cardiology, 2021, 146, 8-14.	1.6	7
1359	Prognostic value of PCSK9 levels in patients with non-ST elevation myocardial infarction undergoing percutaneous coronary intervention (PCI). Hellenic Journal of Cardiology, 2022, 63, 22-31.	1.0	2
1360	Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. Atherosclerosis, 2021, 325, 99-109.	0.8	83
1361	Dissecting polygenic signals from genome-wide association studies on human behaviour. Nature Human Behaviour, 2021, 5, 686-694.	12.0	57
1362	Plasma high-density lipoprotein cholesterol and risk of dementia: observational and genetic studies. Cardiovascular Research, 2022, 118, 1330-1343.	3.8	24
1363	Beneficial effects of brown fat activation on top of PCSK9 inhibition with alirocumab on dyslipidemia and atherosclerosis development in APOE*3-Leiden.CETP mice. Pharmacological Research, 2021, 167, 105524.	7.1	9
1364	Safety and Efficacy of Evacetrapib in Patients with Inadequately-controlled Hypercholesterolemia and High Cardiovascular Risk; A meta-analysis of Randomized Placebo-controlled Trials. Prostaglandins Leukotrienes and Essential Fatty Acids, 2021, 168, 102282.	2.2	0
1365	The role of HDL cholesterol as a measure of 10-year cardiovascular risk should be re-evaluated. European Journal of Preventive Cardiology, 2021, , .	1.8	0
1366	Distinct Fatty Acid Compositions of HDL Phospholipids Are Characteristic of Metabolic Syndrome and Premature Coronary Heart Diseaseâ€"Family Study. International Journal of Molecular Sciences, 2021, 22, 4908.	4.1	9
1367	Associations between low HDL, sex and cardiovascular risk markers are substantially different in sub-Saharan Africa and the UK: analysis of four population studies. BMJ Global Health, 2021, 6, e005222.	4.7	8

#	Article	IF	Citations
1368	SR-B1, a Key Receptor Involved in the Progression of Cardiovascular Disease: A Perspective from Mice and Human Genetic Studies. Biomedicines, 2021, 9, 612.	3.2	20
1369	Hunt for the (Multi)-Marker Grail in the Diverse Landscape of Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 1789-1791.	2.4	0
1370	High-Density Lipoprotein Anti-Inflammatory Capacity and Incident Cardiovascular Events. Circulation, 2021, 143, 1935-1945.	1.6	67
1371	Serum HDL cholesterol uptake capacity in subjects from the MASHAD cohort study: Its value in determining the risk of cardiovascular endpoints. Journal of Clinical Laboratory Analysis, 2021, 35, e23770.	2.1	18
1372	ADAM17 Boosts Cholesterol Efflux and Downstream Effects of High-Density Lipoprotein on Inflammatory Pathways in Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 1854-1873.	2.4	4
1373	Intracoronary monocyte expression pattern and HDL subfractions after non-ST elevation myocardial infarction. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166116.	3.8	1
1374	Cholesterol efflux pathways, inflammation, and atherosclerosis. Critical Reviews in Biochemistry and Molecular Biology, 2021, 56, 426-439.	5.2	63
1375	A Non-Linear Association of High-Density Lipoprotein Cholesterol with All-Cause and Cause-Specific Mortality in Diabetic Patients. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2021, Volume 14, 2851-2862.	2.4	4
1376	HDL Dysfunctionality: Clinical Relevance of Quality Rather Than Quantity. Biomedicines, 2021, 9, 729.	3.2	23
1377	The effect of metabolic syndrome on head and neck cancer incidence risk: a population-based prospective cohort study. Cancer & Metabolism, 2021, 9, 25.	5.0	8
1378	Circulating ceramides as biomarkers of cardiovascular disease: Evidence from phenotypic and genomic studies. Atherosclerosis, 2021, 327, 18-30.	0.8	39
1380	Hyperalphalipoproteinemia and Beyond: The Role of HDL in Cardiovascular Diseases. Life, 2021, 11, 581.	2.4	11
1381	Evaluating marginal genetic correlation of associated loci for complex diseases and traits between European and East Asian populations. Human Genetics, 2021, 140, 1285-1297.	3.8	12
1382	Coronary Heart Disease Risk Associated with Primary Isolated Hypertriglyceridemia; a Populationâ€Based Study. Journal of the American Heart Association, 2021, 10, e019343.	3.7	10
1383	AssociaÃ§Ã£o entre Atividade FÃsica no Tempo Livre e HDL-C em Participantes do Elsa-Brasil: Existem DiferenÃ§as entre Homens e Mulheres no Efeito Dose-Resposta?. Arquivos Brasileiros De Cardiologia, 2021, 117, 494-500.	0.8	3
1384	Contemporary Medical Management of Peripheral Artery Disease. Circulation Research, 2021, 128, 1868-1884.	4.5	53
1385	High-sensitivity CRP may be a marker of HDL dysfunction and remodeling in patients with acute coronary syndrome. Scientific Reports, 2021, 11, 11444.	3.3	12
1386	Black Chokeberry (Aronia melanocarpa) Functional Beverages Increase HDL-Cholesterol Levels in Aging Rats. Foods, 2021, 10, 1641.	4.3	8

#	Article	IF	Citations
1387	High-Density Lipoproteins in Kidney Disease. International Journal of Molecular Sciences, 2021, 22, 8201.	4.1	9
1388	An exploratory analysis of the competing effects of alcohol use and advanced hepatic fibrosis on serum HDL. Clinical and Experimental Medicine, 2021, , 1.	3.6	1
1389	Reusable OIRD Microarray Chips Based on a Bienzyme-Immobilized Polyaniline Nanowire Forest for Multiplexed Detection of Biological Small Molecules. Analytical Chemistry, 2021, 93, 10697-10703.	6.5	11
1390	Structure of Lipoproteins and Their Capacity for Lipid Exchange: Relevance for Development of Atherosclerosis and Its Treatment by HDL Therapy. , 0, , .		1
1392	HDL in Atherosclerotic Cardiovascular Disease: In Search of a Role. Cells, 2021, 10, 1869.	4.1	46
1393	Hepatic cholesterol transport and its role in non-alcoholic fatty liver disease and atherosclerosis. Progress in Lipid Research, 2021, 83, 101109.	11.6	86
1394	Expression of miRNAs Targeting ATP Binding Cassette Transporter 1 (ABCA1) among Patients with Significant Carotid Artery Stenosis. Biomedicines, 2021, 9, 920.	3.2	4
1395	Monogenic and Polygenic Models of Coronary Artery Disease. Current Cardiology Reports, 2021, 23, 107.	2.9	9
1396	High-density Lipoprotein Cholesterol Is Negatively Correlated with Bone Mineral Density and Has Potential Predictive Value for Bone Loss. Lipids in Health and Disease, 2021, 20, 75.	3.0	25
1397	Ketogenic Diets and Chronic Disease: Weighing the Benefits Against the Risks. Frontiers in Nutrition, 2021, 8, 702802.	3.7	83
1398	Investigating causal relationships between exposome and human longevity: a Mendelian randomization analysis. BMC Medicine, 2021, 19, 150.	5.5	10
1399	Evinacumab for treatment of familial hypercholesterolemia. Expert Review of Cardiovascular Therapy, 2021, 19, 739-751.	1.5	6
1400	Shear Stress and Metabolic Disordersâ€"Two Sides of the Same Plaque. Antioxidants and Redox Signaling, 2022, 37, 820-841.	5.4	4
1401	HDL and type 2 diabetes: the chicken or the egg?. Diabetologia, 2021, 64, 1917-1926.	6.3	34
1402	Unraveling the Complexity of HDL Remodeling: On the Hunt to Restore HDL Quality. Biomedicines, 2021, 9, 805.	3.2	5
1403	Is a High HDL-Cholesterol Level Always Beneficial?. Biomedicines, 2021, 9, 1083.	3.2	22
1404	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 2021, 42, 3227-3337.	2.2	2,517
1406	Lipoprotein (a) as a treatment target for cardiovascular disease prevention and related therapeutic strategies: a critical overview. European Journal of Preventive Cardiology, 2022, 29, 739-755.	1.8	8

#	Article	IF	Citations
1407	Associations of Endogenous Hormones With HDL Novel Metrics Across the Menopause Transition: The SWAN HDL Study. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e303-e314.	3.6	5
1408	Association of High-Density Lipoprotein Cholesterol With GFR Decline in a General Nondiabetic Population. Kidney International Reports, 2021, 6, 2084-2094.	0.8	5
1409	Alcohol use and cardiometabolic risk in the UK Biobank: A Mendelian randomization study. PLoS ONE, 2021, 16, e0255801.	2.5	24
1410	Inflammation Alters Relationship Between Highâ€Density Lipoprotein Cholesterol and Cardiovascular Risk in Patients With Chronic Kidney Disease: Results From KNOWâ€CKD. Journal of the American Heart Association, 2021, 10, e021731.	3.7	9
1411	Multitrait GWAS to connect disease variants and biological mechanisms. PLoS Genetics, 2021, 17, e1009713.	3.5	16
1412	Different impacts of metabolic profiles on future risk of cardiovascular disease between diabetes with and without established cardiovascular disease: the Japan diabetes complication and its prevention prospective study 7 (JDCP study 7). Acta Diabetologica, 2021, , 1.	2.5	1
1413	Alcohol consumption in relation to cardiovascular diseases and mortality: a systematic review of Mendelian randomization studies. European Journal of Epidemiology, 2022, 37, 655-669.	5.7	27
1414	Using Mendelian randomization as the cornerstone for causal inference in epidemiology. Environmental Science and Pollution Research, 2022, 29, 5827-5839.	5.3	16
1415	Genetics of coronary artery disease in the postâ€GWAS era. Journal of Internal Medicine, 2021, 290, 980-992.	6.0	46
1416	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Journal of Preventive Cardiology, 2022, 29, 5-115.	1.8	220
1417	A lifestyle intervention with an energy-restricted Mediterranean diet and physical activity enhances HDL function: a substudy of the PREDIMED-Plus randomized controlled trial. American Journal of Clinical Nutrition, 2021, 114, 1666-1674.	4.7	15
1418	Genome-Wide Association Study Identifies a Functional SIDT2 Variant Associated With HDL-C (High-Density Lipoprotein Cholesterol) Levels and Premature Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2494-2508.	2.4	10
1419	Spectrum of Apolipoprotein AI and Apolipoprotein AII Proteoforms and Their Associations With Indices of Cardiometabolic Health: The CARDIA Study. Journal of the American Heart Association, 2021, 10, e019890.	3.7	12
1421	Lysis reagents, cell numbers, and calculation method influence high-throughput measurement of HDL-mediated cholesterol efflux capacity. Journal of Lipid Research, 2021, 62, 100125.	4.2	4
1422	Mendelian Randomization Studies in Stroke: Exploration of Risk Factors and Drug Targets With Human Genetic Data. Stroke, 2021, 52, 2992-3003.	2.0	28
1423	Assessment and management of the heightened risk for atherosclerotic cardiovascular events in patients with lupus erythematosus or dermatomyositis. International Journal of Women's Dermatology, 2021, 7, 560-575.	2.0	7
1424	Association of plasma branchedâ€chain amino acids with overweight: A Mendelian randomization analysis. Obesity, 2021, 29, 1708-1718.	3.0	4
1425	Stroke Genetics: Turning Discoveries into Clinical Applications. Stroke, 2021, 52, 2974-2982.	2.0	9

#	Article	IF	Citations
1426	Distinct Differences in Lipoprotein Particle Number Evaluation between GP-HPLC and NMR: Analysis in Dyslipidemic Patients Administered a Selective PPARÎ± Modulator, Pemafibrate. Journal of Atherosclerosis and Thrombosis, 2021, 28, 974-996.	2.0	10
1427	Endothelial lipase mediates efficient lipolysis of triglyceride-rich lipoproteins. PLoS Genetics, 2021, 17, e1009802.	3.5	18
1428	Dyslipidemia. , 2022, , 387-393.		0
1429	High-density lipoproteins. , 2021, , 487-514.		1
1430	Genetic evidence for independent causal relationships between metabolic biomarkers and risk of coronary artery diseases. Journal of Lipid Research, 2021, 62, 100064.	4.2	1
1431	Gene networks and pathways for plasma lipid traits via multitissue multiomics systems analysis. Journal of Lipid Research, 2021, 62, 100019.	4.2	9
1432	Lipoproteins in chronic kidney disease: from bench to bedside. European Heart Journal, 2021, 42, 2170-2185.	2.2	32
1434	Mendelian randomization under the omnigenic architecture. Briefings in Bioinformatics, 2021, 22, .	6.5	9
1435	High HDL-Cholesterol Paradox: SCARB1-LAG3-HDL Axis. Current Atherosclerosis Reports, 2021, 23, 5.	4.8	23
1436	Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib. Annals of Hematology, 2021, 100, 2005-2014.	1.8	14
1438	Instrumental Variable Analysis. Health Services Research, 2017, , 1-44.	0.2	1
1439	Genetic Disorders of HDL Metabolism. Contemporary Endocrinology, 2015, , 221-233.	0.1	1
1440	Beyond the Genetics of HDL: Why Is HDL Cholesterol Inversely Related to Cardiovascular Disease?. Handbook of Experimental Pharmacology, 2015, 224, 285-300.	1.8	9
1441	ABC Transporters, Cholesterol Efflux, and Implications for Cardiovascular Diseases. Advances in Experimental Medicine and Biology, 2020, 1276, 67-83.	1.6	35
1442	Complications of Diabetes Mellitus. , 2011, , 1462-1551.		8
1443	Novel polymorphisms associated with hyperalphalipoproteinemia and apparent cardioprotection. Journal of Clinical Lipidology, 2018, 12, 110-115.	1.5	8
1444	Inhibidores de PCSK9: ratificaciÃ³n del papel del colesterol LDL en prevenciÃ³n cardiovascular. Â¿Hacia la convergencia en las guÃas de prevenciÃ³n europeas y norteamericanas?. Revista Clinica Espanola, 2020, 220, 374-382.	0.6	5
1445	A Novel Role for CETP as Immunological Gatekeeper: Raising HDL to Cure Sepsis?. Trends in Endocrinology and Metabolism, 2020, 31, 334-343.	7.1	22

#	Article	IF	Citations
1446	Pleiotropy in complex traits: challenges and strategies. , 0, .		1
1447	Mendelian randomization accounting for correlated and uncorrelated pleiotropic effects using genome-wide summary statistics. Nature Genetics, 2020, 52, 740-747.	21.4	298
1448	Altered HDL metabolism in metabolic disorders: insights into the therapeutic potential of HDL. Clinical Science, 2019, 133, 2221-2235.	4.3	24
1449	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 2020, 41, 2313-2330.	2.2	776
1450	Association of apolipoprotein levels with peripheral arterial disease: a meta-analysis of literature studies. European Journal of Preventive Cardiology, 2022, 28, 1980-1990.	1.8	5
1451	High-throughput multivariable Mendelian randomization analysis prioritizes apolipoprotein B as key lipid risk factor for coronary artery disease. International Journal of Epidemiology, 2021, 50, 893-901.	1.9	52
1452	A Novel Cell-Free Fluorescent Assay for HDL Function: Low Apolipoprotein A1 Exchange Rate Associated with Increased Incident Cardiovascular Events. journal of applied laboratory medicine, The, 2020, 5, 544-557.	1.3	12
1453	Inflammation, remodeling, and other factors affecting HDL cholesterol efflux. Current Opinion in Lipidology, 2017, 28, 52-59.	2.7	49
1454	Polygenic scores for dyslipidemia: the emerging genomic model of plasma lipoprotein trait inheritance. Current Opinion in Lipidology, 2021, 32, 103-111.	2.7	11
1455	Predictors of Impaired HDL Function in HIV-1 Infected Compared to Uninfected Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 354-363.	2.1	13
1482	PI3KÎ² Plays a Key Role in Apolipoprotein A-I-Induced Endothelial Cell Proliferation Through Activation of the Ecto-F1-ATPase/P2Y1 Receptors. Cellular Physiology and Biochemistry, 2017, 42, 579-593.	1.6	23
1483	The promise and reality of therapeutic discovery from large cohorts. Journal of Clinical Investigation, 2020, 130, 575-581.	8.2	9
1484	Lymphatic vessels clean up your arteries. Journal of Clinical Investigation, 2013, 123, 1417-1419.	8.2	6
1485	Sex differences in systemic metabolites at four life stages: cohort study with repeated metabolomics. BMC Medicine, 2021, 19, 58.	5.5	32
1486	CETP inhibitors and cardiovascular disease: Time to think again. F1000Research, 2014, 3, 124.	1.6	16
1487	Practical strategies for modulating foam cell formation and behavior. World Journal of Clinical Cases, 2014, 2, 497.	0.8	14
1488	31st G. Heiner Sell Lectureship: Secondary Medical Consequences of Spinal Cord Injury. Topics in Spinal Cord Injury Rehabilitation, 2012, 18, 354-378.	1.8	43
1489	Genomics of Cancer and a New Era for Cancer Prevention. PLoS Genetics, 2015, 11, e1005522.	3.5	21

#	Article	IF	Citations
1490	Genetic Architecture of Atherosclerosis in Mice: A Systems Genetics Analysis of Common Inbred Strains. PLoS Genetics, 2015, 11, e1005711.	3.5	124
1491	Effect of Insulin Resistance on Monounsaturated Fatty Acid Levels: A Multi-cohort Non-targeted Metabolomics and Mendelian Randomization Study. PLoS Genetics, 2016, 12, e1006379.	3.5	20
1492	Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular disease. PLoS Genetics, 2017, 13, e1006706.	3.5	194
1493	Inferring causal direction between two traits in the presence of horizontal pleiotropy with GWAS summary data. PLoS Genetics, 2020, 16, e1009105.	3.5	18
1494	Vitamin D and Risk of Multiple Sclerosis: A Mendelian Randomization Study. PLoS Medicine, 2015, 12, e1001866.	8.4	380
1495	Investigating the Causal Relationship of C-Reactive Protein with 32 Complex Somatic and Psychiatric Outcomes: A Large-Scale Cross-Consortium Mendelian Randomization Study. PLoS Medicine, 2016, 13, e1001976.	8.4	150
1496	Genetic Predisposition to an Impaired Metabolism of the Branched-Chain Amino Acids and Risk of Type 2 Diabetes: A Mendelian Randomisation Analysis. PLoS Medicine, 2016, 13, e1002179.	8.4	324
1497	Childhood adiposity and risk of type 1 diabetes: A Mendelian randomization study. PLoS Medicine, 2017, 14, e1002362.	8.4	90
1498	Life course socioeconomic position, alcohol drinking patterns in midlife, and cardiovascular mortality: Analysis of Norwegian population-based health surveys. PLoS Medicine, 2018, 15, e1002476.	8.4	32
1499	Evaluating the relationship between alcohol consumption, tobacco use, and cardiovascular disease: A multivariable Mendelian randomization study. PLoS Medicine, 2020, 17, e1003410.	8.4	92
1500	The ABCA1 Gene R230C Variant Is Associated with Decreased Risk of Premature Coronary Artery Disease: The Genetics of Atherosclerotic Disease (GEA) Study. PLoS ONE, 2012, 7, e49285.	2.5	69
1501	Genetic Variants from Lipid-Related Pathways and Risk for Incident Myocardial Infarction. PLoS ONE, 2013, 8, e60454.	2.5	8
1502	Age-Period-Cohort Projections of Ischaemic Heart Disease Mortality by Socio-Economic Position in a Rapidly Transitioning Chinese Population. PLoS ONE, 2013, 8, e61495.	2.5	10
1503	The Association of Common SNPs and Haplotypes in CETP Gene with HDL Cholesterol Levels in Latvian Population. PLoS ONE, 2013, 8, e64191.	2.5	23
1504	Association of Hepatic Lipase -514T Allele with Coronary Artery Disease and Ankle-Brachial Index, Dependence on the Lipoprotein Phenotype: The GENES Study. PLoS ONE, 2013, 8, e67805.	2.5	5
1505	Moderate Alcohol Use and Cardiovascular Disease from Mendelian Randomization. PLoS ONE, 2013, 8, e68054.	2.5	44
1506	Gene-Gene Combination Effect and Interactions among ABCA1, APOA1, SR-B1, and CETP Polymorphisms for Serum High-Density Lipoprotein-Cholesterol in the Japanese Population. PLoS ONE, 2013, 8, e82046.	2.5	15
1507	Seven Functional Polymorphisms in the CETP Gene and Myocardial Infarction Risk: A Meta-Analysis and Meta-Regression. PLoS ONE, 2014, 9, e88118.	2.5	24

#	Article	IF	Citations
1508	P2Y13 Receptor Regulates HDL Metabolism and Atherosclerosis In Vivo. PLoS ONE, 2014, 9, e95807.	2.5	18
1509	Using Multivariable Mendelian Randomization to Disentangle the Causal Effects of Lipid Fractions. PLoS ONE, 2014, 9, e108891.	2.5	86
1510	High-Density Lipoprotein Prevents Endoplasmic Reticulum Stress-Induced Downregulation of Liver LOX-1 Expression. PLoS ONE, 2015, 10, e0124285.	2.5	8
1511	Structural and Functional Analysis of the ApolipoproteinA-I A164S Variant. PLoS ONE, 2015, 10, e0143915.	2.5	13
1512	Young Adult Exposure to Cardiovascular Risk Factors and Risk of Events Later in Life: The Framingham Offspring Study. PLoS ONE, 2016, 11, e0154288.	2.5	60
1513	Statin Intensity or Achieved LDL? Practice-based Evidence for the Evaluation of New Cholesterol Treatment Guidelines. PLoS ONE, 2016, 11, e0154952.	2.5	11
1514	Cardiovascular Disease Risk Factors in Ghana during the Rural-to-Urban Transition: A Cross-Sectional Study. PLoS ONE, 2016, 11, e0162753.	2.5	41
1515	Beneficial Effects of Reconstituted High-Density Lipoprotein (rHDL) on Circulating CD34+ Cells in Patients after an Acute Coronary Syndrome. PLoS ONE, 2017, 12, e0168448.	2.5	13
1516	Impaired HDL2-mediated cholesterol efflux is associated with metabolic syndrome in families with early onset coronary heart disease and low HDL-cholesterol level. PLoS ONE, 2017, 12, e0171993.	2.5	12
1517	Revisiting Reverse Cholesterol Transport in the Context of High-Density Lipoprotein Free Cholesterol Bioavailability. Methodist DeBakey Cardiovascular Journal, 2021, 15, 47.	1.0	18
1518	High-Density Lipoprotein Subspecies in Health and Human Disease: Focus on Type 2 Diabetes. Methodist DeBakey Cardiovascular Journal, 2021, 15, 55.	1.0	20
1519	Glucocorticoids impair HDL-mediated cholesterol efflux besides increased HDL cholesterol concentration: a proof of concept. European Journal of Endocrinology, 2020, 183, 297-306.	3.7	6
1520	New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease. European Cardiology Review, 2020, 15, 1-9.	2.2	38
1521	Everything in Moderation: Investigating the U-Shaped Link Between HDL Cholesterol and Adverse Outcomes. US Cardiology Review, 2019, 13, 49-53.	0.5	6
1522	The improvement of large High-Density Lipoprotein (HDL) particle levels, and presumably HDL metabolism, depend on effects of low-carbohydrate diet and weight loss. EXCLI Journal, 2016, 15, 166-76.	0.7	5
1523	MicroRNAs in Lipid Metabolism and Atherosclerosis. Indonesian Biomedical Journal, 2014, 6, 3.	0.3	2
1524	Positive association of familial longevity with the moderate-high HDL-C concentration in Bama Aging Study. Aging, 2018, 10, 3528-3540.	3.1	16
1525	Atherogenic Dyslipidemia and Combination Pharmacotherapy in Diabetes: Recent Clinical Trials. Review of Diabetic Studies, 2013, 10, 191-203.	1.3	11

#	Article	IF	Citations
1526	CANHEART: Is HDL cholesterol a cardiovascular specific risk factor?. Global Cardiology Science & Practice, 2017, 2016, e201634.	0.4	7
1527	Metabolism of HDL and its Regulation. Current Medicinal Chemistry, 2014, 21, 2864-2880.	2.4	27
1528	HDL Dysfunction Caused by Mutations in apoA-I and Other Genes that are Critical for HDL Biogenesis and Remodeling. Current Medicinal Chemistry, 2019, 26, 1544-1575.	2.4	13
1529	Biological Consequences of Dysfunctional HDL. Current Medicinal Chemistry, 2019, 26, 1644-1664.	2.4	65
1530	Cardioprotective Properties of HDL: Structural and Functional Considerations. Current Medicinal Chemistry, 2020, 27, 2964-2978.	2.4	19
1531	Taking Risk Prediction to the Next Level. Advances in Biomarker Research for Atherosclerosis. Current Pharmaceutical Design, 2013, 19, 5929-5941.	1.9	2
1532	Application of Genome-Wide Association Studies in Coronary Artery Disease. Current Pharmaceutical Design, 2020, 25, 4274-4286.	1.9	3
1533	A Journey through Genetic Architecture and Predisposition of Coronary Artery Disease. Current Genomics, 2020, 21, 382-398.	1.6	3
1534	Association of Circulating Cholesterol Level with Cognitive Function and Mild Cognitive Impairment in the Elderly: A Community-based Population Study. Current Alzheimer Research, 2020, 17, 556-565.	1.4	11
1535	Phenotypes and Genotypes of High Density Lipoprotein Cholesterol in Exceptional Longevity. Current Vascular Pharmacology, 2013, 12, 690-697.	1.7	31
1536	Clinical Trial of the Hypolipidemic Effects of a Brown Alga Ecklonia cava Extract in Patients with Hypercholesterolemia. International Journal of Pharmacology, 2015, 11, 798-805.	0.3	25
1537	A Review on HDL-cholesterol Alterations in Metabolic Syndrome. Journal of Biological Sciences, 2013, 13, 679-684.	0.3	3
1538	Two-Sample Mendelian Randomization Study of Lipid levels and Ischemic Heart Disease. Korean Circulation Journal, 2020, 50, 940.	1.9	14
1539	Proprotein convertase subtilisin/kexin type 9 enzyme inhibitors: An emerging new therapeutic option for the treatment of dyslipidemia. Journal of Pharmacology and Pharmacotherapeutics, 2016, 7, 190-193.	0.4	3
1540	High density lipoprotein and cardiovascular diseases. World Journal of Cardiology, 2013, 5, 210.	1.5	19
1541	Endothelial dysfunction: a unifying hypothesis for the burden of cardiovascular diseases in sub-Saharan Africa: review article. Cardiovascular Journal of Africa, 2015, 26, S56-S60.	0.4	8
1542	Primary genetic disorders affecting high density lipoprotein (HDL). Drugs in Context, 2018, 7, 1-11.	2.2	11
1543	Conventional and Advanced Lipid Parameters in Premature Coronary Artery Disease Patients in India. Journal of Clinical and Diagnostic Research JCDR, 2015, 9, BC07-11.	0.8	10

#	Article	IF	Citations
1544	Identifying Potential Therapeutic Applications and Diagnostic Harms of Increased Bilirubin Concentrations: A Clinical and Genetic Approach. Clinical Pharmacology and Therapeutics, 2022, 111, 435-443.	4.7	4
1545	Atorvastatin Ester Regulates Lipid Metabolism in Hyperlipidemia Rats via the PPAR-signaling Pathway and HMGCR Expression in the Liver. International Journal of Molecular Sciences, 2021, 22, 11107.	4.1	23
1546	Altered HDL proteome predicts incident CVD in chronic kidney disease patients. Journal of Lipid Research, 2021, 62, 100135.	4.2	14
1547	Assessing the Causal Role of Selenium in Amyotrophic Lateral Sclerosis: A Mendelian Randomization Study. Frontiers in Genetics, 2021, 12, 724903.	2.3	5
1548	Residual Cardiovascular Risk Factors in Dyslipidemia. , 0, , .		0
1549	Metabolomics in Diabetes and Diabetic Complications: Insights from Epidemiological Studies. Cells, 2021, 10, 2832.	4.1	66
1550	Association of the ApoB/ApoA-I ratio with stroke risk: Findings from the China Health and Nutrition Survey (CHNS). Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 203-209.	2.6	5
1552	A Modern Approach to Dyslipidemia. Endocrine Reviews, 2022, 43, 611-653.	20.1	110
1553	Disorders of Lipid Metabolism. , 2011, , 1633-1674.		5
1554	CETP Pharmacological Manipulation Transforming Human into Mouse: Is this Still a Viable Hypothesis?. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2012, 12, 266-278.	0.5	0
1556	Anamnese und Diagnostik â€“ Informationen fÃ¼r eine erfolgreiche Strategie. , 2014, , 51-74.		0
1557	Non-statin Therapies for CKD with Dyslipidemia. , 2014, , 153-178.		0
1558	Genetic Epidemiology of Atherosclerotic Vascular Disease. , 2014, , 1-24.		0
1559	Epidemiology of Atherosclerotic Vascular Disease. , 2014, , 1-21.		0
1561	Excess cardiovascular risk in patients with type 2 diabetes: do we need to look beyond LDL cholesterol?. British Journal of Diabetes and Vascular Disease, 2014, 14, 10.	0.6	0
1563	Levels of Blood Biomarkers among Patients with Myocardial Infarction in Comparison to Control Group. Ethiopian Journal of Health Sciences, 2020, 30, 5-12.	0.4	9
1564	A Closer Look at Cardioprotective Function of HDL: Revise the HDL â€“ Cholesterol Hypothesis?. Indonesian Biomedical Journal, 2014, 6, 17.	0.3	0
1567	Cholesteryl Ester Transfer Protein Inhibitors â€“ Future Soon to be REVEALed. European Cardiology Review, 2015, 10, 64.	2.2	0

#	Article	IF	Citations
1568	Approach to the Patient with Lipid Disorders. , 2015, , 91-111.		0
1569	Epidemiology of Atherosclerotic Vascular Diseases. , 2015, , 1499-1516.		0
1570	Genetic Epidemiology of Atherosclerotic Vascular Disease. , 2015, , 1517-1539.		0
1571	Biomarker des Lipoproteinstoffwechsels. Cardiovascular Medicine(Switzerland), 2015, 18, 53-60.	0.0	0
1572	HDL therapies â€" past, present and future. Journal of Medicines Development Sciences, 2015, 1, 2.	0.1	0
1573	Genomic Medicine and Ethnic Differences in Cardiovascular Disease Risk. , 2016, , 209-235.		0
1574	Genetic Disorders of Lipoprotein Metabolism: Diagnosis and Management. , 2016, , 331-354.		0
1575	Genetics of Endocrinology. , 2016, , 49-68.		1
1576	8. Sphingosine-1-phosphate-rich high-density lipoprotein in cardiovascular health and disease. Human Health Handbooks, 2016, , 137-154.	0.1	0
1579	é«˜æ¯"é‡ãƒªãƒè›‹ç™½ï¼ˆHDLï¼‰ã®æ–°ãŸãªæ©Ÿèƒ½è©•ä¾¡æ³•ã®å®Ÿç"¨åŒ–ã¨å¿ƒè¡€ç®¡ç—…ãƒªã‚¹ã‚¯ã®å±¤åˆ¥åŒ–. Journal of JC		0
1580	Nonparametric Testing for Heterogeneous Correlation. Contributions To Statistics, 2017, , 229-246.	0.2	1
1581	V. Lipid Managements from the Point of View of Human Genetics. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 711-717.	0.0	0
1582	FACEing reality: productive tensions between our epidemiological questions, methods and mission. International Journal of Epidemiology, 2016, 45, dyw330.	1.9	21
1590	The Warning on Saturated Fat: From Defective Experiments to Defective Guidelines. Kimika, 2017, 28, 42-47.	0.4	1
1592	The High Density Lipoprotein Cholesterol Hypothesis Revisited. Indonesian Biomedical Journal, 2018, 10, 84-103.	0.3	0
1594	Instrumental Variable Analysis. Health Services Research, 2019, , 479-522.	0.2	0
1595	Discussion on the Effectiveness of Elevating HDL-C in Treating Cardiovascular Diseases of Patients with Type 2 Diabetes Mellitus. International Journal of Clinical Medicine, 2019, 10, 293-305.	0.2	0
1597	Cholesterol: Canâ€™t Live With It, Canâ€™t Live Without It. Methodist DeBakey Cardiovascular Journal, 2021, 15, 9.	1.0	8

#	Article	IF	Citations
1598	Analysis of Factors Relating to the Event of Dyslipidemia in Oil and Gas Workers. , 2019, , .		0
1599	Encouragement of Super-aggressive LDL-lowering Therapies. Journal of Coronary Artery Disease, 2019, 25, 84-89.	0.3	0
1608	Prevalence of Dyslipidemia in Urban and Rural Areas of the Northwest of Iran: The Sociodemographic, Dietary and Psychological Determi-nants. Iranian Journal of Public Health, 0, , .	0.5	1
1610	Lipid disorders. , 2020, , 2055-2097.		0
1611	Genetics of chronic kidney disease and stroke. Neurology, 2020, 94, 1060-1061.	1.1	0
1612	LEGACY: Phase 2a Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of the Anti-EL (Endothelial Lipase) Antibody MEDI5884 in Patients With Stable Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 3005-3014.	2.4	6
1614	Clinical characteristics of cardiovascular patients with extremely low levels of high-density lipoprotein cholesterol. Lipids in Health and Disease, 2021, 20, 149.	3.0	0
1615	Risk Assessment in CVD. , 2020, , 33-60.		0
1616	Triglyceride-rich Lipoprotein Cholesterol (Remnant Cholesterol) as a Therapeutic Target for Cardiovascular Disease Risk. Contemporary Cardiology, 2021, , 139-158.	0.1	2
1617	High-Density Lipoproteins. Contemporary Cardiology, 2021, , 341-361.	0.1	1
1618	Linear reverse risk of HDL-C levels for predicting cardiovascular disease: it is not that straightforward!. European Journal of Preventive Cardiology, 2022, 29, 2055-2057.	1.8	3
1619	Benefits and hazards of alcohol-the J-shaped curve and public health. Drugs and Alcohol Today, 2021, 21, 54-69.	0.7	2
1620	Moderate alcohol consumption and lipoprotein subfractions: a systematic review of intervention and observational studies. Nutrition Reviews, 2022, 80, 1311-1339.	5.8	6
1621	Genetics and regulation of HDL metabolism. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2022, 1867, 159060.	2.4	2
1622	Biomarkers in drug development. , 2022, , 323-342.		3
1623	High-density lipoproteins (HDL): Novel function and therapeutic applications. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2022, 1867, 159058.	2.4	17
1624	HDL cholesterol concentrations and risk of atherosclerotic cardiovascular disease â€“ Insights from randomized clinical trials and human genetics. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2022, 1867, 159063.	2.4	19
1625	Thyroid, Lipids, and Risk of Atherosclerosis. , 2020, , 245-262.		1

#	Article	IF	Citations
1626	Genetic risk stratification enables primary prevention of CAD. Journal of Integrative Cardiology, 2020, 6, .	0.1	0
1627	Changes in High-Density Lipoprotein Cholesterol and Risks of Cardiovascular Events: A Post Hoc Analysis from the PICASSO Trial. Journal of Stroke, 2020, 22, 108-118.	3.2	3
1628	Genetic Disorders of Lipoprotein Metabolism: Diagnosis and Management. , 2020, , 387-411.		0
1629	Precision Medicine and Cardiovascular Health: Insights from Mendelian Randomization Analyses. Korean Circulation Journal, 2020, 50, 91.	1.9	7
1631	High density lipoprotein in atherosclerosis and coronary heart disease: Where do we stand today?. Vascular Pharmacology, 2021, 141, 106928.	2.1	7
1632	Causes and Consequences of Polycystic Ovary Syndrome: Insights From Mendelian Randomization. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e899-e911.	3.6	31
1633	High-density Lipoprotein Cholesterol as a Risk Factor of Health-Related Quality of Life in 50â€“70-Year-Old Community-Dwelling Women. Open Access Macedonian Journal of Medical Sciences, 2021, 9, 1092-1096.	0.2	0
1635	Serum from patients with chest pain and significant atherosclerosis resulted in macrophage cholesterol accumulation. Journal of Cardiovascular Medicine and Cardiology, 2020, , 221-225.	0.1	0
1637	High-Density Lipoproteins and Cardiovascular Disease. EMJ Cardiology, 0, , .	0.0	0
1638	HIGH-DENSITY LIPOPROTEINS AND CARDIOVASCULAR DISEASE. EMJ Cardiology, 0, , .	0.0	0
1641	Primary Prevention of Coronary Artery Disease. , 2021, , 81-123.		0
1643	Genetic insights into cardiometabolic risk factors. Clinical Biochemist Reviews, 2014, 35, 15-36.	3.3	28
1645	Atherosclerosis: process, indicators, risk factors and new hopes. International Journal of Preventive Medicine, 2014, 5, 927-46.	0.4	381
1646	H3Africa comes of age. Cardiovascular Journal of Africa, 2015, 26, S3-5.	0.4	7
1647	A Comparative Overview of Prescription Omega-3 Fatty Acid Products. P and T, 2015, 40, 826-57.	0.9	23
1648	Management of Lipid Levels and Cardiovascular Disease in HIV-Infected Individuals: Just Give Them a Statin?. Topics in Antiviral Medicine, 2016, 23, 169-73.	0.1	4
1649	Prevalence of Dyslipidemia in Urban and Rural Areas of the Northwest of Iran: The Sociodemographic, Dietary and Psychological Determinants. Iranian Journal of Public Health, 2019, 48, 925-933.	0.5	3
1650	Physical Activity and HDL-C: Are There Gender Differences in the Dose-response Effect?. Arquivos Brasileiros De Cardiologia, 2021, 117, 501-502.	0.8	0

#	Article	IF	Citations
1651	Abdominal obesity negatively influences key metrics of reverse cholesterol transport. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2022, 1867, 159087.	2.4	7
1652	Recruiting a transcription factor in the liver to prevent atherosclerosis. Journal of Clinical Investigation, 2021, 131, .	8.2	3
1653	An update on emerging drugs for the treatment of hypercholesterolemia. Expert Opinion on Emerging Drugs, 2021, 26, 363-369.	2.4	4
1655	Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?. Cardiovascular Research, 2022, 118, 2919-2931.	3.8	31
1656	Association Between Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations and Cardiovascular Events in Cardiovascular Disease: A Systemic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 2021, 8, 758956.	2.4	2
1657	Dietary quality indices modify the effects of apolipoprotein B polymorphisms on biochemical and anthropometric factors in type 2 diabetes mellitus. Scientific Reports, 2021, 11, 22395.	3.3	1
1658	Assessing HDL Metabolism in Subjects with Elevated Levels of HDL Cholesterol and Coronary Artery Disease. Molecules, 2021, 26, 6862.	3.8	3
1659	Lipid Profile of Coronary Heart Disease Patients: A Prospective Observational Study. World Journal of Cardiovascular Surgery, 2021, 11, 114-124.	0.1	0
1660	Toxicological effect of Artemisinin-Based Combination Therapies plus Paracetamol in malaria patients. Toxicology Reports, 2021, 8, 1930-1936.	3.3	1
1661	Effect of oat supplementation interventions on cardiovascular disease risk markers: a systematic review and meta-analysis of randomized controlled trials. European Journal of Nutrition, 2022, 61, 1749-1778.	3.9	14
1662	High Density Lipoproteins: Is There a Comeback as a Therapeutic Target?. Handbook of Experimental Pharmacology, 2021, , 157-200.	1.8	3
1663	New evidences on the association between high-density lipoprotein cholesterol and cardiovascular risk: a never ending research story. European Journal of Preventive Cardiology, 2022, 29, 842-843.	1.8	6
1664	Very High High-Density Lipoprotein Cholesterol Levels and Cardiovascular Mortality. American Journal of Cardiology, 2022, 167, 43-53.	1.6	21
1665	Phenome-Wide Association Analysis Reveals Novel Links Between Genetically Determined Levels of Liver Enzymes and Disease Phenotypes. Phenomics, 2022, 2, 295-311.	2.9	9
1666	Addressing dyslipidemic risk beyond LDL-cholesterol. Journal of Clinical Investigation, 2022, 132, .	8.2	51
1667	Associations of lipoprotein particle profile and objectively measured physical activity and sedentary time in schoolchildren: a prospective cohort study. International Journal of Behavioral Nutrition and Physical Activity, 2022, 19, 5.	4.6	2
1668	HDL Is Not Dead Yet. Biomedicines, 2022, 10, 128.	3.2	8
1669	The Effect of Circulating Zinc, Selenium, Copper and Vitamin K1 on COVID-19 Outcomes: A Mendelian Randomization Study. Nutrients, 2022, 14, 233.	4.1	21

#	Article	IF	Citations
1670	Cholesterol uptake capacity: A new measure of high-density lipoprotein functionality as a predictor of subsequent revascularization in patients undergoing percutaneous coronary intervention. Atherosclerosis, 2022, , .	0.8	4
1671	Early and late recurrent cardiovascular events among highâ€risk patients with an acute coronary syndrome: Metaâ€analysis of phase III studies and implications on trial design. Clinical Cardiology, 2022, , .	1.8	3
1672	Rare coding variants in 35 genes associate with circulating lipid levelsâ€"A multi-ancestry analysis of 170,000 exomes. American Journal of Human Genetics, 2022, 109, 81-96.	6.2	24
1673	Pharmacological Inhibition of CETP (Cholesteryl Ester Transfer Protein) Increases HDL (High-Density) Tj ETQq1 1 0.784314 rgBT /Over Heart Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 227-237.	2.4	21
1674	HDL maturation and remodelling. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2022, 1867, 159119.	2.4	3
1675	Beyond HDL-Cholesterol: The Search for Functional Biomarkers of High Density Lipoproteins. Cardiometabolic Syndrome Journal, 2022, 2, 28.	0.6	1
1676	Mendelian randomization. Nature Reviews Methods Primers, 2022, 2, .	21.2	393
1677	Oxidant resistant human apolipoprotein A-I functions similarly to the unmodified human isoform in delaying atherosclerosis progression and promoting atherosclerosis regression in hyperlipidemic mice. PLoS ONE, 2022, 17, e0259751.	2.5	4
1678	High-density lipoprotein cholesterol â€" friend or enemy?. Kazan Medical Journal, 2022, 103, 79-88.	0.2	0
1679	Cholesterol Efflux Capacity and Its Association With Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 2021, 8, 774418.	2.4	23
1680	Genomic Variants and Multilevel Regulation of ABCA1, ABCG1, and SCARB1 Expression in Atherogenesis. Journal of Cardiovascular Development and Disease, 2021, 8, 170.	1.6	8
1681	High-density lipoprotein cholesterol and cardiovascular mortality: a prospective cohort study among 15.8 million adults. European Journal of Preventive Cardiology, 2022, 29, 844-854.	1.8	15
1682	Role of HDL in those with diabetes. Current Cardiology Reports, 2014, 16, 512.	2.9	6
1683	Additive Effects of Drinking Habits and a Susceptible Genetic Polymorphism on Cholesterol Efflux Capacity. Journal of Atherosclerosis and Thrombosis, 2023, 30, 23-38.	2.0	5
1684	Free Cholesterol Bioavailability and Atherosclerosis. Current Atherosclerosis Reports, 2022, 24, 323-336.	4.8	10
1685	Effect of thyroid function on pre-Î²1 high-density lipoprotein levels in patients with Gravesâ€™ disease undergoing radioiodine treatment. Endocrine, 2022, , 1.	2.3	0
1686	The metabolic signature of cardiovascular disease and arterial calcification in patients with chronic kidney disease. Atherosclerosis, 2022, 350, 109-118.	0.8	3
1688	Targeting triglycerides to lower residual cardiovascular risk. Expert Review of Cardiovascular Therapy, 2022, , 1-7.	1.5	2

#	Article	IF	Citations
1689	Macrophage SR-B1 in atherosclerotic cardiovascular disease. Current Opinion in Lipidology, 2022, 33, 167-174.	2.7	4
1690	The Role of High-Density Lipoprotein Cholesterol in 2022. Current Atherosclerosis Reports, 2022, 24, 365-377.	4.8	14
1691	Hyperlipidemia management in diabetes: First line or supportive therapy?. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2022, 16, 102470.	3.6	3
1692	Aldehyde dehydrogenase 2 and PARP1 interaction modulates hepatic HDL biogenesis by LXRÎ±-mediated ABCA1 expression. JCI Insight, 2022, 7, .	5.0	3
1693	A community based cross sectional study on the prevalence of dyslipidemias and 10Âyears cardiovascular risk scores in adults in Asmara, Eritrea. Scientific Reports, 2022, 12, 5567.	3.3	2
1694	High triglyceride is an independent predictor of high on-treatment platelet reactivity in ischemic stroke patients. Journal of Stroke and Cerebrovascular Diseases, 2022, 31, 106448.	1.6	1
1696	Modification of High-Density Lipoprotein Functions by Diet and Other Lifestyle Changes: A Systematic Review of Randomized Controlled Trials. Journal of Clinical Medicine, 2021, 10, 5897.	2.4	6
1697	Global prevalence of dyslipidaemia in adult populations: a systematic review protocol. BMJ Open, 2021, 11, e049662.	1.9	5
1698	Predictive value of HDL function in patients with coronary artery disease: relationship with coronary plaque characteristics and clinical events. Annals of Medicine, 2022, 54, 1036-1046.	3.8	9
1699	Whole-exome sequencing reveals damaging gene variants associated with hypoalphalipoproteinemia. Journal of Lipid Research, 2022, 63, 100209.	4.2	2
1700	GuÃa ESC 2021 sobre la prevenciÃ³n de la enfermedad cardiovascular en la prÃ¡ctica clÃnica. Revista Espanola De Cardiologia, 2022, 75, 429.e1-429.e104.	1.2	27
1701	Phosphatidylserine enhances antiâ€inflammatory effects of reconstituted HDL in macrophages via distinct intracellular pathways. FASEB Journal, 2022, 36, e22274.	0.5	8
1703	Visceral Adiposity and Risk of Stroke: A Mendelian Randomization Study. Frontiers in Neurology, 2022, 13, 804851.	2.4	4
1708	Saturated Fat and Cardiovascular Health: Phenotype and Dietary Factors Influencing Interindividual Responsiveness. Current Atherosclerosis Reports, 2022, 24, 391-398.	4.8	0
1710	A genetic variant of the CAPN10 gene in Mexican subjects with dyslipidemia is associated with increased HDL-cholesterol concentrations after the consumption of a soy protein and soluble fiber dietary portfolio. Nutricion Hospitalaria, 2014, 30, 671-7.	0.3	5
1712	Blood lipids and molecular pathways of atherogenesis. , 2022, , 623-637.		0
1713	Association of High-Density Lipoprotein Cholesterol Phenotypes with the Risk of Cardiovascular Diseases and Mortality: A Cohort Study in Korea. Endocrinology and Metabolism, 2022, 37, 261-271.	3.0	3
1714	Ethnic differences in cardiovascular risk: examining differential exposure and susceptibility to risk factors. BMC Medicine, 2022, 20, 149.	5.5	26

#	Article	IF	Citations
1715	2022 Prevention of chronic non-communicable diseases in Of the Russian Federation. National guidelines. Cardiovascular Therapy and Prevention (Russian Federation), 2022, 21, 3235.	1.4	37
1716	Shared components of heritability across genetically correlated traits. American Journal of Human Genetics, 2022, 109, 989-1006.	6.2	7
1717	Lymphocyte activation gene-3-associated protein networks are associated with HDL-cholesterol and mortality in the Trans-omics for Precision Medicine program. Communications Biology, 2022, 5, 362.	4.4	5
1718	A Bayesian model selection approach to mediation analysis. PLoS Genetics, 2022, 18, e1010184.	3.5	8
1719	Polycystic ovary syndrome: a â€œrisk-enhancingâ€•factor for cardiovascular disease. Fertility and Sterility, 2022, 117, 924-935.	1.0	34
1720	Which therapy for which condition?. , 2013, , 463-541.		1
1721	HDL and Cholesterol Ester Transfer Protein (CETP). Advances in Experimental Medicine and Biology, 2022, 1377, 13-26.	1.6	6
1722	HDL and Lipid Metabolism. Advances in Experimental Medicine and Biology, 2022, 1377, 49-61.	1.6	3
1723	HDL Mimetic Peptides. Advances in Experimental Medicine and Biology, 2022, 1377, 141-151.	1.6	0
1724	Association Between High-Density Lipoprotein Cholesterol Levels and Adverse Cardiovascular Outcomes in High-risk Populations. JAMA Cardiology, 2022, 7, 672.	6.1	66
1726	Mendelian Randomization Rules Out Causation Between Inflammatory Bowel Disease and Non-Alcoholic Fatty Liver Disease. Frontiers in Pharmacology, 2022, 13, .	3.5	4
1727	Protein-based HDL subspecies: Rationale and association with cardiovascular disease, diabetes, stroke, and dementia. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2022, 1867, 159182.	2.4	5
1728	The Complete Health Improvement Program and Physical Activity. American Journal of Lifestyle Medicine, 0, , 155982762210898.	1.9	0
1729	Bariatric Surgery-induced High-density Lipoprotein Functionality Enhancement Is Associated With Reduced Inflammation. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 2182-2194.	3.6	6
1730	Clinical Impact of the Capacity-Motivation-Opportunity Pharmacist-Led Intervention in People Living with HIV in Spain, 2019â€“2020. Journal of Multidisciplinary Healthcare, 0, Volume 15, 1203-1211.	2.7	7
1731	Genetic support of a causal relationship between iron status and atrial fibrillation: a Mendelian randomization study. Genes and Nutrition, 2022, 17, .	2.5	8
1735	Mendelian randomization analysis of 37 clinical factors and coronary artery disease in East Asian and European populations. Genome Medicine, 2022, 14, .	8.2	29
1736	Coronary computed tomography angiography evaluation of plaque morphology and its relationship to HDL and total cholesterol to HDL ratio. Journal of Clinical Lipidology, 2022, 16, 715-724.	1.5	5

#	Article	IF	Citations
1737	Causal associations of alcohol consumption with cardiovascular diseases and all-cause mortality among Chinese males. American Journal of Clinical Nutrition, 2022, 116, 771-779.	4.7	13
1738	Impact of different training modalities on highâ€density lipoprotein function in HFpEF patients: a substudy of the OptimEx trial. ESC Heart Failure, 2022, 9, 3019-3030.	3.1	3
1739	The Regulation of Triacylglycerol Metabolism and Lipoprotein Lipase Activity. Advanced Biology, 2022, 6, .	2.5	13
1740	Predictive Value of Serum Uric Acid to HDL Cholesterol Ratio for Incident Ischemic Heart Disease in Non-Diabetic Koreans. Biomedicines, 2022, 10, 1422.	3.2	12
1741	Genome-wide meta-analysis and omics integration identifies novel genes associated with diabetic kidney disease. Diabetologia, 2022, 65, 1495-1509.	6.3	16
1742	Cholesterol-Lowering Therapy in Patients at Low-to-Moderate Cardiovascular Risk. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 327-336.	2.2	2
1743	Editorial: Beyond Cardiovascular Disease: Challenging New Pathways in Lipid and Lipoprotein Metabolism. Frontiers in Cell and Developmental Biology, 0, 10, .	3.7	0
1744	Differential Effects of Genetically Determined Cholesterol Efflux Capacity on Coronary Artery Disease and Ischemic Stroke. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	0
1745	Association of High-Density Lipoprotein Cholesterol, Renal Function, and Metabolic Syndrome: An Assessment of the 2013â€“2018 National Health and Nutrition Examination Surveys. Kidney and Dialysis, 2022, 2, 419-432.	1.0	0
1746	Associations of higher fish consumption and lifestyle with lower monocyte/HDL-C ratio in a Japanese population: Implication for the anti-atherosclerotic effect of fish consumption. Journal of Cardiology, 2022, , .	1.9	1
1747	High-Density Lipoprotein and Cardiovascular Diseaseâ€”Where do We Stand?. Endocrinology and Metabolism Clinics of North America, 2022, , .	3.2	2
1748	Oxidative stress and high-density lipoprotein cholesterol: Cause or consequence?. Revista Portuguesa De Cardiologia, 2022, 41, 841-842.	0.5	1
1750	New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins. Diabetes and Metabolism Journal, 2022, 46, 517-532.	4.7	23
1751	Lipoprotein Subclasses Independently Contribute to Subclinical Variance of Microvascular and Macrovascular Health. Molecules, 2022, 27, 4760.	3.8	2
1752	Associations between the HDL-C/ApoA-I ratio and fasting glucose levels differ by glucose deciles, HDL-C/ApoA-I ratio ranges and sex. Diabetes Research and Clinical Practice, 2022, 190, 110021.	2.8	1
1753	Genetic evidence for the causal relationship between NAFLD and brain functional connectivity. , 2022, , .		0
1754	Independent Effects of Kidney Function and Cholesterol Efflux on Cardiovascular Mortality. Biomedicines, 2022, 10, 1832.	3.2	0
1755	Association of maternal diabetes during pregnancy with visual acuity development in offspring: a prospective cohort study. Acta Diabetologica, 2022, 59, 1461-1468.	2.5	3

#	Article	IF	Citations
1756	Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial. Nature Medicine, 2022, 28, 1672-1678.	30.7	56
1757	Plasma HDL pattern, cholesterol efflux and cholesterol loading capacity of serum in carriers of a novel missense variant (Gly176Trp) of endothelial lipase. Journal of Clinical Lipidology, 2022, 16, 694-703.	1.5	2
1758	Examination on the risk factors of cholangiocarcinoma: A Mendelian randomization study. Frontiers in Pharmacology, 0, 13, .	3.5	5
1759	Hypercholesterolemia-Induced HDL Dysfunction Can Be Reversed: The Impact of Diet and Statin Treatment in a Preclinical Animal Model. International Journal of Molecular Sciences, 2022, 23, 8596.	4.1	6
1760	Modulatory effect of berberine on plasma lipoprotein (or lipid) profile: a review. Molecular Biology Reports, 2022, 49, 10885-10893.	2.3	3
1761	Genetics of circadian rhythms and sleep in human health and disease. Nature Reviews Genetics, 2023, 24, 4-20.	16.3	55
1762	Association of TGFB1 rs1800469 and BCMO1 rs6564851 with coronary heart disease and IL1B rs16944 with all-cause mortality in men from the Northern Ireland PRIME study. PLoS ONE, 2022, 17, e0273333.	2.5	2
1763	HDL, cholesterol efflux, and ABCA1: Free from good and evil dualism. Journal of Pharmacological Sciences, 2022, 150, 81-89.	2.5	9
1764	Identification of a Gain-of-FunctionLIPCVariant as a Novel Cause of Familial Combined Hypocholesterolemia. Circulation, 2022, 146, 724-739.	1.6	7
1765	High HDL (High-Density Lipoprotein) Cholesterol Increases Cardiovascular Risk in Hypertensive Patients. Hypertension, 2022, 79, 2355-2363.	2.7	40
1766	Mechanisms of Lipoproteins and Reverse Cholesterol Transport in Atherosclerotic Cardiovascular Disease. , 2022, , 343-365.		0
1767	The effects of coconut oil on the cardiometabolic profile: a systematic review and meta-analysis of randomized clinical trials. Lipids in Health and Disease, 2022, 21, .	3.0	5
1768	Resolution of apolipoprotein A1 and A2 proteoforms: their cardiometabolic correlates and implications for future research. Current Opinion in Lipidology, 2022, 33, 264-269.	2.7	1
1769	Dicarbonyl-modified lipoproteins contribute to proteinuric kidney injury. JCI Insight, 2022, 7, .	5.0	3
1771	Associations between Alcohol Consumption and HDL Subspecies Defined by ApoC3, ApoE and ApoJ: the Cardiovascular Health Study. Current Problems in Cardiology, 2023, 48, 101395.	2.4	6
1772	Hypothyroidism has a protective causal association with hepatocellular carcinoma: A two-sample Mendelian randomization study. Frontiers in Endocrinology, 0, 13, .	3.5	7
1773	Effect of Exercise on Vascular Function and Blood Lipids in Postmenopausal Women: A Systematic Review and Network Meta-Analysis. International Journal of Environmental Research and Public Health, 2022, 19, 12074.	2.6	4
1774	The grand challenge of discovering new cardiovascular drugs. Frontiers in Drug Discovery, 0, 2, .	2.8	3

#	Article	IF	Citations
1775	Mendelian randomization identifies age at menarche as an independent causal effect factor for gestational diabetes mellitus. Diabetes, Obesity and Metabolism, 2023, 25, 248-260.	4.4	7
1776	CSL112 (Apolipoprotein A-I [Human]) Strongly Enhances Plasma Apoa-I and Cholesterol Efflux Capacity in Post-Acute Myocardial Infarction Patients: A PK/PD Substudy of the AEGIS-I Trial. Journal of Cardiovascular Pharmacology and Therapeutics, 2022, 27, 107424842211215.	2.0	6
1777	Familial Hypercholesterolaemia as a Predisposing Factor for Atherosclerosis. Biomedicines, 2022, 10, 2639.	3.2	2
1778	Crosstalk between high-density lipoproteins and endothelial cells in health and disease: Insights into sex-dependent modulation. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	0
1779	Advances and Applications of Polygenic Scores for Coronary Artery Disease. Annual Review of Medicine, 2023, 74, 141-154.	12.2	9
1780	Time-resolved fluorescence based direct two-site apoA-I immunoassays and their clinical application in patients with suspected obstructive coronary artery disease. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	0
1781	Pleiotropy of Copy Number Variation in Human Genome. Russian Journal of Genetics, 2022, 58, 1180-1192.	0.6	2
1782	Evidence that the pituitary gland connects type 2 diabetes mellitus and schizophrenia based on large-scale trans-ethnic genetic analyses. Journal of Translational Medicine, 2022, 20, .	4.4	2
1783	Can we revive CETP-inhibitors for the prevention of cardiovascular disease?. Current Opinion in Lipidology, 2022, 33, 319-325.	2.7	7
1784	Polygenic risk scores: An overview from bench to bedside for personalised medicine. Frontiers in Genetics, 0, 13, .	2.3	17
1785	Diet-derived antioxidants and nonalcoholic fatty liver disease: a Mendelian randomization study. Hepatology International, 2023, 17, 326-338.	4.2	11
1786	High-density lipoprotein revisited: biological functions and clinical relevance. European Heart Journal, 2023, 44, 1394-1407.	2.2	51
1787	Mid- and long-term changes in satiety-related hormones, lipid and glucose metabolism, and inflammation after a Mediterranean diet intervention with the goal of losing weight: A randomized, clinical trial. Frontiers in Nutrition, 0, 9, .	3.7	4
1788	1â€“2 Drinks Per Day Affect Lipoprotein Composition after 3 Weeksâ€”Results from a Cross-Over Pilot Intervention Trial in Healthy Adults Using Nuclear Magnetic Resonance-Measured Lipoproteins and Apolipoproteins. Nutrients, 2022, 14, 5043.	4.1	2
1789	CETP Inhibitors: Should We Continue to Pursue This Pathway?. Current Atherosclerosis Reports, 2022, 24, 915-923.	4.8	3
1790	Race-Dependent Association of High-Density Lipoprotein Cholesterol Levels With Incident Coronary Artery Disease. Journal of the American College of Cardiology, 2022, 80, 2104-2115.	2.8	15
1791	BMI modifies HDL-C effects on coronary artery bypass grafting outcomes. Lipids in Health and Disease, 2022, 21, .	3.0	9
1792	Assessment of causal associations between uric acid and 25-hydroxyvitamin D levels. Frontiers in Endocrinology, 0, 13, .	3.5	0

#	Article	IF	Citations
1793	Hypertriglyceridemia may contribute to stroke and pancreatitis: A case report and review of the literature. Frontiers in Endocrinology, 0, 13, .	3.5	0
1794	Underestimated prognostic value of depression in patients with obstructive coronary artery disease. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	1
1795	Mendelian randomization analyses identified bioavailable testosterone mediates the effect of sex hormoneâ€binding globulin on prostate cancer. Andrology, 2023, 11, 1023-1030.	3.5	2
1796	Lower levels of small HDL particles associated with increased infectious disease morbidity and mortality: a population-based cohort study of 30 195 individuals. Cardiovascular Research, 2023, 119, 957-968.	3.8	8
1797	Effects of Antirheumatic Treatment on Cell Cholesterol Efflux and Loading Capacity of Serum Lipoproteins in Spondylarthropathies. Journal of Clinical Medicine, 2022, 11, 7330.	2.4	2
1798	Hypertriglyceridemia promotes dysfunctions in high-density lipoprotein increasing the cardiovascular risk. Brazilian Journal of Pharmaceutical Sciences, 0, 58, .	1.2	0
1799	Insights into Causal Cardiovascular Risk Factors from Mendelian Randomization. Current Cardiology Reports, 2023, 25, 67-76.	2.9	1
1800	Very low HDL levels: clinical assessment and management. Archives of Endocrinology and Metabolism, 2023, 67, 3-18.	0.6	4
1801	US Trends in Cholesterol Screening, Lipid Levels, and Lipidâ€lowering Medication Use in US Adults, 1999 to 2018. Journal of the American Heart Association, 2023, 12, .	3.7	9
1802	Investigation of Causal Effects of Protein Biomarkers on Cardiovascular Disease in Persons With HIV. Journal of Infectious Diseases, 2023, 227, 951-960.	4.0	0
1803	Biomedical consequences of elevated cholesterol-containing lipoproteins and apolipoproteins on cardiovascular and non-cardiovascular outcomes. Communications Medicine, 2023, 3, .	4.2	4
1804	Body mass index and the risk of basal cell carcinoma: evidence from Mendelian randomization analysis. PeerJ, 0, 11, e14781.	2.0	2
1805	Imaging modalities for congenital heart disease and genetic polymorphism associated with coronary artery and cardiovascular diseases. , 2023, , 169-203.		0
1806	Smoking, alcohol consumption, diabetes, body mass index, and peptic ulcer risk: A two-sample Mendelian randomization study. Frontiers in Genetics, 0, 13, .	2.3	6
1807	Investigating the potential anti-depressive mechanisms of statins: a transcriptomic and Mendelian randomization analysis. Translational Psychiatry, 2023, 13, .	4.8	4
1808	ATP-binding cassette G1 membrane transporter-mediated cholesterol efflux capacity influences coronary atherosclerosis and cardiovascular risk in Rheumatoid Arthritis. Journal of Autoimmunity, 2023, 136, 103029.	6.5	4
1809	Editorial: in search of environmental risk factors of Crohn's disease and ulcerative colitis with mendelian randomisation. Alimentary Pharmacology and Therapeutics, 2023, 57, 1032-1033.	3.7	1
1810	Analysis of association of apolipoprotein genes APOA2, APOA5 and APOH variants with hyperlipidemia. , 2023, 19, 6-18.	0.1	0

#	Article	IF	Citations
1811	The causal effects of lipid traits on kidney function in Africans: bidirectional and multivariable Mendelian-randomization study. EBioMedicine, 2023, 90, 104537.	6.1	8
1812	Comparison of the effects of 3 kinds of oils rich in omega-3 polyunsaturated fatty acids on glycolipid metabolism and lipoprotein subfractions. Food Science and Human Wellness, 2023, 12, 2221-2231.	4.9	1
1813	KLKB1 and CLSTN2 are associated with HDL-mediated cholesterol efflux capacity in a genome-wide association study. Atherosclerosis, 2023, 368, 1-11.	0.8	2
1814	Mass-Spectrometry-Based Lipidomics Discriminates Specific Changes in Lipid Classes in Healthy and Dyslipidemic Adults. Metabolites, 2023, 13, 222.	2.9	3
1815	Long-term cardiometabolic health in people born after assisted reproductive technology: a multi-cohort analysis. European Heart Journal, 2023, 44, 1464-1473.	2.2	8
1816	Mendelian randomization reveals no associations of genetically-predicted obstructive sleep apnea with the risk of type 2 diabetes, nonalcoholic fatty liver disease, and coronary heart disease. Frontiers in Psychiatry, 0, 14, .	2.6	2
1817	Associations between serum high-density lipoprotein cholesterol levels and cause-specific mortality in a general population of 345Â000 men and women aged 20â€“79 years. International Journal of Epidemiology, 2023, 52, 1257-1267.	1.9	4
1818	Associations between types and sources of dietary carbohydrates and cardiovascular disease risk: a prospective cohort study of UK Biobank participants. BMC Medicine, 2023, 21, .	5.5	18
1819	Disease-modifying vs symptomatic treatments: Splitting over lumping. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 187-209.	1.8	5
1820	Differences in HDL-related mortality risk between individuals with and without hypertension: a prospective cohort study in UK Biobank. European Journal of Preventive Cardiology, 2023, 30, 951-959.	1.8	5
1821	Strategies to investigate and mitigate collider bias in genetic and Mendelian randomisation studies of disease progression. PLoS Genetics, 2023, 19, e1010596.	3.5	12
1822	HDL-Based Therapy: Vascular Protection at All Stages. Biomedicines, 2023, 11, 711.	3.2	1
1823	Distinct metabolic features of genetic liability to type 2 diabetes and coronary artery disease: a reverse Mendelian randomization study. EBioMedicine, 2023, 90, 104503.	6.1	4
1825	Mendelian Randomization Analysis Provides Insights into the Pathogenesis of Serum Levels of Branched-Chain Amino Acids in Cardiovascular Disease. Metabolites, 2023, 13, 403.	2.9	2
1826	HDL Function and Size in Patients with On-Target LDL Plasma Levels and a First-Onset ACS. International Journal of Molecular Sciences, 2023, 24, 5391.	4.1	1
1827	Correlation of apolipoprotein Aâ€Ⅰ with T cell subsets and interferonâ€Ò¯ in coronary artery disease. Immunity, Inflammation and Disease, 2023, 11, .	2.7	0
1828	The Impact of the Blood Lipids Levels on Arterial Stiffness. Journal of Cardiovascular Development and Disease, 2023, 10, 127.	1.6	6
1829	HDL cholesterol and cardiovascular risk: teasing the answer from the complexity. European Journal of Preventive Cardiology, 2023, 30, 644-645.	1.8	1

#	Article	IF	Citations
1830	CSL112 Infusion Rapidly Increases APOA1 Exchange Rate via Specific Serum Amyloid-Poor HDL Subpopulations When Administered to Patients Postâ€“Myocardial Infarction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2023, 43, 855-869.	2.4	5
1831	Leukocyte telomere length and bipolar disorder risk: evidence from Mendelian randomization analysis. PeerJ, 0, 11, e15129.	2.0	1
1832	Lipids, atherosclerosis, and microvascular disease: Translating basic science into pharmacotherapeutics. , 2023, , 97-135.		0
1833	Gene transfer and genome editing for familial hypercholesterolemia. Frontiers in Molecular Medicine, 0, 3, .	1.9	0
1834	Novel and future lipid-modulating therapies for the prevention of cardiovascular disease. Nature Reviews Cardiology, 2023, 20, 600-616.	13.7	22
1835	Cardiovascular risk and the COVID-19 pandemic: A retrospective observational study in a population of healthcare professionals. Nutrition, Metabolism and Cardiovascular Diseases, 2023, 33, 1415-1419.	2.6	4
1836	The burden of cardiovascular risk in individuals with spinal cord injury (SCI) and its association with rehabilitation outcomes â€“ Results from the Swiss SCI Cohort. American Journal of Physical Medicine and Rehabilitation, 0, Publish Ahead of Print, .	1.4	0
1837	Low concentrations of medium-sized HDL particles predict incident CVD in chronic kidney disease patients. Journal of Lipid Research, 2023, 64, 100381.	4.2	2
1838	Endothelial Function in Dyslipidemia: Roles of LDL-Cholesterol, HDL-Cholesterol and Triglycerides. Cells, 2023, 12, 1293.	4.1	6
1839	The association between circulating lipoprotein subfractions and lipid content in coronary atheromatous plaques assessed by near-infrared spectroscopy. IJC Heart and Vasculature, 2023, 46, 101215.	1.1	0
1840	HDL-cholesterol concentration and its association with coronary artery calcification: a systematic review and meta-analysis. Lipids in Health and Disease, 2023, 22, .	3.0	3
1841	Triglycerides, Triglyceride-Rich Lipoproteins, and High-Density Lipoprotein in Coronary Heart Disease Risk Assessment. , 2024, , 32-41.e2.		0
1842	Treatment Guidelines Overview. , 2024, , 113-121.e2.		0
1843	Vegetarian or vegan diets and blood lipids: a meta-analysis of randomized trials. European Heart Journal, 2023, 44, 2609-2622.	2.2	20
1845	Genomic Innovation in Early Life Cardiovascular Disease Prevention and Treatment. Circulation Research, 2023, 132, 1628-1647.	4.5	2
1846	Research Status of Lipoprotein and Residual Risk of Cardiovascular Disease. Advances in Clinical Medicine, 2023, 13, 9211-9216.	0.0	0
1847	Variations in high density cholesterol levels based on apolipoprotein E variant and exercise type. Frontiers in Genetics, 0, 14, .	2.3	1
1849	Triglyceride- and Cholesterol-Rich Remnant Lipoproteins in Risk of Cardiovascular Disease in Diabetes Mellitus. Contemporary Diabetes, 2023, , 195-222.	0.0	0

#	Article	IF	Citations
1851	Vetten. , 2023, , 145-159.		0
1852	Evolving Therapeutic Targets. , 2024, , 275-280.e1.		0
1853	Special Patient Populations. , 2024, , 345-357.e3.		0
1855	HDL Function and Atherosclerosis: Reactive Dicarbonyls as Promising Targets of Therapy. Circulation Research, 2023, 132, 1521-1545.	4.5	10
1856	The Effect of Carbohydrate Restriction on Lipids, Lipoproteins, and Nuclear Magnetic Resonance-Based Metabolites: CALIBER, a Randomised Parallel Trial. Nutrients, 2023, 15, 3002.	4.1	0
1858	Inverse Correlation of Cholesterol Efflux Capacity with Peripheral Plaque Volume Measured by 3D Ultrasound. Biomedicines, 2023, 11, 1918.	3.2	1
1859	Does Elevated High-Density Lipoprotein Cholesterol Protect Against Cardiovascular Disease?. Journal of Clinical Endocrinology and Metabolism, 0, , .	3.6	2
1860	Cardiovascular risk personification: focus on the natriuretic peptide system. , 2023, 19, 131-139.	0.1	0
1861	Very high HDL-C (high-density lipoprotein cholesterol) is associated with increased cardiovascular risk in patients with NSTEMI (non-ST-segment elevation myocardial infarction) undergoing PCI (percutaneous coronary intervention). BMC Cardiovascular Disorders, 2023, 23, .	1.7	2
1862	Integrated omics approach for the identification of HDL structure-function relationships in PCSK9-related familial hypercholesterolemia. Journal of Clinical Lipidology, 2023, 17, 643-658.	1.5	0
1863	Germline mechanisms of immunotherapy toxicities in the era of genomeâ€wide association studies. Immunological Reviews, 2023, 318, 138-156.	6.0	2
1864	HDL abnormalities in type 2 diabetes: Clinical implications. Atherosclerosis, 2023, , 117213.	0.8	4
1865	Effects of Ocimum basilicum mucilage on hyperlipidemia and gut microbiota on mice fed a high-fat diet. Bioactive Carbohydrates and Dietary Fibre, 2023, 30, 100384.	2.7	0
1866	The Role of Biomarkers, Metabolomics, and COVID-19 in Venous Thromboembolismâ€"A Review of Literature. International Journal of Molecular Sciences, 2023, 24, 13411.	4.1	0
1867	A realistic approach to evaluating the effect of baseline lipid profile in postcoronary artery bypass grafting surgery. Clinical Cardiology, 2023, 46, 1408-1417.	1.8	1
1868	Lipoproteins, Cholesterol, and Atherosclerotic Cardiovascular Disease in East Asians and Europeans. Journal of Atherosclerosis and Thrombosis, 2023, 30, 1525-1546.	2.0	6
1869	Systematic comparison of Mendelian randomisation studies and randomised controlled trials using electronic databases. BMJ Open, 2023, 13, e072087.	1.9	0
1870	Effect of Isoenergetic Substitution of Cheese with Other Dairy Products on Blood Lipid Markers in the Fasted and Postprandial State: An Updated and Extended Systematic Review and Meta-Analysis of Randomized Controlled Trials in Adults. Advances in Nutrition, 2023, 14, 1579-1595.	6.4	2

#	Article	IF	Citations
1871	European guidelines for the treatment of dyslipidaemias: New concepts and future challenges. Pharmacological Research, 2023, 196, 106936.	7.1	3
1872	Modulation of the Cellular microRNA Landscape: Contribution to the Protective Effects of High-Density Lipoproteins (HDL). Biology, 2023, 12, 1232.	2.8	2
1873	Associations of High-Density Lipoprotein Functionality with Coronary Plaque Characteristics in Diabetic Patients with Coronary Artery Disease: Integrated Backscatter Intravascular Ultrasound Analysis. Biomolecules, 2023, 13, 1278.	4.0	2
1874	Value of blood lipid in predicting graft dysfunction after organ and tissue transplantation: A study of Mendelian randomization. Heliyon, 2023, 9, e20230.	3.2	0
1876	HDL Function across the Lifespan: From Childhood, to Pregnancy, to Old Age. International Journal of Molecular Sciences, 2023, 24, 15305.	4.1	1
1877	Genetics-based risk scores for prediction of premature coronary artery disease. Indian Heart Journal, 2023, 75, 327-334.	0.5	2
1878	Association of high-density lipoprotein cholesterol with all-cause and cause-specific mortality in a Chinese population of 3.3 million adults: a prospective cohort study. The Lancet Regional Health - Western Pacific, 2023, , 100874.	2.9	0
1879	Complex effects of sequence variants on lipid levels and coronary artery disease. Cell, 2023, 186, 4085-4099.e15.	28.9	1
1880	The pathophysiology of excess plasma-free cholesterol. Current Opinion in Lipidology, 0, , .	2.7	0
1881	Novel therapeutic targets and emerging treatments for atherosclerotic cardiovascular disease. European Heart Journal - Cardiovascular Pharmacotherapy, 0, , .	3.0	0
1882	Cholesterol and lipids. , 2023, , .		0
1883	High-density lipoprotein functionality, cardiovascular health, and patterns of alcohol consumption: new insights and future perspectives. Current Opinion in Lipidology, 0, , .	2.7	0
1884	Host genetics and gut microbiota jointly regulate blood biochemical indicators in chickens. Applied Microbiology and Biotechnology, 2023, 107, 7601-7620.	3.6	2
1885	Genetic overlap for ten cardiovascular diseases: A comprehensive gene-centric pleiotropic association analysis and Mendelian randomization study. IScience, 2023, 26, 108150.	4.1	1
1886	The Role of Endothelial Cells in Atherosclerosis. American Journal of Pathology, 2023, , .	3.8	2
1888	Comparison of the Predicting Value of Neutrophil toÂhigh-Density Lipoprotein Cholesterol Ratio and Monocyte toÂhigh-Density Lipoprotein Cholesterol Ratio for in-Hospital Prognosis and Severe Coronary Artery Stenosis in Patients with ST-Segment Elevation Acute Myocardial Infarction Following Percutaneous Coronary Intervention: A Retrospective Study. Journal of Inflammation Research, 0, Volume 16, 4541-4557.	3.5	0
1891	Causal Associations between Gut Microbiota and Different Types of Dyslipidemia: A Two-Sample Mendelian Randomization Study. Nutrients, 2023, 15, 4445.	4.1	2
1892	Proteomic Determinants of Variation in Cholesterol Efflux: Observations from the Dallas Heart Study. International Journal of Molecular Sciences, 2023, 24, 15526.	4.1	0

#	Article	IF	Citations
1893	Update of HDL in atherosclerotic cardiovascular disease. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2023, 35, 297-314.	0.8	1
1894	High-Density Lipoprotein Cholesterol in Atherosclerotic Cardiovascular Disease Risk Assessment: Exploring and Explaining the â€œUâ€•Shaped Curve. Current Cardiology Reports, 0, , .	2.9	0
1895	Novel Sizeâ€Based Highâ€Density Lipoprotein Subspecies and Incident Vascular Events. Journal of the American Heart Association, 2023, 12, .	3.7	3
1896	Association of LDL-cholesterol subfractions with cardiovascular disorders: a systematic review. BMC Cardiovascular Disorders, 2023, 23, .	1.7	2
1897	Knowledge mapping of B cell and atherosclerosis over the past 20 years: A bibliometric analysis. Human Vaccines and Immunotherapeutics, 2023, 19, .	3.3	0
1898	Properties and physiological effects of dietary fiber-enriched meat products: a review. Frontiers in Nutrition, 0, 10, .	3.7	2
1899	Childhood Non-HDL Cholesterol and LDL Cholesterol and Adult Atherosclerotic Cardiovascular Events. Circulation, 2024, 149, 217-226.	1.6	2
1900	HDL as a Treatment Target: Should We Abandon This Idea?. Current Atherosclerosis Reports, 0, , .	4.8	1
1902	Mendelian Randomization as a Tool for Cardiovascular Research. JAMA Cardiology, 2024, 9, 79.	6.1	5
1903	Eradicating Atherosclerotic Events by Targeting Early Subclinical Disease: It Is Time to Retire the Therapeutic Paradigm of Too Much, Too Late. Arteriosclerosis, Thrombosis, and Vascular Biology, 0, , .	2.4	0
1904	Nonsevere Burn Induces a Prolonged Systemic Metabolic Phenotype Indicative of a Persistent Inflammatory Response Postinjury. Journal of Proteome Research, 0, , .	3.7	1
1905	Assessing the Predictive Value of Different Nutritional Indexes for Contrast-Associated Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Intervention. Circulation Journal, 2023, , .	1.6	1
1906	Update of HDL in atherosclerotic cardiovascular disease. ClÃnica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2023, 35, 297-314.	0.2	0
1907	HDL subfractions determined by microfluidic chip electrophoresis predict the vulnerability of intracranial plaque: A HRMRI study. Clinica Chimica Acta, 2024, 553, 117713.	1.1	0
1909	Remnant Cholesterol is More Strongly Associated with Arterial Stiffness than Traditional Lipids and Lipid Ratios in the General Chinese Population. Journal of Atherosclerosis and Thrombosis, 2023, , .	2.0	0
1911	Association Between HDL2-C and HDL3-C with Cardiovascular Disease: A Nested Case-Control Study in an Iranian Population. International Journal of Endocrinology and Metabolism, 2023, 22, .	1.0	0
1912	Optimization of the MACE endpoint composition to increase power in studies of lipid-lowering therapiesâ€”a model-based meta-analysis. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	0
1913	Does epigenetic markers of HLA gene show association with coronary artery disease in Indian subjects?. Molecular Biology Reports, 2024, 51, .	2.3	0

#	Article	IF	Citations
1914	Genome-Wide Genetic Associations Prioritize Evaluation of Causal Mechanisms of Atherosclerotic Disease Risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 2024, 44, 323-327.	2.4	0
1915	Mendelian randomization studies on coronary artery disease: a systematic review and meta-analysis. Systematic Reviews, 2024, 13, .	5.3	1
1916	Cuban policosanol improves high-density lipoprotein cholesterol efflux capacity in healthy Japanese subjects. Frontiers in Nutrition, 0, 10, .	3.7	0
1917	Controversial causal association between IGF family members and osteoporosis: a Mendelian randomization study between UK and FinnGen biobanks. Frontiers in Endocrinology, 0, 14, .	3.5	0
1918	Keeping translational research grounded in human biology. Journal of Clinical Investigation, 2024, 134, .	8.2	0
1919	Glycation of high-density lipoprotein in type 2 diabetes mellitus. Chinese Medical Journal, 2013, 126, 4162-4165.	2.3	0
1920	High-density lipoprotein cholesterol subfraction HDL2 is associated with improved endothelial function in systemic lupus erythematosus. Lupus Science and Medicine, 2024, 11, e001030.	2.7	0
1922	A Mendelian randomization study on causal effects of inflammatory bowel disease on the risk of erectile dysfunction. Scientific Reports, 2024, 14, .	3.3	0
1923	The Role of Pro-Opiomelanocortin Derivatives in the Development of Type 2 Diabetes-Associated Myocardial Infarction: Possible Links with Prediabetes. Biomedicines, 2024, 12, 314.	3.2	0
1924	Sex differences in the applicability of Western cardiovascular disease risk prediction equations in the Asian population. PLoS ONE, 2024, 19, e0292067.	2.5	0
1926	Revisiting an old relationship: the causal associations of the ApoB/ApoA1 ratio with cardiometabolic diseases and relative risk factorsâ€"a mendelian randomization analysis. Cardiovascular Diabetology, 2024, 23, .	6.8	0
1927	Association between HDLâ€€ and intensive blood pressure control in patients with hypertension: A postâ€hoc analysis of SPRINT. Journal of Clinical Hypertension, 2024, 26, 225-234.	2.0	0
1928	Nutritional Aspects of Fats and Oils. , 2024, , 13-38.		0
1929	Nonlinear relationship between high-density lipoprotein cholesterol and cardiovascular disease: an observational and Mendelian randomization analysis. Metabolism: Clinical and Experimental, 2024, 154, 155817.	3.4	0
1930	A higher nonâ€HDLâ€€/HDLâ€€ ratio was associated with an increased risk of progression of nonculprit coronary lesion in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Clinical Cardiology, 2024, 47, .	1.8	0
1931	The high-density lipoprotein: Attribute matters rather than amount in therapeutic arena. Endocrinology&Metabolism International Journal, 2023, 11, 61-73.	0.1	0
1932	Causal association between lipoproteins and risk of coronary artery diseaseâ€"a systematic review and meta-analysis of Mendelian randomization studies. Clinical Research in Cardiology, 0, , .	3.3	0
1933	Highâ€density lipoprotein in diabetes: Structural and functional relevance. Journal of Diabetes Investigation, 0, , .	2.4	0

#	Article	IF	Citations
1934	Hawthorn leaf flavonoids alleviate the deterioration of atherosclerosis by inhibiting SCAP-SREBP2-LDLR pathway through sPLA2-â…¡A signaling in macrophages in mice. Journal of Ethnopharmacology, 2024, 327, 118006.	4.1	0
1935	The Association of the Cholesterol Efflux Capacity with the <i>Paraoxonase 1</i> Q192R Genotype and the Paraoxonase Activity. Journal of Atherosclerosis and Thrombosis, 2024, , .	2.0	0
1936	Fibrinogen to HDL-Cholesterol ratio as a predictor of mortality risk in patients with acute myocardial infarction. Lipids in Health and Disease, 2024, 23, .	3.0	0